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Summary 
 
VEGF family members play a pivotal role in angiogenesis and lymphangiogenesis, two important 
biological responses that crucially contribute to the outgrowth of solid tumors and the 
development of metastases. Despite the importance of VEGF-A in neo-angiogenesis, drugs 
interfering with VEGF-A only show modest effects in most cancers and resistance tends to 
develop after a transitory period of clinical benefit, resulting in regrowth of the tumors and 
progression of the disease. Angiogenic escape involving the compensatory expression of VEGF-
related and non-related angiogenic factors has been proposed to contribute to this limited 
response to VEGF-A directed angiogenic therapy. Within this context, we performed an 
expression profiling of the human VEGF family members (VEGF-A, VEGF-B, VEGF-C, VEGF-
D and PlGF) in different stages of colon cancer, namely colon adenoma, carcinoma and liver 
metastasis. A literature search for the expression of these angiogenic genes yields contradictory 
results due to methodological differences and fragmented approaches of studies on VEGFs 
expression in colon cancer. Therefore, we performed a systematic and comprehensive expression 
analysis, determining in a single experimental setup the mRNA expression levels of all human 
VEGF family members during the progression from colon adenoma to carcinoma and liver 
metastasis. A preliminary study revealed that colon samples obtained by surgical resection are 
susceptible to hypoxia elicited during the surgical procedure. This sampling-induced hypoxia in 
resection samples but not in biopsy samples affects the marker-reliability of VEGF family 
members. Therefore, biopsy samples provide a more accurate report on VEGF family mRNA 
levels. 
The results obtained by our expression analysis provide important new insights into the redundant 
expression of VEGF family members in colon carcinoma and their association with progression 
from adenoma to carcinoma to metastasis. In addition to VEGF-A, especially PlGF emerges from 
our analysis as a prominently expressed VEGF member in all stages of colon cancer. VEGF-B and 
VEGF-C were identified as angiogenic genes upregulated only in carcinoma and metastasis 
samples. Analysis of individual patient expression signatures revealed major progression-
associated shifts in the VEGF signatures. Whereas colon adenoma patients showed 
overexpression of one or two VEGFs, a shift toward the expression of multiple VEGF family 
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members was observed with disease progression. Hence, patients with colon carcinoma or liver 
metastases had a predominant overexpression of three or four VEGF family members. In view of 
this multiplicity of VEGF expression, we found a remarkable conservation of angiogenic 
signatures between colon carcinomas and liver metastases. The striking broadening of angiogenic 
gene expression with tumor progression in samples from untreated patients provides an 
explanatory basis for the differing therapeutic outcomes of targeting a single VEGF factor such 
as VEGF-A as well as for the overall weak to modest efficacy of anti-angiogenic therapy. 
Considering eicosanoids as potential drivers for the VEGFs expression signatures, a correlated 
analysis of COX2, 5-LOX and VEGFs mRNA expression revealed the complex and intertwined 
nature of inflammatory and angiogenic gene expression already at the stage of adenoma. 
Distinctive 5-LOX and COX2 expression profiles were revealed for colon adenoma and 
carcinoma and the presence of these enzymes was clearly associated with cumulative co-
expression of VEGF family members. Finally, in colon adenoma, the dual expression of COX2 
and 5-LOX may indicate an increased risk for malignant transformation. Considering the 
observed association between eicosanoids and co-expression of VEGF family members, colon 
cancer patients may benefit from a combination therapy targeting angiogenic VEGF signaling as 
well as eicosanoids to additionally suppress the co-expression of multiple VEGFs. 
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Samenvatting 
 
De VEGF familieleden spelen een vooraanstaande rol in angiogenese en lymfangiogenese, twee 
belangrijke biologische processen die een cruciale bijdrage leveren aan de uitgroei van vaste 
tumoren en de ontwikkeling van metastasen. Therapie gericht tegen de angiogene sleutelfactor 
VEGF-A heeft echter niet het verwachte effect en na verloop van tijd hervallen de meeste 
patiënten. Angiogene ontsnappingsmechanismen waarbij andere factoren de rol van VEGF-A 
gaan uitvoeren, liggen waarschijnlijk aan de beperkte werking van therapie gericht tegen VEGF-
A. In deze context hebben we een expressieprofilering van de verschillende VEGF familieleden 
(VEGF-A, VEGF-B, VEGF-C, VEGF-D en PlGF) uitgevoerd in verschillende stadia van 
colonkanker, namelijk colonadenoma, coloncarcinoma en levermetastasen. Een literatuurstudie 
naar de expressie van deze angiogene genen levert tegenstrijdige resultaten door de verschillende 
methodologische en gefragmenteerde benaderingen van studies naar de expressie van VEGFs in 
colonkanker. Daarom hebben wij een systematische en uitvoerige expressie-analyse uitgevoerd 
om in een enkele experimentele opstelling de mRNA expressie levels van alle VEGF 
familieleden te bepalen tijdens de progressie van colonadenoma naar -carcinoma en naar 
levermetastasen. Een voorafgaand onderzoek onthulde dat colonstalen verkregen via chirurgische 
resectie onderhevig zijn aan hypoxie die veroorzaakt wordt tijdens de chirurgische procedure. 
Deze hypoxie geïnduceerd door de staalname heeft in resectiestalen een invloed op de 
betrouwbaarheid van de VEGF familieleden als merker voor colonkanker. Daarom leveren stalen 
verkregen via biopsie een meer accuraat zicht op de mRNA expressie van de VEGF familieleden. 
De resultaten die bekomen werden in onze expressie-analyse leveren belangrijke nieuwe 
inzichten over de redundante expressie van VEGF familieleden in colonkanker en hun associatie 
met progressie van adenoma naar carcinoma en metastasen. Naast VEGF-A, blijkt vooral PlGF 
uit onze analyse naar voor te komen als een VEGF-lid met een prominente expressie in alle stadia 
van colonkanker. VEGF-B en VEGF-C werden geïdentificeerd als tumorspecifieke angiogene 
genen met enkel een opregulering in stalen van carcinoma en metastasen. Analyse van de 
expressie-signaturen van individuele patiënten onthulde aanzienlijke verschuivingen die 
geassocieerd waren met progressie. Waar colonadenoma patiënten een overexpressie van een of 
twee VEGFs toonden, was een verschuiving naar de expressie van meerdere VEGF familieleden 
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waarneembaar bij progressie van de ziekte. Zo hadden patiënten met colonkanker of 
levermetastasen een uitgesproken overexpressie van drie of vier VEGF familieleden. Tevens 
vonden we een opmerkelijke bewaring van de angiogene signaturen tussen stalen van 
coloncarcinoma en levermetastasen. De opvallende uitbreiding van angiogene genexpressie 
tijdens tumorprogressie in stalen van onbehandelde patiënten kan een verklaring bieden voor de 
uiteenlopende resultaten van therapie gericht tegen een enkele VEGF alsook voor de zwakke tot 
matige efficiëntie van anti-angiogenese therapie.  
Met het oog op de mogelijke sturende rol van eicosanoïden in de expressiesignaturen van de 
VEGFs, werd een gecorreleerde analyse uitgevoerd van de mRNA-expressie van COX2, 5-LOX 
en VEGFs. Deze onthulde het complexe en verweven karakter van de inflammatoire en 
angiogene genexpressie reeds vanaf het adenoma stadium en tijdens verdere progressie naar het 
carcinoma stadium. Daarbij werden opvallende expressieprofielen van 5-LOX en COX2 
gevonden in respectievelijk colonadenoma en -carcinoma en de aanwezigheid van deze enzymen 
was duidelijk geassocieerd met de cumulatieve expressie van VEGF familieleden. Tenslotte lijkt 
de dubbele expressie van 5-LOX en COX2 een verhoogd risico in te houden voor maligne 
transformatie van colonadenoma naar -carcinoma. Gezien de geobserveerde associatie tussen 
eicosanoïden en co-expressie van de VEGF familieleden, zouden colonkanker patiënten mogelijk 
voordeel halen uit een combinatietherapie die zowel de angiogene VEGF-signalisatie onderdrukt 
als de eicosanoïden om aldus de co-expressie van verschillende VEGFs te onderdrukken. 
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Chapter 1 
Colorectal cancer 
 
Colorectal cancer is often referred to as a single disease although it is a collective term for cancer 
of the colon (colon/colonic cancer) and of the rectum (rectal cancer). Tumors located within 15 
cm of the anal margin are classified as rectal while those more proximal are colonic [1]. Of those 
patients with colorectal cancer, approximately 35% are diagnosed with rectal and 65% with colon 
cancer [1, 2]. Although colon cancer is sometimes used as a synonym for colorectal cancer, 
throughout the thesis the following terms will be used when referring to these specific diseases: 
colorectal cancer for cancer of rectum and colon, colon cancer for cancer of the colon and rectal 
cancer for cancer of the rectum. 
1.1  Facts and figures 
Cancer is the third leading cause of death globally; preceded only by cardiovascular and 
infectious and parasitic diseases, and accounts for about 13% of all deaths per annum [3]. 
According to the most recent global study, approximately 7.6 million people died of cancer 
worldwide and 12.7 million people were diagnosed with invasive cancer in 2008 [3]. Colorectal 
cancer is worldwide the third and second most common cancer in men (10% of all cases) and 
women (9.4% of all cases), respectively (Figure 1.1) [3, 4]. In addition, colorectal cancer is the 
fourth most lethal type of cancer, accounting for 8% of all cancer deaths and with an estimated 
608,700 deaths worldwide in 2008 [3]. 
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Figure 1.1 - Estimated incidence and mortality rates of cancer worldwide. Estimated age-standardized rates for 
the top 15 cancer sites. Source: Globocan 2008 [3]. 
 
Recent estimates for colorectal cancer predicted over 1.2 million new cases in 2008 [4]. Almost 
60% of these cases occur in developed countries whereby the life-time risk for colorectal cancer 
is 5% for average-risk individuals in these industrialized regions [5]. The highest colorectal 
cancer incidence rates are observed in Australia and New Zealand, Western Europe and North 
America whereas the lowest incidence rates are found in Africa and South-Central Asia (Figure 
1.2). Over the past two decades, incidence rates of colorectal cancer have stabilized in the 
majority of the economically developed countries, and have even declined in the United States as 
a result of national screening programs. However, incidence rates are rapidly rising in several 
historically low-risk areas including Spain and certain eastern-European and -Asian countries. 
The increase in these economically transitioning countries is probably due to their westernization 
including changing dietary patterns, obesity, physical inactivity, aging populations and increased 
smoking [4, 6, 7]. 
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Figure 1.2 - Estimated age-standardized incidence rate of colorectal cancer per 100,000 inhabitants for male and 
female in 2008. Source: Globocan 2008 [3]. 
 
According to the latest data from the Belgian Cancer Registry, 8294 people were diagnosed with 
colorectal cancer in Belgium in 2010 [8]. The cumulative risk of developing colorectal cancer 
before the age of 75 years – in the absence of competing causes of death – was 5.1 and 3.2 % for 
Belgian men and woman, respectively [8]. In contrast to the United States, incidence rates of 
colorectal cancer have increased significantly for both sexes during the last decade, at least in the 
Flemish Region1 (1.2% in males and 1.5% in females; Figure1.3). The mortality rates, however, 
have decreased significantly with 2.9% in males and 2.1% in females. 
When comparing Belgium with countries exhibiting the highest incidence rates of colorectal 
cancer, Belgium ranks at eighth place in Europe, and twelfth place globally [3]. 
 
Figure 1.3 – Age-standardized incidence of colorectal cancer in the Flemish Region, 2000-2010. World 
standardized incidence rates per 100,000 persons for male and female from 2000 until 2010. Data were obtained 
from the Belgian Cancer Registry [8]. 
                                                 
1
 10 years registry data are not available for the Walloon Region. 
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1.2  Pathophysiology and progression 
1.2.1 Precursor lesions 
As demonstrated by epidemiologic, clinical, pathological, and molecular genetic findings, most 
cases of colorectal cancer develop from benign precursor lesions, i.e. adenomatous polyps or 
adenoma [5, 9, 10]. Premalignant adenoma evolves into malignant carcinoma through a series of 
genetic and epigenetic changes – the adenoma-carcinoma sequence – during a time interval of at 
least 10 years (Figure 1.4) [5, 10, 11]. Only ~5% of colon adenomas will eventually advance to 
the stage of carcinoma. This implies a significant biological difference between the formation of 
adenoma from healthy colon epithelium and the malignant transformation of colon adenomas into 
carcinomas [11]. The risk of transformation into colorectal cancer is believed to be affected by 
the number and size of polyps, the histological type and the presence of epithelial dysplasia [9, 
10]. Premalignant colon adenomas arise from the lining of the intestine mostly by (epigenetic) 
silencing or DNA mutations in the APC tumor suppressor gene, disrupting the Wnt-signaling 
pathway [12]. 
 
Figure 1.4 -The adenoma-carcinoma sequence in colorectal cancer. Histopathological and morphological (as 
viewed by colonoscopy) features of the initiation and progression of tumorigenesis from a normal colonic mucosa 
into an adenoma and a frank carcinoma with main associated molecular events. Adapted from Cardoso et al. [13] 
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Two widespread histologic types of polyps are discerned, namely serrated (including 
hyperplastic) and adenomatous polyps. 60 to 70% of all polyps removed at colonoscopy are 
adenomatous polyps or adenomas, the most common type [14]. They have typically 
hyperchromatically enlarged, cigar-shaped nuclei that are tightly packed in a palisade pattern and 
display varying levels of dysplasia [9]. Adenomas are classified as tubular, tubulovillous or 
villous. The most common adenomas are of the tubular type which histologically consists of 
tubular branches while the villous adenomas contain digitiform villi arranged in a cauliflower-
like structure. In comparison, tubulovillous adenomas contain characteristic elements from both 
the tubular and villous types [9, 10]. High-risk or advanced adenomas are the most likely to 
become cancerous and either have a large size (i.e. >1cm), severe dysplasia or villous or 
tubulovillous characteristics [10, 15]. Adenomatous polyps give rise to 70 to 80% of all 
colorectal carcinomas. 
The other 20 to 30% of colorectal carcinomas arise through the serrated pathways. Serrated 
polyps are characterized by their “saw-tooth” architectural features. Among the serrated lesions, 
hyperplastic polyps are the most common type but remain mostly small and localized to the distal 
part of the colon [16]. These polyps have serrations limited to the luminal outlines. An increased 
number of glandular cells with decreased cytoplasmic mucus but without nuclear 
hyperchromatism, stratification, or cytological atypia are histological references for hyperplastic 
polyps [15]. Hyperplastic polyps have generally little association with colorectal cancer [15, 17]. 
A link between the serrated pathway and colorectal cancer is presented by the sessile serrated 
lesions and traditional serrated adenomas, which generally arise within a hyperplastic polyp [9, 
15]. Sessile serrated lesions are characterized by structural crypt abnormalities, like dilated crypt 
bases and lateral growth but the absence of cytological dysplasia. Traditional serrated adenomas 
on the other hand have the opposite characterizations, namely cytological dysplasia but a relative 
normal architecture [14, 15]. Filiform villi with stromal bulbous ends are typical for traditional 
serrated adenomas [15]. The characteristic alterations in the APC gene in conventional adenomas 
are absent in serrated polyps which often show BRAF (sessile serrated) and KRAS mutations 
(traditional serrated) and exhibit extensive DNA methylation, especially in DNA repair genes [9, 
14]. Similar characteristics are observed in colorectal carcinoma with high microsatellite 
instability (MSI-H) arising from the serrated adenoma [9]. Table 1.1 summarizes the differences 
between sessile and traditional serrated adenomas, hyperplastic polyps, and adenomatous polyps. 
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Table 1.1 - Comparison of colon polyp types. The microscopic views of adenoma are derived from tubulovillous 
adenoma with tubular (arrows) as well as villous elements (arrowheads). The microscopic views of serrated adenoma 
are derived from sessile serrated lesions. AP: Adenomatous Polyp (tubular, tubulovillous and villous adenoma), 
SSA: Sessile Serrated Lesion, TSA: Traditional Serrated Adenoma HP: Hyperplastic Polyp. Pictures were obtained 
from Prof. Dr. K. Geboes [personal communication], Dr. M. Fleming [18] and Solunetti [19]. Table adapted from 
Freeman [16] and Makkar [14].  
 AP SSA / TSA HP 
Location Throughout,  more right  Right colon / Left colon Rectosigmoid 
Size Variable 
Often ≥ 10 mm / 
< 10 mm 
Small, often ≤5 mm 
Prevalence Extremely common Common / Rare Very Common 
Shape Pedunculated 
Sessile, flat / 
Pedunculated 
Sessile, flat 
Cytologic dysplasia Present Minimal / Present Absent 
Serration Absent Present Present 
Basal crypt dilation May be present Present / Absent Absent 
Horizontal crypts May be present Present / Absent Absent 
Branched crypts May be present Present / Absent Absent 
Ectopic crypts May be present Absent / Present Absent 
Basal serration Absent Present Absent 
Nuclear shape Tall columnar 
Round to oval /  
Tall columnar 
Flat or low columnar 
Precancerous Yest Yes No 
Low power 
microscopic view 
(~40x) 
 
 
 
High power 
microscopic view 
(~200x) 
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1.2.2 Hereditary colorectal cancer 
Two genetic syndromes represent ~5% of colorectal cancer cases, namely familial adenomatous 
polyposis (FAP; ~1% of all colorectal cancers) and hereditary non-polyposis colorectal cancer 
(HNPCC or Lynch syndrome; 2-5% of all colorectal cancers). FAP is caused by a germline 
mutation in the APC gene and is characterized by hundreds of colon polyps [9, 10]. Unless the 
colon is removed, individuals with FAP will have developed cancer by the age of 40 [10]. 
HNPCC is caused by dominantly inherited germline mutations in DNA mismatch repair genes, 
mostly MLH1, MSH2 or MSH6. Individuals with HNPCC may develop colorectal cancer at an 
early age (average age of 45 years) and have an increased risk of malignancy at specific 
extracolonic locations including the endometrium, ovary, stomach and pancreas [10, 20]. The 
growth of multiple polyps is less often preceding the cancer but the developed adenomas contain 
more villous components and are more dysplastic. Furthermore, adenomas in HNPCC have an 
earlier onset and show an accelerated carcinogenesis (2-3 years versus ≥ 10 years) when 
compared to the general population [10, 20].  
1.2.3 Sporadic colorectal cancer 
Sporadic colorectal cancer is the result of a long-term (i.e. years to decades) multistep cascade of 
genetic and epigenetic mutations steering to disturbed DNA replication and accelerated mitosis in 
colonic cells. Eventually, progressive accumulation of genetic alterations leads to the adenoma-
carcinoma sequence [9, 20]. Table 1.2 lists the most common molecular genetics of sporadic 
colorectal cancer. 
1.2.4 Risk factors 
Approximately 10-30% of colorectal carcinomas develop in persons with a clear family history of 
the disease but without defined disease-causing mutations [21]. Despite the lack of specific 
colorectal cancer-associated mutations in those families, these cancers are probably due to 
mutations in several genes in combination with environmental factors [10, 21]. In addition to 
genetic alterations and clear family history, environmental and demographic factors are also 
important elements in the etiology of colorectal cancer. The latter factors are presumed to 
modulate the risk of genetic mutations responsible for colon cancer although their specific 
mechanisms are currently unknown. The most prominent environmental factors are a sedentary 
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lifestyle concomitant with a high-fat diet, inadequate fiber intake and obesity, as well as 
alcoholism and smoking [9, 10, 20]. In addition, individuals with diabetes or inflammatory bowel 
disease, mainly ulcerative colitis and Crohn’s disease, are at risk of developing colorectal cancer. 
For inflammatory bowel disease patients, the risk increases with the duration of illness (2% at 10 
years; 18% by 30 years) and severity and extent of the inflammation [2, 10, 20]. 
Gene Chromosome 
location 
Physiologic function of 
encoded protein 
Clinical manifestations of mutation 
APC 5q Regulates cell growth and 
apoptosis. 
Mutated in 80-85% of sporadic colon 
cancer. 
Homozygous somatic mutation associated 
with colon adenomas. 
K-ras 
family 
Various 
chromosomes 
Encodes a small GTP-
binding protein involved 
in transduction of 
mitogenic signals across 
cell membrane. 
Mutated in ~50% of colon cancers. 
May act in an intermediate stage of 
carcinogenesis. 
Promotes colonocyte replication. 
Mutation common in hyperplastic polyps. 
P53 17p Regulates G1 cell cycle 
and apoptosis. 
Mutated in ~75% of frank cancer. 
Critical in transition from late adenoma to 
early cancer. 
DCC 18q Encodes a neural cell 
adhesion molecule. 
Facilitates apoptosis. 
Tumor suppressor. 
Believed to promote progression to frank 
carcinoma. 
Mismatch 
repair 
genes 
Various 
chromosomes 
Recognize errors in 
nucleotide matching on 
complementary 
chromosome strand and 
initiate excision of 
erroneous strand. 
Progressive accumulation of mutations 
throughout the genome in affected cells 
leading to hypermutability and genetic 
chaos. Mutations of oncogenes or tumor 
suppressor genes can lead to colon 
cancer. 
Table 1.2 - Molecular genetics of sporadic colon cancer. APC: adenomatous polyposis coli, DCC: deleted in 
colorectal cancer, GTP: Guanosine Triphosphate. Adapted from Cappell [9]. 
 
1.2.5 Metastasis 
Colorectal cancer cells can spread to nearby lymph nodes causing local metastases or to remote 
organs forming distant metastases. Of all patients initially presented with colorectal cancer, 
approximately 20-30% is identified with synchronous metastases. An additional 20-30% of 
colorectal cancer patients will develop metachronous metastases over time [9, 10]. In colorectal 
cancer, the regional lymph nodes and the liver are the most common sites of metastases. Liver 
metastasis can occur early in colorectal cancer due to the venous drainage of the colon via the 
portal system straight to the liver. Approximately 75% of synchronous metastases in colorectal 
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cancer are liver metastases [22]. In the last few years, prognosis of liver metastases in colorectal 
cancer has improved substantially by the implementation of multidisciplinary management 
comprising chemotherapy and surgery [23]. Other sites of metastases become involved at a later 
stage and include the lungs, peritoneum, pelvis and adrenal glands [9, 10].  
1.3  Diagnosis and treatment 
1.3.1 Symptoms and presentation 
The main symptoms of colorectal cancer are tiredness caused by anemia, weight loss, nausea, 
changes in bowel habits, melena or hematochezia and abdominal pain. However, these symptoms 
are also common with other pathological conditions [2, 24]. The cancer location and size and the 
presence of metastases determine the presented symptoms. Distal cancers may clearly produce 
rectal bleeding but this is not the case for proximal cancers. Because the blood is mixed with 
feces and chemically degrades during the passage through the colon, bleeding from proximal 
cancers is less obvious [9]. These patients then present anemia caused by iron deficiency instead 
of rectal bleeding. Symptoms associated with this type of anemia are weakness, fatigue, dyspnea 
or palpitations. Cancer cachexia can be present during the advanced stage, particularly when 
metastatic. The cachexia is characterized by poor health encompassing involuntary weight loss, 
anorexia and muscle weakness [9]. Occasionally, patients with colorectal cancer present as 
surgical emergencies with acute abdominal symptoms due to complications of the cancer [2, 25, 
26]. Several complications can occur in colon cancer patients including bowel obstruction (8%-
29% of cases), bowel perforation (2.5-10% of cases), abscess formation (0.3-4% of cases), acute 
appendicitis (3-25% of acute appendicitis cases) and ischemic colitis (1-11% of obstructive colon 
cases) [26]. 
1.3.2 Diagnosis, staging and prognosis 
Diagnosis of colorectal cancer is based on the results of colonoscopy and pathologic examination 
of biopsies or removed polyps. The presence of metastases is generally imaged by CT of the 
chest, abdomen and pelvis. In addition, ultrasound and MRI determine the extent of the 
metastatic disease [9, 20]. 
After diagnosis, the colorectal cancer is staged according to either of two methods. The modified 
Dukes’ staging system is based on postoperative findings while the tumor-node-metastases 
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(TNM) classification identifies the depth of tumor invasion (T), lymph node involvement (N) and 
presence of distant metastases (M). Invasive cancer in the TNM staging is classified from stage I 
to IV [9, 10, 20]. Table 1.3 summarizes the different classification systems in view of the stage 
dependent prognosis. If colorectal cancer is diagnosed at an early stage, the five-year survival 
exceeds 90%. But, in case of lymph node involvement, the five-year survival decreases to ~60% 
and below 10% if distal metastases are present [5]. However, early detection is challenging since 
clinical symptoms develop late in the progression of the disease [9]. 
TNM status Stage 
Modified Dukes’ 
stage 
5-years overall 
survival 
T in situ N0 M0 0 - likely to be normal 
T1 N0 M0 
I 
A >90% 
T2 N0 M0 B1 85% 
T3 N0 M0 IIa B2 
70-80% 
T4 N0 M0 IIb B3 
T1-2 N1-2 M0 
III 
C1 
25-60% T3 N1-2 M0 C2 
T4 N1 M0 C3 
Any T Any N M1 IV D 5-30% 
Table 1.3 - Five-year survival rates by stage at diagnosis. Adapted from Cooper et al. [10].  
1.3.3 Screening 
The asymptomatic nature of early colorectal cancer and its precursor lesions renders them hard to 
detect by clinical presentation. Therefore, screening of the population at risk (i.e. ≥ 50 years) is 
needed for early detection. Early diagnosis is crucial for increasing the chance at survival of 
colorectal cancer patients. In addition, timely removal of adenomas may decrease colorectal 
cancer incidence and mortality rate [27]. Colorectal cancer is an excellent candidate for screening 
because the disease has a high prevalence with recognized precursors and a clear benefit from 
early treatment [5]. However, screening for colorectal cancer is hindered by a lack of patient-
friendly and affordable detection methods. Existing serum markers are currently restricted from 
use since they lack sufficient specificity and sensitivity. The most common serum marker, 
carcinoembryonic antigen (CEA), has mostly been used for postoperative surveillance [28]. Fecal 
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occult blood testing, notwithstanding it being a widely used screening modality, exhibits 
disadvantages like low sensitivity and specificity for carcinomas, and particularly for adenomas 
[27, 28]. Other stool-based tests which detect fecal DNA markers (e.g. K-ras, APC, p53) perform 
better, but are relatively expensive and far more laborious [28]. Tissue-based markers have been 
widely studied but rather for their potential prognostic and predictive value than for screening 
purposes. Currently, the gold standard for detection of colon carcinoma and adenoma remains 
endoscopic examination by colonoscopy. The main advantage of colonoscopy is that adenomas 
and early carcinomas can be removed immediately whereas blood and fecal based tests require 
colonoscopy afterwards for confirmation [27]. However, colonoscopy is an invasive procedure 
that requires hospitalization and anesthesia and carries the risk of complications [5]. This strongly 
impedes the broad application of colonoscopy as a screening tool because it renders the method 
particularly unpopular and unfit for large-scale screening. 
1.3.4 Treatment 
Colorectal cancer treatment is either curative or palliative. This is largely dependent on the 
location of the carcinoma, the extent of invasion into the bowel, and the infiltration into other 
organs. The treatment strategy therefore differs significantly for colon as compared to rectal 
cancer. 
The current curative therapy for rectal cancer, both non-metastatic and metastatic, is based on 
combinations of chemotherapy, radiation therapy and total mesorectal excision (TME)-surgery. 
The preferred strategy comprises surgery preceded by neoadjuvant chemoradiation to reduce the 
size of the carcinoma and to facilitate effective surgery [20]. Radiation, combined with either 5-
fluorouracil (5-FU) or capecitabine (Xeloda), is most commonly used as a preoperative therapy 
[29]. In case of metastatic rectal cancer, the metastatic lesion(s) may be resected simultaneously 
with the primary tumor or post-surgery [30]. The recommended adjuvant therapy is FOLFOX 
(infused 5-FU, leucovorin i.e. folinic acid and oxaliplatin) although the use of adjuvant 
chemotherapy following preoperative chemoradiation and surgery has not yet been optimally 
defined [29]. 
In contrast to rectal cancer patients, non-metastatic colon cancer patients receive no 
neoadjuvant therapy and their primary treatment is based on direct surgery followed by adjuvant 
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chemotherapy [30, 31]. Generally, early colon cancer, i.e. Tis/T1 N0 M0, is removed by 
polypectomy and does not require adjuvant therapy. For colon cancer stage T2 N0 M0 and 
higher, wide surgical resection with anastomosis is compulsory. Adequate distal margins of 5 cm 
or more are recommended and lymphadenectomy of at least 12 lymph nodes is needed for proper 
node staging [20, 30]. Due to small gains in survival, adjuvant therapy is controversial in stage II 
colon cancer patients and is considered on an individual basis. However, high-risk stage II 
patients2 and especially stage III patients benefit from adjuvant therapy. Also here, infused 
FOLFOX is the standard adjuvant treatment [20, 29, 30].  
The treatment of advanced colon cancer with synchronous metastases is mostly based on 
achieving R0 resection (i.e. microscopically cancer-free at the resection margins) of the primary 
tumor and metastases either before or after preoperative conversion treatment (Figure 1.5) [23, 
30]. The basic strategy for treatment of colon cancer with synchronous metastases is summarized 
in figure 1.5. The treatment of advanced colon cancer comprises various active drugs, either as 
single agents or in combination. Basic cytotoxic chemotherapeutic agents which inhibit DNA 
replication are 5-FU/leucovorin, capecitabine, irinotecan and oxaliplatin [20, 23, 30, 31]. Recent 
progress in molecular biology has prompted the development of novel targeted therapies. Three 
of them are currently included in the first line treatment of metastatic colon cancer in 
combination with cytotoxic chemotherapy. Bevacizumab is a humanized monoclonal antibody 
against vascular endothelial growth factor A (VEGF-A), whereas the monoclonal antibodies 
cetuximab and panitumumab act by targeting the epidermal growth factor receptor (EGFR) [20, 
23, 30, 31]. These targeted therapies are discussed in chapter 3 (3.4 Anti-angiogenesis therapy). 
                                                 
2
 High-risk stage II patients have T4 tumors, vascular/lymphatic/perineural invasion, colonic obstruction or 
perforation, fewer than 12 harvested lymph nodes or indeterminate/positive resection margins. 
 
Introduction – Colorectal cancer | 15 
 
 
 
Figure 1.5 - Treatment algorithm for synchronous metastatic colon cancer. Adapted from Shmoll et al. [30] 
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Chapter 2 
Inflammation and cancer: encounters at the eicosanoid level 
 
2.1  Introduction 
The connection between inflammation and cancer has already been described some 5000 years 
ago in Ayurveda1. The characteristics and consequences of inflammation were firstly described as 
“redness (rubor), swelling (tumor), heat (calor) and pain (dolor)” in the first century by Aulus 
Cornelius Celsus, who was a Roman medical writer. In the 19th century, Rodolf Virchow 
postulated that inflammation caused by irritation leads to the development of most chronic 
diseases, including cancer. Yet only in recent years has this association been recognized as a 
generally accepted paradigm [1-3]. Colotta and colleagues have even postulated that 
inflammation is the seventh hallmark of cancer (Figure 2.1) [2]. 
The link between inflammation and cancer is clearly illustrated by the increased risk of cancer 
development in patients suffering from chronic inflammatory conditions. For example, cervical 
infection by human papillomavirus may lead to cervical cancer; hepatitis B and C or alcoholic 
liver cirrhosis can cause the development of hepatic cancer; and inflammatory bowel disease 
increases the risk of colon cancer [3, 4]. Physical, chemical or infectious tissue damage provokes 
a coordinated inflammatory response to eliminate the responsible agent and to initiate tissue 
repair. Inflammation should hence abate after elimination of the pathogen and promotion of 
wound healing. However, failure in the meticulous control of the immune response may result in 
an unresolved inflammation that continuously stirs the microenvironment. This can lead to a 
persistent induction of cell proliferation and tissue repair by alterations in cancer-related genes 
and posttranslational modifications in signaling proteins involved in cell cycle control, DNA 
repair and apoptosis [3]. The development of neoplastic cells is further encouraged by an 
environment with abundant inflammatory cells, pro-inflammatory cytokines and chemokines, and 
growth and survival factors [5].  
                                                 
1
 Ayurveda means “the science of long live”. It is an ancient healing system that originated in India. 
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Figure 2.1 - Inflammation as the seventh hallmark integrated in the six hallmarks of cancer from Hanahan and 
Weinberg. Figure from Colotta et al. [2]. 
Endogenous promoters involved in cancer related inflammation are inflammatory transcription 
factors such as nuclear factor-kappa B (NF-κB) and signal transducer activator of transcription 3 
(STAT3), as well as primary inflammatory cytokines such as interleukin (IL)-1α/β, IL-6 and 
tumor necrosis factor (TNF) [1-3]. NF-κB plays a central role in inflammation and carcinogenesis 
as evidenced by its constitutive activation in many cancers [1, 2]. Figure 2.2 summarizes NF-κB 
related inflammatory networking in cancer. In tumor, epithelial and immune cells, NF-κB 
activates the expression of genes encoding inflammatory cytokines, adhesion molecules, enzymes 
from the eicosanoid synthesis pathway, angiogenic factors and inducible nitric oxide synthase 
(iNOS). These NF-κB-activated factors may contribute to various processes of cancer 
development and maintenance like survival, transformation, angiogenesis, proliferation, invasion 
and metastasis. Inflammation-induced factors cyclooxygenase 2 (COX2) and 5-lipoxygenase (5-
LOX), involved in eicosanoid synthesis pathways, and vascular endothelial growth factor 
(VEGF), contributing to (neo)-angiogenesis, will be discussed in detail in Chapters 2 and 3 
respectively.  
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Figure 2.2 - Inflammatory interactions in cancer orchestrated by NF-κB. 5-LOX: 5-lipoxygenase, bcl-2/XL: B-
cell lymphoma 2/extra-large, COX2: cyclooxygenase 2, IAP1/2: inhibitor of apoptosis protein, iNOS: inducible 
nitric oxide synthase, MMPs: matrix metalloproteinase, NF-κB: nuclear factor-kappa B, TWIST: twist basic helix-
loop-helix transcription factor, VEGF: vascular endothelial growth factor, XIAP: X-linked inhibitor of apoptosis 
protein. Adapted from Aggarwal et al. [1, 6] 
 
2.2  Eicosanoid mediators in cancer 
2.2.1 Eicosanoid synthesis pathways 
Eicosanoids is a generic term for the biologically active lipids derived from arachidonic acid. 
Arachidonic acid is a polyunsaturated fatty acid present in the phospholipids of the cell 
membranes of mammalian cells. A major source of arachidonic acid is dietary animal fats. 
Eicosanoids, including prostanoids, leukotrienes, hydroxyeicosatetraenoic acids (HETEs), 
epoxyeicosatrienoic acids (EETs) and hydroperoxyeicosatetraenoic acids (HPETEs), are 
generated through the metabolism of arachidonic acid by cyclooxygenases (COX), lipoxygenases 
(LOX) and cytochrome P450 mono-oxygenases (Figure 2.3) [7]. In this chapter we will focus on 
the roles of cyclooxygenase, lipoxygenase and their main derivatives (i.e. prostanoids and 
leukotrienes) in sustaining established cancers. 
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Figure 2.3 - Overview of eicosanoid biosynthesis pathways. Primarily the factors marked in red are discussed 
throughout the thesis. Adapted from Calder [8]. 
 
2.2.2 Cyclooxygenases in cancer 
Cyclooxygenases catalyze the rate-limiting step of prostanoid synthesis by converting 
arachidonic acid into PGH2, an intermediary metabolite used by specific prostaglandin and 
thromboxane synthases as substrate for prostaglandins (PG) and thromboxane A2 (TXA2) 
synthesis (Figure 2.3). The COX enzyme possesses two active sites, a cyclooxygenase site where 
arachidonic acid is converted into PGG2, and a haem site with peroxidase activity that reduces 
PGG2 to PGH2 [9]. 
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The COX enzyme family consists of three isoforms, namely COX1, COX2 and COX3. The most 
recently discovered COX3 is a splice variant of COX1 in which intron 1 is retained [10]. COX3 
has a low potency to generate prostanoids and therefore COX3 will not be further discussed. In 
general, COX1 is constitutively present in most human cells and tissues and performs multiple 
housekeeping functions, including promoting platelet aggregation, vasoconstriction and 
protection of the inner stomach mucosae [9, 11]. Increased COX1 expression has been observed 
in various human cancers, including cervical [12], ovarian [13] and prostate cancer [14] and 
cancer of the head and neck [15]. COX2 differs structurally from COX1 at a number of amino 
acids in the hydrophobic channel. This creates an extra side pocket whereupon the selectivity of 
COX2-inhibitors is based [16, 17]. In contrast to COX1, COX2 is an immediate-early response 
gene that is absent in most normal tissues except the kidney, colon and brain. COX2 is however 
induced strongly and rapidly in response to inflammatory cytokines, Toll-like receptors (TLR), 
hypoxia and tissue damage [11, 16, 18-20]. This rapid induction of COX2 generally subsides 
after 24 to 48 hours [21]. Constitutive overexpression of COX2 has been documented in various 
cancers, including gastrointestinal [22-27], genitourinary [28, 29], breast [30-32] and gynecologic 
cancers [33-35] as well as leukemia [36, 37] and head and neck cancers [38-40]. Besides in 
neoplastic cells in these tumors, COX2 is also expressed in stromal fibroblasts, infiltrating 
immune cells and endothelial cells of the tumor vasculature [19]. A key role of inducible COX2 
in cancer has been demonstrated by numerous studies reflecting the pro-tumoral functions of the 
COX2-derived prostanoids (see 2.2.4. The contribution of eicosanoid mediators to colorectal 
cancer). The contributions of COX2 overexpression to the progression of colorectal cancer are 
summarized in figure 2.4. Overall, overexpression of COX2 in colorectal cancer is associated 
with lymph node and liver metastasis [41, 42], poor survival and prognosis [25, 43, 44] and 
tumor vascularization [41]. 
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Figure 2.4 - The effects of overexpression of COX2 in colorectal cancer patients.  
 
2.2.3 Lipoxygenases in cancer 
Lipoxygenases catalyze the dioxygenation of arachidonic acid to a specific HPETE that is further 
metabolized to leukotrienes (LT) by 5-LOX, or reduced to the corresponding HETE (Figure 2.3) 
[45, 46]. The human LOX enzyme family consists of three groups classified according to their  
oxygenation position in arachidonic acid, namely 5-LOX, 12-LOX and 15-LOX. 5-LOX 
converts arachidonic acid into 5-HPETE and metabolizes it further into LTA4 [47]. Unique to 5-
LOX is its dependence on Ca2+ for translocation from the cytosol to the nuclear membrane, its 
linking to the transmembrane 5-LOX activating protein (FLAP) and its oxygenation and LTA4 
synthase activities [47, 48]. 5-LOX is generally found in cells of myeloid origin involved in 
inflammation and immune responses such as monocytes, macrophages, eosinophils, basophils, 
mast cells and B-lymphocytes [49]. However, increments of 5-LOX and its metabolites have 
been found in various types of cancers including prostate [50], bladder [51], breast [52], 
hepatocellular [53], colon [54], pancreatic [55], esophageal [56] and oral cancer [57]. This 
anomalous expression has been implicated in increased cell proliferation [58, 59], angiogenesis 
[60, 61] and resistance to apoptosis [56, 62]. In addition, 5-LOX overexpression has been 
observed in colon polyps [63, 64]. 12-LOX has a distinct species-specific tissue distribution. In 
COX2 
expression
associated 
with liver 
metastasis
associated 
with poor 
survival
independent 
prognostic 
facor
involved in 
lymph node 
metastasis
involved in 
tumor 
vascular-
ization
associated 
with poor 
prognosis
increased 
compared to 
healthy 
colon
Introduction – Inflammation and cancer | 25 
humans, 12-LOX expression is found in platelets and the skin [65] but has also been detected in 
different cancers like prostate [66, 67], bladder [51], breast [30] and stomach cancer [68]. In 
addition, 12-LOX activity has been associated with tumor progression in prostate cancer [66]. 
The 15-LOX enzyme is found in reticulocytes, eosinophils and the respiratory epithelium [46]. 
On this basis, the reticulocyte or leukocyte-type (i.e. 15-LOX-1) and the epidermis-type (i.e. 15-
LOX-2) are discerned [69]. In addition to arachidonic acid-derived eicosanoids, 15-LOX-1 also 
produces 13-S-hydroxyoctadecadienoic acid (HODE) from linoleic acid [70]. Although the role 
of 15-LOX in cancer remains controversial, recent reports indicate the enzyme exerts anti-
tumoral effects in line with its decreased expression in cancer. Thus, loss of 15-LOX-1 
expression has been observed in major human cancers, including those of the colon [71], 
esophagus [72], breast [73], pancreas [74], bladder [75] and lungs [76]. Moreover, re-expression 
of 15-LOX-1 in colon and esophageal cancer has anti-tumoral effects [71, 72]. Similarly, 15-
LOX-2 has been described as a functional tumor suppressor in prostate cancer [77], and to be 
decreased in esophageal [78] and breast cancer [73]. 
2.2.4 The contribution of eicosanoid mediators to colorectal cancer 
The observed overexpression of COX1, COX2, 5-LOX and 12-LOX in various types of cancer 
results in an aberrant arachidonic acid metabolism and constitutively high levels of COX- and 
LOX-derived eicosanoids. These eicosanoids orchestrate complex interactions between tumor 
cells and the surrounding microenvironment through several mechanisms crucial for tumor 
survival, proliferation, progression, angiogenesis and metastasis. This section will focus on the 
effects of PGE2 as predominant pro-tumoral prostanoid and of the leukotrienes LTB4 and LTD4, 
in sustaining colorectal cancer, summarized in figure 2.5.  
2.2.4.1 Tumor growth 
Deregulation of the balance between cell proliferation and cell death is the main hallmark of 
cancer. Enhanced cell divisions increase the number of cells while inhibition of apoptosis 
prolongs the survival of neoplastic cells and thus allows the further accumulation of genetic 
alterations. This leads to a process of natural selection that favors the multiplication and survival 
of genetically altered cells that facilitate neoplasia. Evidence from mouse models demonstrates 
that PGE2 is a potent mediator of cell proliferation and survival in colorectal cancer. PGE2 
treatment in Apc-/- mice increases the adenoma burden, enhances epithelial cell proliferation, and 
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induces COX2 expression leading to a self-amplifying loop [79]. Also in azoxymethane-induced 
colon cancer, tumor incidence and multiplicity is enhanced by PGE2 treatment [80]. On the other 
hand, deletion of prostaglandin E synthase (Ptges) and consequent inhibition of endogenous 
PGE2 suppresses intestinal tumorigenesis in Apc-/- and azoxymethane models [81, 82]. PGE2 
induces proliferation by activation of the Ras-ERK pathway [79] and the β-catenin signaling 
pathway [83]. In addition to proliferation, PGE2 promotes also survival of colon tumor cells in 
Apc-/- mice by activation of a PI3K-Akt-PPARδ cascade [84]. Moreover, an increased expression 
of the anti-apoptotic protein Bcl-2 has been associated with PGE2 as well as LTB4 and LTD4 [85-
87]. 
LTD4 promotes survival of human intestinal epithelial cells by inducing the activation of the 
PKC-CREB and β-catenin signaling pathways as well as by preventing the activation of caspase 
8 and the cleavage of BID [86, 88, 89]. LTB4, on the other hand, inhibits apoptosis of colon 
cancer cells via the activation of ERK and β-catenin signaling pathways [87, 90]. LTB4 and LTD4 
are also involved in colorectal cancer cell proliferation as indicated by the suppression of 
proliferation in colon cancer cell lines by inhibition of either LTB4 or LTD4 [90-92]. Binding of 
LTD4 to its CysLT1 receptor regulates proliferation of intestinal epithelial cells by a PKC-
mediated activation of the ERK1/2 pathway [88, 93] whereas LTB4 induces cell proliferation in 
pancreatic cancer cells through MEK/ERK and PI-3 kinase/Akt pathways [94]. 
2.2.4.2 Angiogenesis 
Tumor growth and metastasis is highly dependent on the tumor’s ability to increase vascular 
supply for nutrient and oxygen delivery to growing tumor cells. Various cells in the tumor 
microenvironment, including tumor, stromal and immune cells, may contribute to tumor 
angiogenesis by the secretion of proangiogenic factors such as vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF). These 
proangiogenic factors stimulate endothelial cell recruitment, proliferation, migration and tube 
formation. PGE2 is an important factor in the induction of VEGF expression and synthesis. 
Binding of PGE2 to the EP1 receptor on colon cancer cells results in the activation of ERK. ERK 
activation subsequently leads to the translocation of hypoxia inducible factor-1 (HIF-1) to the 
nucleus and the induction of VEGF [95]. HIF-1, a major stimulus for angiogenesis, upregulates 
COX2 during hypoxia and hence increases PGE2 levels. Elevated PGE2 levels then further 
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enhance the expression of VEGF and transcriptional activity of HIF1 which in turn its contributes 
to COX2 expression. A positive feedback loop is therefore created which leads to COX2 and 
VEGF upregulation during hypoxia [20]. PGE2 also induces the expression of CXCL1 in 
colorectal cancer cells. CXCL1 is a pro-angiogenic chemokine that stimulates endothelial cell 
migration and tube formation [96]. The correlation between PGE2 signaling and angiogenesis has 
also been described in stromal cells in mouse models of breast cancer and lung carcinoma [97, 
98]. In endothelial cells, PGE2 promotes αVβ3-integrin dependent migration and spreading, and 
induces VEGF and bFGF expression through stimulation of the ERK-JNK signaling pathway [99, 
100]. In addition, PGE2 also stimulates immune cells, such as mast cells to secrete VEGF and the 
pro-angiogenic monocyte chemoattractant protein-1 (MCP-1) chemokine [101, 102]. 
The contribution of leukotrienes to angiogenesis has been less well characterized. However, 
binding of LTB4 to the BLT2 receptor on endothelial cells has been reported to stimulate VEGF-
induced angiogenesis as well as endothelial cell migration and tube formation, thus indicating a 
role also for leukotrienes in neo-angiogenesis [103]. 
2.2.4.3 Metastasis 
The progression of solid tumors relies on the ability of transformed cells to invade surrounding 
tissues (local metastasis) and to spread through blood or lymphatic vessels to distant tissues 
(distant metastasis). Metastasis is a multi-step process that displays a sensitive balance between 
host and tumor cell interactions. This process involves the invasion of tumor cells into the host 
stroma and blood vessels. Subsequently, tumor cells have to extravagate into the parenchyma of 
the new organ where they have to establish cell proliferation along with vascularization to form a 
metastatic focus [104]. Colorectal cancer cell migration and invasion is induced by PGE2 through 
transactivation of epidermal growth factor receptor (EGFR)-PI3K-Akt signaling. EGFR 
transactivation is accomplished by the PGE2-mediated induction of a β-arrestin1-Src kinase 
complex and stimulates colorectal cancer cell migration in vitro and metastatic spread to the liver 
in vivo [105]. PGE2 treatment in vitro, up-regulates urokinase and matrix metalloproteinase 
(MMP)-9 expression via the JNK1/2 signaling pathway, thus causing degradation of the 
extracellular matrix and promoting cellular motility of human colon cancer cells [106]. 
Next to prostanoids, also leukotrienes may contribute to invasion and metastasis. As such, LTD4 
has been shown to trigger motility in non-transformed intestinal epithelial cells via a PI3K-Rac 
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signaling pathway [107]. In addition, the LTB4 receptor-2 has been demonstrated to promote 
invasion and metastasis of ovarian cancer cells by a STAT3 upregulation of MMP-2 [108]. 
Although few in number, these studies indicate a role for leukotriene signaling in invasion and 
metastasis. 
 
Figure 2.5 – The promotion of cancer progression by PGE2, LTB4 and LTD4. Inspired by Wang [7]. 
 
2.2.5. Chemoprevention of colon cancer 
Chemoprevention is the employment of pharmacological or nutritional agents to prevent, reverse 
or delay carcinogenesis before the development of invasive disease. Colorectal cancer is an 
excellent candidate for prevention since the progression to carcinoma after detection of an 
adenoma usually takes about a decade. 
2.2.5.1 Nutritional agents 
Research into the advancement of chemopreventive agents is largely focused on natural agents 
targeting important carcinogenic pathways but without adverse side effects. Epidemiological, 
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experimental and clinical studies have investigated the potential anti-colorectal cancer activity of 
folic acid, calcium and micronutrient anti-oxidants like vitamin E and selenium [109]. In 
addition, nutrients like certain omega-3 polyunsaturated fatty acids (PUFAs), polyphenols and 
flavonoids exhibit inherent anti-inflammatory activity and have shown efficacy against colorectal 
carcinogenesis in rodent and in vitro models [109]. One such agent is eicosapentaenoic acid 
(EPA), a naturally occurring omega-3 PUFA with anti-inflammatory properties found in high 
quantity in oily fish. Dietary administration of EPA reduced colorectal tumor size and 
multiplicity in rodents [109] and showed reduced rectal polyp number and size in patients with 
FAP [110]. Furthermore the dietary administration of curcumin, a polyphenol derived from the 
spice tumeric, inhibited the development of azoxymethane -induced colonic premalignant lesions 
in an obesity-related colorectal carcinogenesis mouse model [111]. Inhibition of the production of 
PGE2 and 5-HETE contributes to the anti-inflammatory and anti-carcinogenic properties of 
curcumin by direct inhibition of COX-1/2, Ptges, 5-LOX and the NFκB signaling pathway, [112, 
113]. The Polyp Prevention Trial is a randomized dietary intervention trial examining the 
effectiveness of  low-fat, high-fiber, high-fruit and high-vegetable diets on adenoma recurrence. 
Results from this trial associated a decreased risk of advanced adenoma recurrence with a high 
intake of flavonols, i.e. a class of flavonoids found in high concentration in beans, onions, apples 
and tea [114]. Again, inhibition of PGE2 by interference with COX2 may contribute to the anti-
tumorigenic effects of flavonols [115] 
2.2.5.2 Pharmacological agents 
Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDS), which are inhibitors of 
COX1 and/or COX2, are the most widely studied agents for chemoprevention of colorectal 
cancer. A decreased incidence of colorectal cancer for chronic aspirin users was observed for the 
first time in 1988 [116]. Since then , more than 100 randomized, double-blind, placebo-controlled 
animal studies have showed that NSAIDS consistently decreased the number of tumors per 
animal and animals with tumors [117]. In addition, multiple epidemiological studies (case-control 
and cohort) have reported a reduced colorectal cancer incidence and mortality, and adenoma 
development in men and woman treated with NSAIDS [117, 118]. The long-term use of 
traditional non-selective NSAIDs, however, is limited because it can cause serious 
gastrointestinal and renal side-effects. It has been shown that approximately 30% of daily 
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NSAIDs users develop gastrointestinal tract toxicity [119]. Traditional NSAIDs inhibit both the 
COX1 and COX2 isoforms and their toxicity is caused by the inhibition of COX1 housekeeping 
functions, namely the defense mechanisms of the gastrointestinal and renal mucosae by COX1-
derived prostaglandins [117]. Therefore, specific COX2 inhibitors (COXIBs) were developed to 
obtain the beneficial effect of NSAIDs in the prevention of colorectal cancer but without their 
potential hazards. Several studies on colorectal cell lines treated with COXIBs, including 
meloxicam and celecoxib have shown the repression of neoplastic growth from the earliest stage 
of adenoma, i.e. the aberrant crypt foci [117, 120, 121]. These data were confirmed in animal 
models where COXIBs markedly reduced the number and size of azoxymethane -induced polyps 
and reduced the tumor burden up to 87% [117, 122-124]. The utility of COXIBs as 
chemopreventive agents was further demonstrated in about 40 observational studies in patients 
with FAP [125]. A 6 months placebo-controlled study of celecobix (Celebrex, Pfizer, New York) 
in FAP patients showed a 30% reduction in polyp burden [126]. Another study observed a 70%-
100% reduction in the rate of polyp formation after treatment with rofecoxib (Vioxx, Merck, 
Whitehouse station, New Jersey) [127]. In 1999 and 2000, three randomized trials were launched 
in individuals with a recent history of adenomas to examine the role of different COXIBs for 
three years, namely APPROVe2, APC3 and PreSAP4. Despite the fact that all three clinical 
studies found a decreased incidence of adenomas, they were arrested early in 2004 because of 
cardiovascular toxicity [128-132]. A meta-analysis of the USPSTF5 in 2007 confirmed the 
efficacy of COXIBs in the prevention of adenoma but did not recommend their use as a 
chemopreventive because of the cardiovascular risk, except for special groups at high risk of 
colorectal cancer [118]. For now, only celecoxib is approved by the regulatory agencies for 
chemoprevention in patients with FAP. For these patients, celecoxib is however merely used as a 
way to delay the time to surgery or as a secondary prevention therapy after prophylactic surgery. 
Thus, despite these promising experimental and clinical data, currently no chemopreventive 
strategy is available that replaces surgery and endoscopic surveillance. 
  
                                                 
2
 APPROVe: Adenomatous Polyp Prevention On Vioxx 
3
 APC: Prevention of Sporadic Colorectal Adenomas With Celecoxib 
4
 PreSAP: Prevention of Colorectal Sporadic Adenomatous Polyps 
5
 USPSTF: U.S. Preventive Services Task Force 
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Chapter 3 
Wound healing and cancer: the angiogenic link 
 
3.1 Wound healing 
3.1.1 Introduction 
Wound healing is a highly orchestrated process that is evolutionarily conserved and involves 
complex interactions of extracellular matrix (ECM) molecules, soluble mediators, various 
resident cells, and infiltrating immune cells. The healing process consists of three consecutive yet 
overlapping phases: inflammation with blood clotting, new tissue formation and tissue 
remodeling [1-4]. The onset of wound healing occurs immediately upon injury by the formation 
of a hemostatic blood clot with a platelet plug that seals the wound and initiates inflammation 
(Figure 3.1a). Inflammatory cells are attracted to the wound site by signaling of the activated 
platelets to prevent infection and remove debris. In addition, these inflammatory cells release 
growth factors, cytokines and proteinases, which initiate the phase of tissue formation [1-4]. 
During this phase, migrating fibroblasts proliferate and produce large amounts of ECM. This new 
tissue is called granulation tissue because of the granular appearance of the numerous capillaries 
that are sprouting at the wound edge as angiogenesis induces the development of new vasculature 
[3, 4]. In the final phase, granulation tissue is replaced by mature scar tissue through matrix 
remodeling. Eventually, the inflammatory response abates and the cellularity normalizes [3, 4]. 
Impaired wound healing represents a serious cause of morbidity and mortality, primarily 
affecting aged individuals (i.e. ≥ 65 years) and diabetic or immunosuppressed patients, as well as 
patients receiving chemo- or radiotherapy [3, 6]. Chronic wounds are, by definition, wounds that 
have failed to progress through the stepwise process of physiologic healing. Instead, they are 
trapped in a phase of pathologic inflammation that causes a delayed, incomplete and 
uncoordinated healing process and impairs the restoration of anatomic and functional integrity of 
the tissue [6, 7]. At the opposite end of the spectrum, excessive healing causes fibrosis with 
overabundant collagen deposition and reduced remodeling. This fibrosis results in loss of the 
anatomical structure of the tissue and thus compromises its function [8]. 
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Figure 3.1 - Wound healing versus invasive tumor growth. a. Normal tissues have a highly organized structure 
with epithelial cells upon a basement membrane which separates them from the vascularized stromal compartment. 
Upon tissue damage, activated platelets form a hemostatic plug and release vasoactive factors that regulate 
vasoconstriction and formation of the fibrin clot. The activated platelets also release chemotactic factors like TGF-β 
and PDGF that initiate the formation of granulation tissue as well as the activation of fibroblasts and remodeling of 
the ECM. In addition, granulocytes and monocytes are recruited, and the venous network is restored. After re-
epithelialization and healing of the wound, signaling subsides. b. Invasive carcinomas are less organized. The 
interaction of neoplastic cells with other cell types (i.e. mesenchymal, hematopoietic and lymphoid) causes the 
production of a chaotic vascular organization of blood and lymphatic vessels by angiogenesis an lymphangiogenesis. 
Neoplastic cells release cytokines and chemokines that are mitogenic and/or chemoattractants for granulocytes, mast 
cells, monocytes, macrophages, fibroblasts and endothelial cells. In return, these activated fibroblasts and 
inflammatory cells produce cytokines and chemokines that are mitogenic for neoplastic and endothelial cells.  
 
3.1.2 “Cancers are wounds that do not heal” 
Already in 1863 Rudolf Virchow proposed that malignant transformation represents the most 
severe complication of both impaired and excessive healing. He hypothesized that chronic 
irritation and previous injuries are a precondition for carcinogenesis [3]. The American 
pathologist Harald Dvorak then postulated in 1986 that “cancers are wounds that do not heal” [9]. 
He had recognized remarkable similarities between the granulation tissue of healing skin wounds 
and the composition of the stroma of malignant tumors. Therefore, he presumed that tumors 
activate the wound healing response of their host for the formation of the tumor stroma. Both 
postulations have been supported by numerous clinical observations and experimental studies [3].  
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Hallmark Cancer Wound healing 
Proliferative signaling Sustained Transient 
Evasion of growth suppression Sustained Transient  
Cell migration With invasion and 
metastasis 
Without invasion and 
metastasis 
Enabling replicative immortality Yes No 
Angiogenesis Sustained Transient 
Cell death Resisting Transient increase 
Inflammation Sustained Transient 
Table 3.1 - Comparison between the hallmarks of cancer and wound healing. Adapted from Arwert et al. [1]. 
 
Although many components of wound healing have been found in cancer, there are also 
important differences as illustrated in figure 3.1 and summarized in table 3.1. The most important 
difference is that wound healing is a self-limiting process whereas cancer is not [1]. This 
difference is caused by a dissimilar expression and activation of microenvironmental factors [1, 
3]. Thus, the released growth factors, cytokines and chemokines show striking similarities 
between healing wounds and tumors [10]. However, these factors differ in the kinetics of their 
expression and become constitutively activated in solid tumors (Table 3.2) [1]. Furthermore, 
vessels in wounds and tumors are initially immature and leaky. This hyperpermeability allows the 
continuous release of plasma proteins and the deposition of a fibrin and fibronectin matrix, 
typical for most cancers and for healing wounds. This leakiness of the vessels with the deposition 
of the matrix is an acute and transient event in wound healing, whereas it is a persistent event in 
most cancers [3]. 
3.2 Angiogenesis and lymphangiogenesis as part of tumor vascularization 
3.2.1 Introduction 
The formation of new blood vessels is crucial for the supply of oxygen and nutrients to the 
healing tissue as well as to growing solid tumors. Neovascularization has an essential role in the 
growth of tumors beyond a diameter of 2mm and in metastasis [11]. Angiogenesis is the 
predominant approach of neovascularization in wound healing as well as in tumors [3]. Upon the 
onset of angiogenesis in healing wounds, also lymphangiogenesis is initiated in order to 
reconstruct the lymphatic vasculature. This process is particularly important for metastasis in 
tumorigenesis [12].  
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 Functions in wounds  Functions in cancer  
Growth Factors 
EGF family  Epidermal and mesenchymal regeneration; 
accelerates wound healing  
Cancer cell invasion, macrophage 
signaling and autocrine growth of 
tumor cells  
FGF family  Early angiogenesis, fibroblast proliferation and 
re-epithelialization via keratinocyte migration  
Angiogenesis and fibroblast 
proliferation  
TGFβ family  Attracts neutrophils and macrophages, mediates 
ECM deposition, angiogenesis, epithelial cell 
migration and wound healing  
Tumor development, tumor cell 
invasion and metastasis  
PDGF  Attracts neutrophils and macrophages, and 
mediates ECM deposition and angiogenesis.  
Recruits inflammatory cell infiltration 
and mediates angiogenesis and 
lymphangiogenesis  
VEGF  Angiogenesis  Tumor cell invasion and angiogenesis  
Cytokines and chemokines 
IL-1α/β  Fibroblast and keratinocyte proliferation and 
neutrophil recruitment  
Tumor cell proliferation, angiogenesis 
and inflammation  
IL-6  Fibroblast proliferation and neutrophil 
recruitment  
Tumor development, tumor cell 
invasion and metastasis  
TNF  Leukocyte infiltration  Tumor promotion or suppression  
CSF1  Recruitment of macrophages and  
re-epithelialization  
Tumor cell invasion and migration  
MCP1  Macrophage recruitment, angiogenesis, re-
epithelialization and ECM production  
Monocyte recruitment, tumor cell 
invasion and metastasis  
CXCL1  Neutrophil infiltration, epithelial migration and 
neovascularization  
Angiogenesis, invasion and migration  
CXCL2  Epithelial proliferation  Recruits inflammatory cell infiltration 
and migration  
CXCL8 
(also known as 
IL-8)  
Inflammation, wound contraction and epithelial 
proliferation  
Angiogenesis, migration and invasion  
CXCL12   Angiogenesis  Migration, invasion and angiogenesis  
Table 3.2 - Cytokines, chemokines and growth factors that influence wound healing and tumor progression. 
Cytokines, chemokines and growth factors are included on the basis that they have been shown to influence both 
wound healing and tumor invasion or progression in vivo. CSF: colony stimulating factor, CXCL: C-X-C motif 
ligand, EGF: epidermal growth factor, FGF: fibroblast growth factor, IL: interleukin, PDGF: platelet-derived growth 
factor, MCP1: monocyte chemoattractant protein 1, TGF: transforming growth factor, TNF: tumor necrosis factor, 
VEGF: vascular endothelial growth factor. Adapted from Arwert et al. [1]. 
 
3.2.2 Tumor vascularization  
Autopsies of individuals who died from non-cancer causes has led to the discovery of dormant 
tumors. Initially, tumors grow avascular, until an equilibrium between proliferation and apoptosis 
is reached. Unless they progress to a vascularized growth, these tumors persist in a dormant 
encapsulated state [13]. Vascularized tumors are associated with a poor prognostic outcome 
because vascularization is correlated with aggressiveness and metastasis [14]. The growth of 
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tumor vessels is a hallmark of cancer since it is an essential adaptation of the microenvironment 
for the development of clinically relevant tumors [15]. The tumor associated vascularization 
exploits canonical mechanisms of physiological vessel growth, yet in a deregulated manner. 
However, tumors may also develop additional strategies to ensure their blood supply. As a result, 
tumor vascularization may be heterogeneous and muddled [13]. Angiogenesis is defined as the 
formation of new blood vessels from pre-existing vessels. This can be achieved by either 
sprouting angiogenesis or intussusceptive angiogenesis. Sprouting angiogenesis involves 
proliferation and migration of endothelial cells (Figure 3.2.A). It starts by degradation of the 
ECM and the basement membrane surrounding the endothelial cells by activated proteases. 
Hence, the endothelial cells are capable to invade the surrounding matrix, to proliferate and to 
migrate through the matrix [13, 16]. Intussusceptive angiogenesis is faster than sprouting 
angiogenesis since it does not primarily depend on the proliferation of endothelial cells [17]. 
Instead of endothelial cell proliferation, the capillary network increases its complexity and 
vascular surface through the insertion of multiple transcapillary pillars of connective tissue to 
partition the vessel lumen (Figure 3.2.C) [17]. Besides angiogenesis, the recruitment of bone 
marrow-derived cells (BMDCs) can also contribute to tumor vascularization (Figure 3.2.B). The 
majority of these BMDCs (e.g. neutrophils, leukocytes and tumor associated macrophages) are 
not physically incorporated in the vessel wall but gather in the tumor microenvironment to 
sustain angiogenesis [18]. Angioblasts (i.e. endothelial progenitor cells) on the other hand, can 
actually form blood vessels together with endothelial cells [16]. Vasculogenic mimicry is another 
way of vascularization that occurs mainly in aggressive tumors (Figure 3.2.D). It is a process of 
cell plasticity in which tumor cells dedifferentiate and gain the ability to form vessel-like 
structures [13, 16]. In addition, cooption can be used for vascularization by tumors in highly 
vascularized tissues, like the brain and the lungs (Figure 3.2.E). Hereby, tumor cells grow 
alongside pre-existing vessels at the early stage of tumor development. As the tumor progresses, 
apoptosis of the coopted endothelial cells is induced, provoking hypoxia and angiogenesis [13, 
16]. 
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Figure 3.2 - Representation of the different mechanisms involved in tumor vascularization. Tumor 
vascularization may occur through five different mechanisms. These mechanisms are: (A) tumor sprouting 
angiogenesis, (B) bone marrow-derived cells, (C) intussusceptive angiogenesis, (D) vasculogenic mimicry and (E) 
vascular co-option. Figure from de Oliveira et al. [13]. 
 
The tumor vasculature is characterized by its atypical morphology with irregularly shaped and 
tortuous vessels that lack the normal hierarchical arrangement of arterioles, capillaries and 
venules (Figure 3.3). The endothelial cells in tumor vessels show an anomalous gene expression 
and require growth factors for their survival. Furthermore, the cells don’t form tight monolayers 
like in normal blood vessels, resulting in a leaky vasculature [19, 20]. Together with pericytes, 
these aberrant endothelial cells generate a defective basement membrane, which contributes to 
tumor cell invasion. The basement membrane of tumor blood vessels has an irregular thickness as 
well as focal holes and broad extensions into the tumor stroma [19, 20]. In addition, the basement 
membrane and the pericytes are only loosely attached to the endothelial cells, which may weaken 
the blood vessels and increase the risk of hemorrhage [19, 20]. 
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Figure 3.3 - Comparison between normal and tumor blood vessels. A, B, D and E are schematic diagrams, at two 
magnifications, comparing the vasculature of a normal organ with that of a tumor. All blood vessels consists of 
endothelial cells (green), pericytes (red) and vascular basement membrane (blue). (A-B) The normal vasculature 
shows a hierarchy of arterioles (a), capillaries (b) and venules (c). Pericytes are wrapped around the arterioles and 
accompany the capillaries and venules. The thin basement membrane surrounds all mural and endothelial cells. (D-E) 
Tumor blood vessels show a disorganized, anastomotic network of vessels, lacking the normal hierarchy. Gaps are 
present between the endothelial cells. Pericytes are loosely associated with endothelial cells and have irregular 
shapes. The basement membrane has multiple layers in some places. Scanning electron micrographs (C) of normal 
blood vessels where a smooth and tight endothelial cell monolayer covers the luminal surface of the vessel and (F) of 
the disorganized endothelium of a blood vessel in a RIP-Tag2 tumor. Adapted from Baluk et al. [19]. 
 
3.2.3 Lymphangiogenesis in cancer 
Besides angiogenesis, also lymphangiogenesis occurs during inflammation, wound healing and 
carcinogenesis. The lymphatic network is an open ended, one way transport system, that drains 
extravasated fluid, collects lymphocytes and returns it to the blood circulation. There is 
accumulating evidence that the lymphatic systems plays a role in tumor progression. One of the 
early signs of malignant cancer spread is the metastasis to regional lymph nodes. This event 
represents the first step of tumor dissemination for many human cancers, including breast, colon 
and prostate cancer [21]. From the lymphatic system, cancer cells can disseminate to other tissues 
[16]. Tumor lymphangiogenesis has received less scientific attention than tumor angiogenesis 
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due to the lack of specific markers for lymphatic vessel endothelial cells (LVECs). Recent 
improvements of isolation techniques for LVECs has led to the discovery of LVEC markers like 
vascular endothelial growth factor receptor-3 (VEGFR-3), lymphatic vessel endothelial 
hyaluronan receptor -1 (LYVE-1), podoplanin and Prox1 [16, 22]. However, the mechanism of 
lymphangiogenesis has not yet been determined. Neo-lymphatic vessels in tumors may originate 
from bone marrow-derived endothelial cells in a similar way as new blood vessels [23]. Other 
studies claimed that new intratumoral lymphatic vessels are formed by “budding” of pre-existing 
lymphatic vessels and even by transformation of other cells into LVECs [24, 25]. The newly 
formed intratumoral lymphatic vessels have similar structures than new physiological vessels but 
the intratumoral vessels have thinner walls and lack tight junctions, facilitating tumor metastasis 
[26]. Intratumoral lymphatic vessels have been associated with lymph node metastasis as well as 
local recurrence and poor prognosis. Yet, peritumoral lymphatic vessels are believed to play a 
more important role in tumor metastasis because they provide more channels for lymphatic 
invasion and metastatic spread [27]. 
3.3 Angiogenic mediators in cancer 
3.3.1 Introduction 
Physiological angiogenesis is initiated by ischemic and hypoxic signaling and is tightly regulated 
by a balance between pro- and anti-angiogenic factors. A shift in this balance in favor of 
pro-angiogenic molecules causes an upregulated and continuous active angiogenic network 
during tumor angiogenesis [20]. Table 3.3 summarizes various mediators involved in tumor 
vascularization. Some factors contribute to several mechanisms, indicating the collaboration of 
these mechanisms to warrant tumor vascularization. From this overview the vascular endothelial 
growth factor (VEGF) family members emerge as crucial mediators as they are involved in every 
mechanism of tumor vascularization.  
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Sprouting angiogenesis 
VEGF-A Induction of eNOS; increase of vessel permeability; production of 
proteases; stimulation of endothelial cell proliferation, migration and 
survival; stimulation of tube formation 
PDGF-B Stimulation of mural cell proliferation and migration 
Ang1 Stimulation of endothelial cell survival and migration; induction of 
vessel stabilization  
Ang2 Pericyte/endothelial cell interaction loosening; stimulation of 
endothelial cell proliferation 
TGF-β Production of proteases and ECM; stimulation of endothelial cell 
proliferation and migration; modulation of junctional adhesion 
molecules 
VEGF-B Stimulation of endothelial and mural cell survival 
bFGF Production of proteases; stimulation of endothelial cell proliferation; 
stabilization of newly formed vessels 
PlGF Regulation of VEGF-A-mediated angiogenic switch 
IL-8 Stimulation of endothelial cell migration 
Intussusceptive angiogenesis 
VEGF-A Formation of larger vessels and small holes in the capillary plexus 
TGF-β Increasing intussusception 
Ang1 Formation of larger vessels and small holes in the capillary plexus 
Lymphangiogenesis 
VEGF-C Stimulation of proliferation, migration and survival of lymphatic 
endothelial cells 
VEGF-D Induces dilation of collecting lymphatic vessels 
Angioblast recruitment 
VEGF-A Induction of MMP-9; mobilization of endothelial precursor cells from 
the bone marrow; mobilization of circulating endothelial precursor 
cells in blood; differentiation of multipotent adult progenitor cells 
into endothelial cell. 
Ang1 Mobilization of endothelial precursor cells from the bone marrow 
PlGF Mobilization of endothelial precursor cells from the bone marrow 
SDF-1 Mobilization of endothelial precursor cells from the bone marrow; 
activation of MMP-9  
Selectins, integrins Adhesion of endothelial precursor cells to the vessel wall 
Cooption 
VEGF-A Induction of sprouting angiogenesis during remodeling 
Ang2 Induction of vessel degradation in absence of VEGF-A; induction of 
sprouting angiogenesis during remodeling (with VEGF-A) 
Vasculogenic mimicry 
PI3K Activation of MMP-2 
TFPI-2 Formation of vasculogenic network; activation of MMP-2 
VEGF-A Stimulation of tumor cell plasticity; induction of MMPs 
VE-cadherin Stimulation of MMP-2 and -9 
Table 3.3 - Factors contributing to tumor vascularization. Ang: angiopoietin, bFGF: basic fibroblast growth 
factor, IL: interleukin, PDGF: platelet-derived growth factor, PlGF: placental growth factor, SDF-1: stromal cell-
derived factor-1, PI3K: phosphatidylinositide 3 kinase, TFPI-2: tissue factor pathway inhibitor-2, TGF: transforming 
growth factor, VEGF: vascular endothelial growth factor. Adapted from Auguste et al [28] and supplemented with 
[16, 29-31]. 
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3.3.2 The VEGF family 
The human VEGF family consists of five members, namely VEGF-A, VEGF-B, VEGF-C, 
VEGF-D and placental growth factor (PlGF). The VEGF family of ligands interacts with three 
receptor protein-tyrosine kinases on endothelial cells and BMDCs, namely VEGFR1 (i.e. Flt-1), 
VEGFR2 (i.e. FLK-1/KDR) and VEGFR3 (Flt-4) as well as with two non-enzymatic 
co-receptors, neuropilin-1 and -2 (NP-1 and NP-2), which are expressed on vascular endothelium 
and neurons. In addition, several of the VEGF family members bind heparan sulfate 
proteoglycans that are found on the plasma membrane and in the extracellular matrix [32, 33]. 
The different VEGF members possess distinct binding specificities to the separate receptors, 
which may contribute to their divergent physiological functions (Table 3.4).  
3.3.2.1 VEGF-A 
VEGF-A (initially referred to as VEGF) is the first identified and best characterized member of 
the VEGF family. The VEGF-A gene is located on the short arm of chromosome 6 and contains 
eight exons separated by seven introns [34]. Alternative splicing results in the generation of four 
major isoforms of which VEGF-A165 (i.e. the mature protein of 165 amino acids) is the 
predominant one, followed by VEGF-A189, VEGF-A121 and VEGF-A206. Other isoforms are less 
commonly expressed in vivo and include VEGF-A183, VEGF-A165b, VEGF-A162, VEGF-A148 and 
VEGF-A145 [33, 35, 36]. VEGF-A exerts its angiogenic effects through interaction with 
VEGFR-1, VEGFR-2, NP-1 and NP-2. VEGFR-2 is the main receptor for mediating the 
angiogenic effects of VEGF-A, whereas VEGFR-1 has been proposed as a ‘decoy’ receptor [37, 
38]. The expression of VEGF-A is directly upregulated by HIF-1 under hypoxic conditions [39]. 
Furthermore, several major growth factors, including PDGF, EGF, TGF-α/-β and bFGF as well 
as inflammatory mediators like PGE2, TNF-α, IL-1α and IL-6 upregulate the expression of 
VEGF-A [35, 40]. 
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VEGF-A is the most effective and pleiotropic angiogenic factor, and induces proliferation, 
sprouting, survival and tube formation of endothelial cells [35, 41, 42]. In addition, VEGF-A also 
causes vasodilation and hyperpermeability of the endothelium [43, 44]. Besides its role on 
endothelial cells, VEGF-A induces mobilization of hematopoietic stem cells from the bone 
marrow, monocyte chemoattraction and osteoblast-mediated bone formation [35]. The vital role 
of VEGF-A in physiologic vasculogenesis is demonstrated in VEGF-A null mice, which die at 
embryonic day 8.5 due to impaired vasculogenesis. Also the loss of a single VEGF-A allele leads 
to embryonic death (between days 11 and 12) due to vascular deformities [45, 46]. Besides 
embryonic vasculogenesis, VEGF-A affects physiological angiogenic processes during wound 
healing, ovulation, maintenance of blood pressure, menstruation and pregnancy [35, 36]. 
Moreover, established vascular beds in the adult intestine, pancreas, thyroid and liver depend on 
VEGF-A for their maintenance and to prevent partial regression [47, 48]. Overexpression of 
VEGF-A in the skin causes abundant cutaneous angiogenesis and accelerates experimental tumor 
growth in transgenic mice, whereas loss of VEGF-A delays wound healing and impedes tumor 
formation [49-51]. VEGF-A is a key effector also in pathological conditions in which 
angiogenesis is involved, including cancer as well as ocular, inflammatory, vascular and ischemic 
diseases [40]. 
As described above, VEGF-A plays a critical role in all mechanisms of tumor vasculogenesis 
(Table 3.3). In line herewith, VEGF-A is expressed in practically all solid tumors and some 
hematological malignancies, including melanoma, glioblastoma, colorectal, gastric, lung, and 
breast cancer [52]. In addition, high levels of VEGF-A have been associated with disease 
progression and reduced survival in several cancers like lung, colorectal, gastric and breast cancer 
[53-56]. The critical involvement of VEGF-A in tumor vasculogenesis has led to the 
development of anti-angiogenesis therapy against VEGF-A, which will be further discussed in 
section 3.4.2.1. 
3.3.2.2 VEGF-B 
The VEGF-B gene is located on chromosome 11 and contains eight exons. Alternative splicing 
yields two isoforms, VEGF-B167 and VEGF-B186 [57, 58]. VEGF-B167 is the predominant form 
and binds to heparan sulfate proteoglycan whereas VEGF-B186 is secreted and freely diffusible 
[33]. The VEGF homology domain of VEGF-B is approximately 47% and 37% identical in 
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amino acid sequence to those of VEGF and PlGF respectively [59]. The promoter region of 
VEGF-B contains transcription factor binding sites for Sp1 and AP-2, just like VEGF-A. 
However, in contrast to VEGF-A, the VEGF-B promoter lacks HIF-1 and AP-1 sites, rendering 
VEGF-B expression insensitive to hypoxia or cold [60, 61]. Similarly, the expression of VEGF-B 
is not induced by molecular stimulators of VEGF-A expression like growth factors or steroid 
hormones [61, 62]. Whatever molecular mechanism regulates the expression of VEGF-B remains 
poorly understood [59, 63]. 
The in vivo role of VEGF-B has long been elusive since VEGF-B appeared to be inert without an 
obvious function under normal conditions [59, 63]. VEGF-B deficient mice are largely healthy 
and also their pathological angiogenesis is not affected in the organs studied, such as wounded 
skin and hypoxic lung or limb [59, 64, 65]. In addition, VEGF-B is the only VEGF family 
member whose transgenic overexpression did not induce angiogenesis or lymphangiogenesis 
[65]. However, instead of an angiogenic factor, VEGF-B has recently been shown to act as a 
survival factor for vascular endothelial and mural cells as well as their progenitor cells [29]. 
VEGF-B appears to be critical for the survival of blood vessels under pathological or stress 
conditions [59]. The survival effects of VEGF-B are established by promoting the expression of 
vascular pro-survival genes and inhibiting the expression of pro-apoptotic genes via VEGFR-1 
and NP1 [29, 66]. In addition to its survival effect on blood vessels, VEGF-B is also a survival 
factor for different types of neurons, including brain cortical neurons, retinal neurons and motor 
neurons in the spinal cord [66, 67]. In contrast, recent studies indicate a highly unexpected role of 
VEGF-B as an endogenous inhibitor of growth and angiogenesis under certain conditions [68]. 
Apparently, the specific context determines if VEGF-B will act as a survival factor or as an 
anti-growth/anti-angiogenesis factor (Figure 3.4). Under degenerative conditions, VEGF-B exerts 
a survival function to protect from cell death. VEGF-B acts instead as a suppressive factor to 
prevent the overgrowth of tumors, blood vessels or body mass in the presence of high levels of 
growth factors [59]. Thus, the role of VEGF-B appears to be safeguarding the homeostatic 
balance between blood vessel growth and blood vessel degeneration to ensure normal blood 
vessel density and integrity [59].  
VEGF-B expression has been demonstrated in a broad range of human cancers [69]. Increased 
VEGF-B expression levels have been observed in ovarian [70], colorectal [71], renal-cell [72] 
and prostate cancer [73]. In addition, the expression of VEGF-B correlates with disease stage in 
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neuroblastoma [74], and with advanced stage, tumor multiplicity and vascular invasion in 
hepatocellular carcinoma [75].  
 
Figure 3.4 - Multifaceted actions of VEGF-B under different conditions. Left: under degenerative conditions 
VEGF-B acts as a survival factor for different types of vascular cells to rescue the endangered blood vessels from 
degeneration. Middle: under normal conditions VEGFB displays no obvious function and appears to be inert. Right: 
in the presence of high levels of potent angiogenic/growth factors, VEGF-B may act as an inhibitory factor to 
prevent excessive blood vessel or tissue growth. Figure from Li et al. [59]. 
 
3.3.2.3 VEGF-C 
The VEGF-C gene is located on chromosome 4 and is made up of seven exons but does not 
undergo alternative splicing [58]. The synthesized precursor VEGF-C protein goes through an 
intricate proteolytic maturation that generates multiple processed forms which bind and activate 
VEGFR-3 and NP-2. Only the fully mature VEGF-C protein can also bind VEGFR-2 [33, 36, 
76]. The promoter region of VEGF-C contains binding sites for Sp-1, AP-2 and NF-κB 
transcription factors, which implies the regulation of VEGF-C expression by PKA and TGF-β 
(AP-2) as well as by IL-1 and TNF-α (NF-κB) [77]. Although an hypoxia responsive element 
(HRE) is absent, hypoxia has been shown to induce VEGF-C expression [78, 79]. In addition, 
VEGF-C is upregulated by PGE2 [80, 81]. 
VEGF-C induces proliferation, migration and survival of endothelial cells and is involved in 
developmental lymphangiogenesis as well as the maintenance of adult lymphatic vasculature 
[82]. The vital role of VEGF-C in the development of lymphangiogenesis is indicated by the 
embryonic lethality of VEGF-C null mice [83]. On the other hand, VEGF-C is not involved in 
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developmental angiogenesis because blood vessels are normal in VEGF-C null mice [83]. 
Heterozygous loss of VEGF-C results in a defective lymphatic development and causes 
lymphedema [83]. Adenoviral VEGF-C gene transduction induces the growth of lymphatic 
vessels in several different animal models [84, 85]. 
The expression of VEGF-C has been observed in a significant fraction of human cancers 
including breast [86], cervix [87], colon [88], lung [89], prostate [90] and stomach cancer [91]. 
VEGF-C plays an important role in tumor lymphangiogenesis and in the formation of lymph 
node metastases [92-94]. Moreover, several clinical studies in cancer patients have shown a 
positive correlation between the expression of VEGF-C and lymphatic invasion and metastasis as 
well as patient survival [90, 91, 93, 95]. 
3.3.2.4 VEGF-D 
The VEGF-D (or c-fos induced growth factor (FIGF)) gene is located on the X chromosome and 
contains seven exons [96]. Like VEGF-C, VEGF-D does not undergo alternative splicing but is 
synthesized as precursor protein. Proteolytic processing generates the mature form of VEGF-D 
which binds to both VEGFR-2 and VEGFR-3 [97]. In addition, VEGF-D binds NP-2 in a heparan 
sulfate-dependent manner [76]. The VEGF-D promoter contains a canonical AP-1 binding site 
[96]. The expression of VEGF-D is also regulated by hypoxia though no HRE was found in the 
promoter region [79, 98]. 
VEGF-D promotes the growth of blood and lymphatic vessels by induction of endothelial cell 
proliferation, migration, and survival [99]. However, VEGF-D null mice are viable and exhibit a 
normal lymphatic vasculature, suggesting that other growth factors can substitute for VEGF-D 
[100]. 
VEGF-D enhances lymphangiogenesis, angiogenesis and metastatic spread in experimental 
tumors [101]. In humans, the expression of VEGF-D is upregulated in breast [102], cervical 
[103], ovarian [104] and thyroid cancer [105] as well as in glioblastoma [106]. In addition, the 
expression of VEGF-D correlates with metastatic spread and poor outcome in melanoma [107], 
gastric [108], colorectal [109, 110], lung [111], and ovarian carcinomas [112]. However, other 
studies reported contradictory results with reduced VEGF-D expression in colorectal cancer [88] 
or an inverse correlation of VEGF-D expression with prognostic indicators in lung [113] and 
colorectal cancer [114].  
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3.3.2.5 PlGF 
The human PlGF gene is mapped on chromosome 14 and contains seven exons [115]. Alternative 
splicing yields four isoforms, namely PlGF-1 (PlGF131), PlGF-2 (PlGF152), PlGF-3 (PlGF203), and 
PlGF-4 (PlGF224), which all bind to VEGFR-1 [116-118]. PlGF-2 can also bind to both NP-1 and 
NP-2 [119]. The promoter region of PlGF contains recognition sequences for metal transcription 
factor 1 (MTF-1) and NF-κB, and both have been shown to modulate PlGF expression under 
hypoxic conditions [120, 121]. Although there is no HRE in the PlGF promoter region, the 
expression of PlGF is induced by hypoxia and stimulated by HIF-1α [122, 123]. 
PlGF is a pleiotropic factor regulating various biological activities and affecting multiple cell 
types. It exerts survival, migration, proliferation, metabolism and activation effects on vascular 
(i.e. endothelial and mural cells) as well as nonvascular cells (e.g. macrophages, BM-derived 
progenitors, fibroblasts, dendritic cells and neurons) [5]. Yet, PlGF is dispensable for 
development and physiolgical homeostasis in adults [124]. The redundancy of PlGF in health is 
demonstrated by PlGF knockout mice which do not exhibit an apparent phenotype [124]. 
However, these mice recover poorly after myocardial infarction. So, PlGF is important in 
pathological conditions where loss of PlGF impairs angiogenesis, collateral vessel growth during 
ischemia, wound healing, inflammation and cancer [124]. In line herewith, up-regulation of PlGF 
has been found in several conditions associated with pathologic angiogenesis like ischemic 
myocardial infarction [125], cerebral and limb ischemia [126, 127], as well as skin wound 
healing [128], sepsis [129], atherosclerosis [130], rheumatoid arthritis [131] and colitis [132]. 
Also in several cancers, the expression of PlGF is increased. In addition, PlGF levels correlate 
with tumor stage, invasion, metastasis, tumor recurrence and inversely with survival in several 
cancers, including those of the breast[133], stomach [134], lung [135] and colon [136]. PlGF may 
promote tumor growth via various mechanisms and cell types, summarized in figure 3.5. In 
addition, PlGF is associated with relapse of cancer patients treated with VEGF-A inhibitors 
[137]. The pleiotropic effects of PlGF on tumor angiogenesis has led to the development of an 
antibody against PlGF for the treatment of cancer. This antibody is further discussed in section 
3.4.2.1. 
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3.4 Anti-angiogenesis therapy  
3.4.1 Introduction 
Considering the dependence of a solid tumor on angiogenesis, therapies targeting tumor 
vascularization to starve the tumor to death appear highly promising. Such strategy was first 
proposed by Judah Folkman in 1971 [138]. New insights on the complex nature of angiogenesis 
along with the ongoing identification of pro- and anti-angiogenic factors, have provided several 
potential targets for the development of anti-angiogenesis therapies. However, except for drugs 
targeting VEGF ligands and receptors, most of the angiogenesis inhibitors failed to fulfill the 
expectations raised by promising preclinical results [139]. In addition, the concept of “starving” 
tumors by obliterating their blood supply has been revoked because aggressive angiogenesis 
Figure 3.5 - Pleiotropic effects of PlGF on multiple cell types in cancer. In a tumor, PlGF affects multiple cell 
types and processes. PlGF promotes angiogenesis by promoting proliferation and migration of endothelial cells, 
maturation of the vessels and mobilization of BM progenitors. The recruitment of macrophages provides additional 
angiogenic and lymphangiogenic factors. To suppress anti-tumor immune responses, PlGF reduces the accumulation 
and function of dendritic cells. PlGF also stimulates proliferation of tumor cells which in turn activate stromal cells 
to produce PlGF. In hepatocellular carcinoma, PlGF stimulates the proliferation and migration of activated hepatic 
stellate cells. TAM: tumor-associated macrophage. PlGF may also be implicated in the mobilization of BM-derived 
progenitor cells to pre-metastatic niches. Figure from Dewerchin et al. [5] 
54 | Introduction – Wound healing and cancer 
inhibition may aggravate tumor metabolism and/or promote metastasis [140, 141]. The current 
goal for anti-angiogenic therapy therefore is to correct the abnormal structure and functionality of 
tumor vessels, making them more accessible for the delivery of chemotherapeutic drugs [142]. 
Several anti-angiogenic therapies are currently approved for the treatment of various cancers and 
other therapies are in late stage-clinical development [20]. These are summarized in Table 3.5. 
Therapeutic 
agent/trade name 
VEGF family 
target(s) 
Target(s) other(s) Clinical development 
(main indications)  
References 
Monoclonal antibodies 
Bevacizumab/Avastin 
(Genentech Inc.) 
VEGF-A - Approved for CRC, 
RCC, NSCLC, GB,  
[143] 
Cetuximab/Erbitux 
(Bristol-Myers 
Squibb/Eli Lilly and 
Company) 
- EGFR Approved for CRC, 
H&NC  
[144] 
Panitumumab/Vectibix 
(Amgen) 
- EGFR Approved for CRC [145] 
Nimotuzumab/Theraloc 
(Oncoscience) 
- EGFR Phase III (GB, H&NC) [146, 147] 
Zalutumumab/HuMax-
EGFr (Genmab) 
- EGFR Phase III (H&NC) [148, 149] 
Necitumumab/IMC-
11F8 (Bristol-Myers 
Squibb/Eli Lilly and 
Company) 
- EGFR Phase III (NSCLC, 
CRC) 
[150, 151] 
Ramucirumab/IMC-
1121B (ImClone 
Systems) 
VEGFR-2 - Phase III (BC, HCC, 
NSCLC, GC, CRC) 
[152] 
IMC-18F1/ Icrucumab 
(ImClone Systems) 
VEGFR-1 - Phase II [153] 
mabPlGF/TB-403 
(Thrombogenics) 
PlGF - Phase I [154] 
Tyrosine kinase inhibitors 
Sorafenib/Nexavar 
(Bayer/Schering.) 
VEGFR-1, -2, -3 PDGFR, Raf, Flt3, 
c-Kit 
Approved for RC, 
HCC 
[155] 
Sunitinib/Sutent 
(Pfizer) 
VEGFR-1, -2, -3 PDGFR, c-Kit, 
Flt3, RET, CSF-1R 
Approved for RCC, 
HCC, GIST, PNET 
[156] 
Pazopanib/Votrient 
(GlaxoSmithKline) 
VEGFR-1, -2, -3 PDGFR, c-Kit, Itk, 
Lck, c-Fms 
Approved for RCC [157] 
Gefitinib/Iressa 
(AstraZeneca/Teva) 
- EGFR  Approved for NSCLC [158] 
Erlotinib/Tarceva 
(Genentech Inc.) 
- EGFR  Approved for NSCLC, 
PaC 
[159] 
Vandetanib/Caprelsa 
(AstraZeneca) 
VEGFR-2 EGFR, RET Approved for MTC [160] 
Lapatinib/Tykerb 
(GlaxoSmithKline) 
- EGFR, HER-2 Approved for BC [161] 
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Therapeutic 
agent/trade name 
VEGF family 
target(s) 
Target(s) other(s) Clinical development 
(main indications)  
References 
Tyrosine kinase inhibitors (continuation) 
Regorafenib/Stivarga 
(Bayer) 
VEGFR-2, -3 PDGFR, Raf, RET, 
c-Kit, FGFR 
Approved for CRC [162] 
Cabozantinib/Cometriq 
(Exelixis) 
VEGFR-2 c-Met, RET, c-Kit, 
Flt3 
Approved for MTC [163] 
Vatalanib/ PTK787 
(Novartis 
Pharmaceuticals) 
VEGFR-1, -2 PDGFR, c-Kit Phase III (CRC) [164] 
Neratinib/ HKI-272 
(Puma Biotechnology 
Inc.) 
- EGFR, HER-2 Phase III (BC) [165] 
Brivanib alaninate 
(Bristol-Myers Squibb) 
VEGFR-2 FGFR Phase III (HCC, CRC) [166] 
Cediranib/Resentin 
(AstraZeneca) 
VEGFR-1, -2, -3 - Phase III (CRC, GB, 
OC, BTC, NSCLC) 
[167-169] 
Icotinib (BetaPharma) - EGFR  Phase III (NSCLC) [170] 
Afatinib/Tomtovok 
(Boehringer Ingelheim) 
- EGFR, HER-2 Phase III (NSCLC, 
H&NC, BC) 
[171, 172] 
Axitinib/Inlyta (Pfizer) VEGFR-1, -2, -3 PDGFR, c-Kit Phase III (RCC, PaC) [173, 174] 
Nintedanib/Vargatef 
(Boehringer Ingelheim) 
VEGFR-2 PDGFR, FGFR  Phase III (NSCLC, 
OC, BTC) 
[175] 
Linifanib (Abott) VEGFR-1, -2, -3 PDGFR  Phase II (HCC ) [176] 
Motesanib (Amgen) VEGFR-1, -2, -3 PDGFR, c-Kit Phase III (NSCLC) [177] 
Tivozanib (Abott) VEGFR-1, -2, -3 - Phase III (RCC) [178] 
Dovitinib (Novartis 
Pharmaceuticals) 
VEGFR-1, -2, -3 FGFR  Phase III (RCC) [179] 
Receptor fusion protein 
Aflibercept/Zaltrap 
(Regeneron/Sanofi-
Aventis) 
VEGF-A, 
VEGF-B, 
PlGF 
- Approved for CRC [180] 
c-Fms: transmembrane glycoprotein receptor tyrosine kinase, c-Kit: v-kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog, c-Met: hepatocyte growth factor receptor, CSF-1R: colony stimulating factor 1 receptor, EGFR: 
epidermal growth factor receptor, FGFR: fibroblast growth factor receptor, Flt-3: fms-like tyrosine kinase 3, HER-2: 
human epidermal growth factor receptor 2, Itk: interleukin-2 receptor inducible T-cell kinase, Lck: leukocyte-
specific protein tyrosine kinase, PDGFR: platelet-derived growth factor receptor, PlGF: placental growth factor, Raf: 
murine leukemia viral oncogene, RET: ret proto-oncogene 
BC: breast cancer, BTC: biliary tract cancer, CRC: colorectal cancer, GB: glioblastoma, GC: gastric 
adenocarcinoma, GIST: gastrointestinal stromal tumor, H&NC: head and neck cancer, HCC: hepatocellular 
carcinoma, MTC: medullary thyroid cancer, NSCLC: non-small cell lung cancer, OC: ovarian cancer, PaC: 
pancreatic cancer, PNET: pancreatic neuroendocrine tumors, PrC: prostate cancer, RCC: renal cell carcinoma 
 
Table 3.5 - Approved and late-stage development therapeutic agents that target angiogenesis in the treatment 
of cancer. Adapted from Hoff et al. [20] and Tugues et al. [181]. 
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3.4.2 VEGF family-targeting therapy 
Because the VEGF family and their receptors are crucial mediators involved in every mechanism 
of tumor vascularization, it is not surprising that many therapeutic agents have been developed 
that target in one way or the other these mediators of tumor angiogenesis. These therapeutic 
agents are either monoclonal antibodies or tyrosine kinase inhibitors (Table 3.5, Figure 3.6).  
 
 
Figure 3.6 - VEGF signaling inhibitors and their targets. The human VEGF family members (VEGF-A, -B, -C, -
D and PlGF) bind to their cognate receptors (VEGFR1, VEGFR2 and VEGFR3) as indicated. VEGF antagonists 
either interfere with binding of VEGF ligands on the extracellular domain of receptors (Bevacizumab, VEGF-Trap, 
Veglin, IMC-18F1, Ramuciumab/CDP791) or compete for ATP-binding to the intracellular kinase domain (axitinib, 
brivanib, cediranib, linifanib, pazopanib, sorafenib, sunitinib, tivozanib, vandetanib, vatalanib). Figure adapted from 
Tugues et al. [181] 
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3.4.2.1 Monoclonal antibodies 
Monoclonal antibodies bind either a VEGF ligand or a receptor for VEGF and consequently 
inhibit the interaction between ligand(s) and receptor(s) (Figure 3.6). 
Bevacizumab is a humanized monoclonal antibody against VEGF-A and the first approved anti-
angiogenic agent for the treatment of cancer. In preclinical xenograft models, tumor growth and 
metastasis were inhibited by bevacizumab as single-agent therapy. Combination of bevacizumab 
with chemotherapy or radiotherapy, resulted in a synergistic inhibition of tumor growth with 
decreased vascular permeability and tumor vessel diameter and density [182]. Several 
mechanisms are postulated for the precise mechanism by which bevacizumab enhances 
chemotherapy. These mechanisms include: normalization of the tumor vasculature causing 
improved delivery of cytotoxic agents [183]; direct effect on cells that are dependent on VEGF-A 
as a growth and survival factor [184]; sensitization of tumor endothelial or circulating cells to 
cellular damage [185]. Clinical phase I trials have found bevacizumab to be relatively well-
tolerated and non-toxic [186]. The addition of bevacizumab to IFL chemotherapy (i.e. ironotecan, 
5-FU and leucovorin) significantly increased the median duration of survival of metastatic 
colorectal cancer patient with 4.7 months as compared to IFL alone [187]. These overall positive 
results have led to the approval of bevacizumab by the FDA and EMEA [188]. Since its approval 
in 2004, bevacizumab is used as first-line treatment for metastatic colorectal cancer in 
combination with established chemotherapeutic agents, including 5-FU, capecitabine, irinotecan 
and oxaliplatin, as well as combinations of these agents [188-190]. The ECOG E32001 study 
found that the addition of bevacizumab to FOLFOX4 (i.e. oxaliplatin, 5-FU and leucovorin) 
significantly increased the overall survival and progression-free survival by 2.1 and 2.6 months 
respectively, as compared to FOLFOX4 alone in previously treated metastatic colorectal cancer 
patients [191]. These results led to the approval in 2006 of bevacizumab also as second-line 
treatment for metastatic colorectal cancer [32, 188]. In addition to its usage as first- and second-
line treatment of metastatic colorectal cancer, the use of bevacizumab has expanded to non-small 
cell lung cancer, glioblastoma and metastatic renal cell carcinoma [143]. 
Ramucirumab is a fully human monoclonal antibody that binds VEGFR-2, thus blocking 
VEGF-A from binding. As such, preclinical studies showed that ramucirumab inhibits cell 
                                                 
1
 Eastern Cooperative Oncology Group E3200 
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proliferation in vitro as well as tumor progression in murine xenograft models [152, 192]. 
Ramucirumab was well tolerated in phase I clinical trials and these studies also showed 
promising levels of partial responses and stable disease [193]. Therefore, ramucirumab is 
currently being evaluated in about 30 clinical studies, including phase III clinical trials for 
colorectal cancer, gliomas, head and neck cancer as well as breast, gastric and non-small cell lung 
cancer (Table 3.5) [194].  
IMC-18F1 is a fully human monoclonal antibody that targets the human VEGFR-1, thereby 
blocking the binding of VEGF-A, VEGF-B, and PIGF to the receptor. Based on preclinical 
studies, IMC-18F1 may provide clinical benefit to cancer patients as it suppressed tumor growth 
in xenograft models [153, 195]. Phase I clinical trials have indicated a favorable safety profile for 
IMC-18F1 mono-therapy [196]. IMC-18F1 is currently evaluated in phase II clinical trials for the 
treatment of advanced colorectal, breast and urologic cancers [197-199]. 
TB-403 is a humanized recombinant monoclonal antibody directed against PlGF. By binding to 
PlGF, TB-403 inhibits the interaction of PlGF with VEGFR-1, which may result in the inhibition 
of tumor angiogenesis and tumor cell proliferation. TB-403 inhibits growth and metastasis in 
various tumor models and exhibits an exceptional safety profile in preclinical in vivo models 
compared with other anti-angiogenic treatments [200]. Based on the favorable safety profile, 
which was confirmed in phase I clinical studies, and supportive preclinical proof-of-concept 
studies, further clinical studies with TB-403 are now in progress [201, 202]. 
3.4.2.2 Tyrosine kinase inhibitors  
Tyrosine kinase inhibitors are small molecular weight compounds that block VEGFR2 signaling 
by competing for the ATP-binding site in the kinase. Often, these inhibitors target a broad 
spectrum of kinases due to the high degree of conservation of the ATP-binding sites of tyrosine 
kinases [203]. Nevertheless, tyrosine kinase inhibitors differ from each other in the spectrum of 
targeted kinases, their pharmacokinetics as well as specific adverse effects [204]. Although 
tyrosine kinase inhibitors are overall well tolerated, they are also associated with an increased 
risk of developing potentially life-threatening conditions such as arterial thrombotic events, 
bleeding and congestive heart failure [204, 205]. Selective tyrosine kinase inhibitors may 
minimize these adverse effects. Multi-target kinase inhibitors or combination therapy containing 
these inhibitors may affect multiple angiogenic pathways, thus providing a broader efficacy and 
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resistance [203]. Currently, six tyrosine kinase inhibitors targeting VEGFR(s) are approved for 
use in specific cancers, namely sorafenib, sunitinib, pazopanib, vandetanib, regorafenib and 
cabozantinib [155-157, 160, 162, 163]. Many others are in late-stage clinical development (Table 
3.5). Preclinical and clinical results of these inhibitors are reviewed by Ribatti [206] and specific 
for advanced colorectal cancer by Grothye and Allegra [188]. 
3.4.2.3 VEGF-A Trap  
Aflibercept also known as VEGF-Trap, is a recombinant, decoy receptor fusion protein that binds 
VEGF-A with higher affinity than its native receptors. In addition, it prevents also VEGF-B and 
PlGF from binding to their receptors [207, 208]. For this purpose, it comprises the second 
immunoglobulin (Ig) domain of VEGFR-1 and the third Ig domain of VEGFR-2, fused to the 
constant region of human IgG1 [209]. In different tumor mouse models, aflibercept significantly 
reduces tumor growth and vascularization and extends survival [209, 210]. These preclinical 
results have supported the investigation of aflibercept in clinical trials. Phase I and II clinical 
trials have revealed a significant survival advantage and patient-dependent clinically meaningful 
results, as well as a manageable safety profile [210]. Aflibercept is currently in phase III clinical 
trials for the treatment of prostate, ovarian and non-small cell lung cancer and has been approved 
for the treatment of advanced colorectal cancer in 2012 (Table 3.5).  
3.4.3 Resistance to VEGF therapy 
Despite clinical benefits such as improved 2-year survival in patients treated with drugs targeting 
the VEGF pathway, the global impact of the current agents is relatively modest as no gains have 
been made in 5-year survival [211]. VEGF targeting agents may lead to disease stabilization and 
prolonged periods of progression free or overall survival in patients with metastatic disease, but 
eventually tumors become non-responsive or do not respond at all. As a consequence, the 
benefits in progression free or overall survival time are mostly measured in months [140]. 
A tumor may evade specific anti-angiogenic therapies by the activation of compensatory 
mechanisms involving alternative pro-angiogenic signaling, resulting in intrinsic or adaptive 
resistance. Signaling by redundant angiogenic pathways are a major mechanism of this resistance 
[212]. Alternative pathways in human non-cancerous cells may help to overcome deviations in 
normal signaling, but in cancer cells the same pathways may offer resistance to current anti-
VEGF therapies. In line herewith, treatment of pancreatic tumors with anti-VEGFR agents has 
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been demonstrated to increase the expression levels of among others members of the FGF family 
and angiopoietins [213]. Increased levels of these factors may allow persisting neovascularization 
despite VEGF-A blockade. Also increased levels of non-tumor-derived pro-angiogenic factors 
may contribute to resistance. Systemic increases in proangiogenic factors like VEGF-A, PlGF, 
G-CSF, bFGF and SDF-1 have been observed after administration of VEGF(R) inhibitors and in 
colon cancer recurrence [214, 215]. The increased systemic levels of these factors may provide 
alternative pathways for angiogenesis as well as engulf anti-VEGF therapy, causing resistance. In 
addition, these factors may also facilitate secondary metastasis [216]. Other major mechanisms of 
resistance derives from the selection of hypoxia-resistant tumor cells by anti-angiogenic drugs 
and recruitment of myeloid and circulating cells for VEGF-independent angiogenesis [140, 217]. 
Approaches to overcome this resistance may include the combined blocking of redundant 
angiogenic pathways and ligands, inhibition of cellular migration and the use of vascular 
disruptive agents such as tubulin-binding agents, flavonoids and TNF [216, 218]. Clearly, such 
approaches will require an individualized approach based on biomarkers and/or gene expression 
profiling for the selection of responders to a specific therapy. Wild-type KRAS is a predictive 
marker for EGFR-therapy since activating mutations in KRAS are recognized as a strong 
predictor of resistance to EGFR-targeted drugs [219]. However, no others biomarkers are yet 
known to predict reliably whether or not a patient should receive a particular therapy [211]. 
Continued research to fully clarify cellular and molecular angiogenesis networks and to identify 
eligible predictive biomarkers will lead us to treat cancer patients with personalized combination 
treatments exhibiting the highest level of efficacy and safety. 
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Objectives and strategy 
The present assessment of the expression levels in colon cancer of the individual VEGF family 
members still has some major limitations. Despite several studies documenting the (mRNA) 
overexpression of certain VEGF family members, the data are scattered and often contradictory. 
As a result it is challenging to obtain a global picture of the expression of the VEGF family in 
colon cancer. We have assessed two potential mechanisms that may explain why such 
contradictory and inconsistent results are reported in literature. For a start, several studies have 
used samples obtained by two different clinical procedures, namely surgical resection or 
colonoscopic biopsy. We therefore compared in Chapter 4, the expression patterns of the VEGF 
family members between healthy colon and colon carcinoma samples obtained by either biopsy 
or resection. COX2, 5-LOX, glucose transporter 1 (GLUT-1) and carbonic anhydrase IX (CAIX) 
were included as markers for cellular stress and hypoxia. This analysis revealed the occurrence of 
sampling-induced hypoxia in resection samples which influenced the reliability of the VEGF 
family members as colon cancer markers.  
Secondly, published studies have analyzed the VEGF members individually and/or in small 
groups by means of different analytical methods. In Chapter 5, we conducted a systematic and 
comprehensive study to determine in a single experimental setup the mRNA expression 
signatures of all VEGF family members in colon carcinoma samples. Comparison with colon 
adenomas and liver metastases further allowed addressing the mRNA expression of VEGFs 
during malignant progression. In addition, we determined to what extent individual carcinoma 
samples concomitantly express VEGF family members, and also the degree to which these 
individual signatures evolve during progression from adenoma to carcinoma and liver metastasis. 
These expression signatures were subsequently compared with clinicopathological variables to 
verify if they could be associated with a specific feature of malignancy. Next we verified if the 
observed mRNA expression patterns could be translated to serum levels in order to offer a much 
needed non-invasive and cost-effective screening method for the detection of colon cancer. 
Finally, we aimed to clarify the molecular basis of the progression-associated expression patterns 
of the VEGF family members observed in human colon cancer. Inflammatory eicosanoids 
derived from COX2 and 5-LOX are pivotal factors in both angiogenesis and tumorigenesis. 
Because COX2 and 5-LOX have been associated with the expression of VEGF-A and VEGF-C, 
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we performed a similar systematic expression analysis in Chapter 6 to determine the mRNA 
expression levels of COX2 and 5-LOX in relation to the mRNA expression of VEGF family 
members during malignant progression from adenoma to carcinoma. To verify the causal relation 
of the observed associations between the expression of eicosanoid enzymes and VEGF family 
members and the higher risk of malignancy, human colon cell lines were subsequently treated 
with eicosanoid-stimulatory and -inhibitory conditions in two in vitro experiments. In a first 
setup, we verified the effect of eicosanoids on malignancy with the invasiveness of colon cancer 
cells as a measurable criteria for malignancy. In a second setup, we verified the impact of COX2- 
and 5-LOX-derived eicosanoids on the mRNA expression of COX2, 5-LOX and the VEGF 
family members. 
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How clinical procedures impact science 
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Abstract 
mRNA levels of members of the Vascular Endothelial Growth Factor family (VEGF-A, -B, -C, -D, 
Placental Growth Factor/PlGF) have been investigated as tissue-based markers of colon cancer. These 
studies, which used specimens obtained by surgical resection or colonoscopic biopsy, yielded 
contradictory results. We studied the effect of the sampling method on the marker accuracy of VEGF 
family members. Comparative RT-qPCR analysis was performed on healthy colon and colon carcinoma 
samples obtained by biopsy (n=38) or resection (n=39) to measure mRNA expression levels of individual 
VEGF family members. mRNA levels of genes encoding the eicosanoid enzymes cyclooxygenase 2 
(COX2) and 5-lipoxygenase (5-LOX) and of genes encoding the hypoxia markers glucose transporter 1 
(GLUT-1) and carbonic anhydrase IX (CAIX) were included as markers for cellular stress and hypoxia. 
Expression levels of COX2, 5-LOX, GLUT-1 and CAIX revealed the occurrence in healthy colon resection 
samples of hypoxic cellular stress and a concurrent increment of basal expression levels of VEGF family 
members. This increment abolished differential expression of VEGF-B and VEGF-C in matched 
carcinoma resection samples and created a surgery-induced underexpression of VEGF-D. VEGF-A and 
PlGF showed strong overexpression in carcinoma samples regardless of the sampling method. Sampling-
induced hypoxia in resection samples but not in biopsy samples affects the marker-reliability of VEGF 
family members. Therefore, biopsy samples provide a more accurate report on VEGF family mRNA 
levels. Furthermore, this limited expression analysis proposes VEGF-A and PlGF as reliable, sampling 
procedure insensitive mRNA-markers for molecular diagnosis of colon cancer.  
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4.1.1 Introduction 
Colorectal cancer is the second most commonly diagnosed cancer in females and the third in 
males. It is the second leading cause of cancer-related death [1]. Worldwide, it accounts for over 
1.2 million new cases every year, and in 2008 it caused about 608,700 deaths. Colon carcinoma 
evolves from a premalignant adenoma precursor stage or polyp. The progression from adenoma 
to carcinoma is a multistep process involving cumulative genetic and epigenetic alterations in 
proto-oncogenes, tumor suppressor genes and DNA repair genes [2-4]. 
Colon carcinoma tissue samples have been intensively studied in search for tissue-based 
diagnostic, prognostic and predictive markers. Samples are routinely obtained by two different 
clinical procedures. During colonoscopy, which is the gold standard for detection of colon 
carcinoma and adenoma, biopsies of polyp-like extrusions are obtained for pathological 
examination, and these extrusions are removed whenever possible. In surgical resection, 
carcinoma-like outgrowths are removed by cutting out part of the colon containing the suspected 
outgrowth as well as some surrounding healthy tissue. However, little is known about the impact 
of the sampling method on the overall condition of the sampled tissue or the expression levels of 
potential cancer biomarker genes. 
Vascular Endothelial Growth Factor (VEGF; VEGF-A) has long been proposed as a biomarker 
for cancer as well as a target for anti-angiogenic cancer therapy. Several studies consistently 
showed elevated VEGF-A expression levels in most solid tumors, including colon carcinoma [5-
9]. Furthermore, these elevated expression levels have been correlated with tumor progression 
[10-12]. VEGF-A is an inflammation and hypoxia responsive gene, and its biomarker function is 
believed to be related to the hypoxic growth conditions characteristically associated with rapidly 
growing solid tumors and to its ability to promote the development of new vasculature [11, 13].  
Fewer studies addressed the mRNA expression levels in colon cancer of the other VEGF family 
members: VEGF-B, VEGF-C, VEGF-D and Placental Growth Factor (PlGF). Furthermore, some 
of these studies reported contradictory results. As such, similar expression levels of VEGF-C in 
healthy and carcinoma tissue were reported in three studies [5, 8, 14]. However, other studies 
reported higher levels [6, 7] that were correlated with lymph node metastasis and poor prognosis 
[8]. 
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We believe that some of these controversial findings might have resulted from the use of different 
types of colon tissue samples. Several studies performed expression analysis on samples obtained 
during surgical resection [5, 7, 8]. Others used biopsies obtained during colonoscopy [14] or did 
not specify the sampling method [6]. Yet, both sampling procedures differ strikingly; the 
acquirement of colon biopsies requires only minutes, whereas during surgical resection part of 
the colon is clamped off for a considerable length of time. To examine to what extent the 
sampling procedure may affect VEGF gene expression, we analyzed mRNA expression levels of 
all five VEGF family members in colon carcinoma samples obtained by biopsy and in others 
obtained by surgical resection. mRNA expression levels in healthy colon tissue of the eicosanoid 
enzymes, cyclooxygenase 2 (COX2) and 5-lipoxygenase (5-LOX), were included as markers of 
cellular stress induced by inflammation, tissue damage and/or hypoxia [15-19]. In addition, 
mRNA expression levels of glucose transporter 1 (GLUT-1) and carbonic anhydrase IX (CAIX) 
were included as markers of hypoxia [20, 21]. 
4.1.2 Materials and methods  
Biological samples 
Samples were obtained from primary colon carcinomas either by biopsy (n=38) or by surgical 
resection (n=39) at the Ghent University Hospital. Carcinomas were sampled in the infiltrating 
area of the growth, avoiding the necrotic center. Histopathological examination confirmed the 
carcinoma state of the tissue. From each patient, a corresponding healthy colon mucosa sample 
was taken from the same colon segment. None of the patients had received chemo- or 
radiotherapy before surgery or colonoscopy. Immediately after isolation, the biopsies were placed 
in RNAlater® Solution (Ambion/Applied Biosystems, Foster City, CA). Surgical resection 
samples were also placed in RNAlater® Solution at the end of the surgical procedure and after an 
initial examination by the pathologist. All samples were kept at –80°C until RNA extraction. The 
clinicopathological features of the patients are summarized in table 4.1. All tissues were obtained 
following informed consent of the patients and approval of the study by the Ethics Committee of 
the Ghent University Hospital. 
RNA extraction, RNA quality control and cDNA synthesis 
Total RNA was extracted with the RNeasy Plus mini kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s instructions. This kit contains a gDNA-elimination step to avoid gDNA 
Results – How clinical procedures impact science | 83 
 
 
contamination. After extraction, RNA quality and integrity was verified using an RNA 6000 
Nano Chip Kit on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). 
Only samples with adequate quality and integrity (77/80) were used for the RT-qPCR analysis. 
cDNA was synthesized from 1 µg of total RNA using Superscript® II reverse transcriptase 
(Invitrogen, Merelbeke, Belgium) according to the manufacturer’s instructions. 
RT-qPCR 
Real-time quantitative PCR (RT-qPCR) was performed using the LC 480 Sybr Green I master kit 
on a LightCycler® 480 Real-Time PCR system (both from Roche Applied Science, Penzberg, 
Germany). Primers were designed using PrimerSelect (DNASTAR, Madison, USA) and 
purchased from Invitrogen. The primers were designed for gene-specific expression profiling and 
cover all splice variants. The sequences of the forward and reverse primers were as follows: 
VEGF-A 5’-TGAGTTGCCCAGGAGACCAC-3’ and 5’-GAAGGGGAGCAGGAAGAGGAT-
3’; VEGF-B 5’-CCGGAAGCTGCGAAGGTGACA-3’ and 5’-
GGGAGACAAGGGATGGCAGAAGAG-3’; VEGF-C 5’-CACGGCTTATGCAAGCAAAGA-
3’ and 5’-TCCTTTCCTTAGCTGACACTTGT-3’; VEGF-D 5’-
GCAGCCCTAGAGAAACGTG-3’ and 5’-AGGTGCTGGTGTTCATACAGAT-3’; PlGF 5’-
TGCGGCGATGAGAATCTGC-3’ and 5’-AGCGAACGTGCTGAGAGAAC-3’; COX2 5’-
TTGCTGGAACATGGAATTACC-3’ and 5’-TGCCTGCTCTGGTCAATG-3’; 5-LOX 5’-
TGGCGCGGTGGATTCATAC-3’ and 5’-CAGGGGAACTCGATGTAGTCC-3’; GLUT-1 5’-
CTTTGTGGCCTTCTTTGAAGT-3’ and 5’-CCACACAGTTGCTCCACAT-3’; CAIX 5’-
GGAAGGCTCAGAGACTCA-3’ and 5’- CTTAGCACTCAGCATCAC-3’. All samples were 
assayed in triplicate. Relative expression values were calculated using the 2(-delta delta C(T)) 
method and were normalized against reference genes: tata-binding protein (TBP) and succinate 
dehydrogenase complex subunit A (SDHA) (primers: TBP 5’-CGGCTGTTTAACTTCGCTTC-3’ 
and 5'-CACACGCCAAGAAACAGTGA-3’; SDHA 5’-TGGGAACAAGAGGGCATCTG-3’ 
and 5’-CCACCACTGCATCAAATTCATG-3’). In these calculations we took into account the 
PCR efficiency of the individual PCR reactions, calculated on the basis of linear regression as 
described in Ruijter et al [22]. For the comparison between healthy colon biopsies and resections, 
the normalized relative expression values were scaled against the median of the healthy biopsies 
(median of biopsies set to 1). The specificity of amplification was confirmed by evaluation of the 
melting curves. 
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Variable Number of patients 
Biopsy Resection 
Sex 
    Male   22 25 
    Female 16 14 
Age at diagnosis 
    Median age (range, years) 70 (39–85) 67 (39–84) 
Site of tumor 
    Sigmoid 20 14 
    Colon descendens 2 2 
    Colon transversum 1 4 
    Hepatic flexure 1 3 
    Colon ascendens 5 5 
    Caecum and valve of Bauhin 8 7 
    Not specified 1 4 
Tumor grade 
    Low 3 5 
    Moderate 18 24 
    High 12 7 
    Unknown 5 3 
Dukes classification 
    Dukes’ A 3 8 
    Dukes’ B 15 12 
    Dukes’ C 6 12 
    Dukes’ D 13 5 
    Unknown 1 2 
T category 
    T1-T2 3 8 
    T3-T4 26 29 
    Tx 9 2 
Lymphatic spread 
    N0 18 21 
    N+ 10 16 
    Nx 10 2 
Metastasis 
    M0/Mx 25 34 
    M+ 13 5 
Table 4.1 - Clinicopathological features of the colon carcinoma patients 
 
Statistical analysis 
Statistical analysis was performed using the GraphPad Prism® software (GraphPad Software Inc., 
La Jolla, California, USA). Statistical significance of comparisons between two independent 
groups was determined with the two-tailed Mann-Whitney U test. The comparison between 
paired samples was performed with the Wilcoxon signed-rank test.  The accuracy of the markers 
was determined with receiver operator characteristic curves (ROC). The statistical significance of 
the difference between two areas under the ROC curves was calculated by the method of DeLong 
et al. and performed with MedCalc® software (MedCalc Software, Mariakerke, Belgium) [23]. 
Significant p-values were ranked as p<0.05 (*), p<0.01 (**) and p<0.001 (***). 
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4.1.3 Results 
Surgical resection induces hypoxic cellular stress in healthy colon tissue 
To examine to what extent the sampling procedure (biopsy versus surgical resection) may affect 
the overall condition of the sampled tissue, we analyzed the mRNA expression of COX2 and 
5-LOX in samples of healthy colon tissue. As shown in figure 4.1A , expression levels of COX2, 
an inflammation and hypoxia responsive gene used here as a biomarker of cellular stress, were 
significantly higher in resections than in biopsies. Also the expression levels of GLUT-1 and 
CAIX, two hypoxia markers, were significantly increased in resected samples compared to biopsy 
samples (Figure 4.1C-D). Finally, the expression levels of 5-LOX, included here as a control gene 
induced by cellular stress but insensitive to hypoxia, were identical in the two groups of samples 
(Figure 4.1B). Combined, these results indicate the induction by the surgical resection procedure 
of hypoxic cellular stress in the resected tissue. 
 
 
Figure 4.1 – Effect of sampling method on the expression of inflammatory and hypoxic stress responsive genes 
in healthy colon tissue samples. Relative mRNA expression levels of the inflammatory eicosanoid enzymes 
COX2 (A) and 5-LOX (B) and of the hypoxia markers GLUT-1 (C) and CAIX (D) are shown for healthy colon 
biopsy and healthy colon resection samples. Expression levels were normalized against reference genes TBP and 
SDHA and were scaled against the median of the biopsy samples (median set to 1). Expression data are depicted as 
scatter plots of the values obtained for each individual sample. The horizontal line represents the median; ns: not 
significant; *: p<0.05; **: p<0.01; ***: p<0.001 with Mann-Whitney U Test. 
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Surgical resection increases expression levels of VEGF family members in healthy colon 
tissue 
We next determined whether the occurrence of surgery-related hypoxic stress in resected healthy 
tissue samples was reflected in the expression levels of the individual VEGF family members. As 
shown in figure 4.2, highly significant (p<0.001) differences between resected and biopsy healthy 
colon samples were observed for all the VEGF family members. For these genes, the median 
expression levels were two- to three-fold (VEGF-A, -B, -C and PlGF) higher in resected than in 
biopsy samples, up to a striking 22-fold increase for VEGF-D. 
 
Figure 4.2 – Effect of sampling method on the expression of VEGF family members in healthy colon tissue 
samples. Relative mRNA expression levels of VEGF-A (A), VEGF-B (B), VEGF-C (C), VEGF-D (D) and PlGF (E) 
are shown for healthy colon biopsy and healthy colon resection samples. Expression levels were normalized against 
reference genes TBP and SDHA and were scaled against the median of the healthy colon samples (median set to 1). 
Expression data are depicted as scatter plots of the values obtained for each individual sample. The horizontal line 
represents the median; ***: p<0.001 with Mann-Whitney U Test. 
 
The sampling procedure affects the biomarker read-out of VEGF family members 
We next assessed the extent to which the sampling-induced differences in VEGF gene expression 
observed in healthy tissue affected the magnitude of the difference between healthy and 
carcinoma tissue. To that end, we compared VEGF gene induction in colon carcinoma to 
matched healthy tissue samples obtained by biopsy or by surgical resection. Expression levels of 
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VEGF-A were significantly induced in carcinoma tissues towards healthy tissues independent of 
the sampling method (Figure 4.3A). However, for the other VEGF family members, the 
magnitude of the difference between healthy and carcinoma tissue in resection samples was 
affected by the increment of expression in healthy tissue caused by the surgical sampling 
procedure. For VEGF-B, VEGF-C and PlGF, this resulted in reduced expression differences 
between healthy and carcinoma tissue in resected samples (Figure 4.3B, C and E). The 
consequences are most pronounced for VEGF-B that albeit significantly induced in biopsy 
carcinoma samples, no longer showed significance in carcinoma samples obtained by surgical 
resection (Figure 4.3B). A similar sampling procedure induced turnaround of biomarker value is 
observed for VEGF-D, although in an opposite direction. Here, the pronounced increase in the 
expression of VEGF-D in healthy resected tissue as opposed to the near absence of such an 
increase in carcinoma tissue resulted in a highly significant underexpression of VEGF-D in 
carcinoma resection samples (Figure 4.3D). On the contrary, in biopsy samples no difference in 
VEGF-D expression between healthy colon and colon carcinoma samples was observed.  
 
Figure 4.3 – Influence of sampling method on the biomarker read-out of VEGF family members. n-Fold 
induction levels in carcinoma samples of VEGF-A (A), VEGF-B (B), VEGF-C (C), VEGF-D (D) and PlGF (E) are 
shown. The n-fold induction value represents the ratio of the expression value of the carcinoma sample against the 
expression value of the paired healthy sample. The box represents the median with interquartile range and the 
whiskers represent minimum and maximum ratios. ns: not significant; *:p<0.05; ***: p<0.001 with Wilcoxon 
signed-rank test. 
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Cancer biomarker accuracy of VEGF family members  
Receiver-operating characteristics (ROC) analysis is commonly used to assess the reliability and 
accuracy of potential biomarkers. ROC-based assessment of the individual VEGF family 
members as biomarkers for colon cancer identified overexpression of PlGF (AUC 0.9342) as the 
most effective mRNA-marker for samples obtained by biopsy with VEGF-A (AUC 0.8760) and 
VEGF-C (AUC 0.8977) following as close seconds (figure 4.4). This ranking however changes 
dramatically when considering samples obtained by resection. Here, underexpression of VEGF-D 
emerges as the most potent biomarker with an AUC of 0.9047 (p<0.0001) and a ROC-curve 
significantly different (p<0.0001) from the biopsy curve (Figure 4.4D). Overexpression of 
VEGF-A (AUC 0.8573) now precedes PlGF (AUC 0.8231), VEGF-C (AUC 0.6200) and 
especially VEGF-B (AUC 0.5621) shows strongly reduced accuracy as colon cancer mRNA-
marker (Figure 4.4).  
4.1.4 Discussion 
Biomarker expression profiles have become a valuable tool in diagnostic research, patient 
management and cancer therapy. We explored the influence of different sampling methods on the 
expression of VEGF family biomarkers in colon cancer. Samples obtained by either biopsy or 
surgical resection were compared for the differential expression of VEGF-A, VEGF-B, VEGF-C, 
VEGF-D and PlGF. To examine the occurrence of cellular stress caused by the sampling 
procedure, the expression levels of the eicosanoid enzymes COX2 and 5-LOX were quantified in 
healthy colon tissue. COX2 is a key inflammatory enzyme, and its expression is strongly induced 
by NF-κB and HIF-1 transcription factors in response to inflammatory insults and hypoxic 
growth conditions, respectively [19, 24-28]. In contrast, expression of 5-LOX is largely 
insensitive to hypoxia but is similarly induced by various inflammatory insults [19, 29, 30]. 
Strikingly, we observed a pronounced expression increment of COX2 in healthy colon resection 
samples relative to healthy biopsy samples. This was not the case for 5-LOX. This differential 
expression pattern of COX2 as opposed to 5-LOX indicates that considerably more hypoxic stress 
may be present in resection samples than in samples obtained by biopsy. The presence of hypoxia 
in resection samples was further substantiated by the significantly increased expression in 
resection samples of the hypoxia markers GLUT-1 and CAIX. There is a large difference in the 
time needed to obtain samples by the two procedures. Whereas the collection of colon biopsies 
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requires only minutes, surgical resection takes 30 to 90 minutes, during which the colon is 
clamped off. This cuts off blood circulation and oxygen delivery and could cause hypoxia in the 
clamped colon. The observed increment in COX2, GLUT-1 and CAIX mRNA levels in healthy 
colon tissue resections might therefore be a direct consequence of the clamping of part of the 
colon inducing a hypoxic stress signal. 
 
Figure 4.4 – ROC-analysis of the biomarker accuracy of VEGF family members for biopsy and resection 
samples. ROC-curves of VEGF-A (A), VEGF-B (B), VEGF-C (C), VEGF-D (D) and PlGF (E) are shown for 
biopsy and resection samples. The ROC-curves represent the sensitivity and specificity of the individual VEGF 
family members as colon carcinoma biomarkers. The insert gives the area under the curve (AUC), which quantifies 
the ability of the marker to distinguish between healthy colon and colon carcinoma. The accompanying p-value tests 
the null hypothesis, namely, that the AUC equals 0.50 and thus the biomarker is incompetent. The identity-line 
(Identity%) represents the null hypothesis. *: p<0.05; ***: p<0.001 calculated with the method of DeLong et al. [23]. 
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VEGF-A is readily induced by COX2 derived prostaglandins such as PGE2 [31, 32]. 
Concomitant with the clear induction of COX2 mRNA in resected healthy tissue, VEGF-A 
expression levels were increased in healthy tissue resections. However, besides VEGF-A also 
other VEGF family members showed significant mRNA expression increments in resected 
healthy tissue ranging from 2-3 fold (VEGF-B, VEGF-C, PlGF) up to 22-fold (VEGF-D). Two 
recent reports described the induction during hypoxia of these VEGF family members in lung and 
lymphatic endothelial cells [33, 34]. It is therefore likely that the combined action of clamping-
induced hypoxia and COX2 derived prostaglandins are at the basis of the increased mRNA 
expression of VEGF-A as well as of the other VEGF family members we observed in resected 
healthy colon samples.  
A determining factor in defining a biomarker is its accuracy in differentiating a healthy from a 
diseased state. Therefore, we assessed the ability of the individual VEGF members to 
discriminate between healthy and cancerous colon tissue and the influence of the sampling 
method on this ability. Although the cohort size (n=77) so far is rather limited, VEGF-A and 
PlGF emerged as potential mRNA-markers discriminating with relatively high accuracy between 
healthy and carcinoma tissue in samples obtained by biopsy or by surgical resection. Our results 
confirm previous studies reporting significantly increased expression levels of VEGF-A in colon 
carcinoma samples compared to healthy tissue [5-9]. The same conclusion holds true for PlGF. 
Of all VEGF family members, PlGF emerged from our ROC-analysis as the most accurate 
biomarker in both the sampling methods and was even more accurate than VEGF-A in biopsies. 
It is therefore remarkable that PlGF has received less attention than other VEGF members in 
colon carcinoma. Wei and colleagues studied resection samples from colorectal carcinoma 
patients and also documented increased PlGF mRNA expression levels and their association with 
reduced survival [9]. A similar result was obtained for both PlGF isoforms, PlGF-1 and PlGF-2, 
by Escudero-Esparza and colleagues [35]. Our observations further confirm these findings.  
For VEGF-B, VEGF-C and VEGF-D we observed a significant impact of the sampling procedure 
on the mRNA expression levels in healthy versus colon carcinoma tissues. Table 4.2 compares 
our observations with previously reported data taking into account the reported sampling method 
but also other potential confounding factors such as the inclusion or not of rectal samples.  
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VEGF 
family 
member 
Own data  Published data 
∆ expression  ∆ 
expression 
Sampling 
method 
Other 
confounders Refs Resection Biopsy  
VEGF-B = ↗ *** 
 = Resection - [5] 
 = Resection Rectal incl. [7] 
 = Resection Rectal incl. [8] 
VEGF-C ↗ * ↗ *** 
 = Resection - [5] 
 ↗ n.s. Rectal incl. [6] 
 ↗ Resection Rectal incl. [7] 
 = Resection Rectal incl. [8] 
 = Biopsy Rectal incl. [14] 
VEGF-D ↘ *** = 
 ↘ n.s. Rectal incl. [6] 
 ↘ Resection Rectal incl. [7] 
 ↘ Resection Rectal incl. [8] 
 ↘ Biopsy Rectal incl. [14] 
∆ expression: differential expression in carcinoma samples compared to healthy tissue samples 
↗: significantly increased  
↘: significantly decreased   
=: no significance 
n.s.: not specified 
Rectal incl.: rectal samples included in the analysis 
*: p<0.05 with Wilcoxon signed rank test 
***: p<0.001 with Wilcoxon signed rank test 
Table 4.2 - Comparison of expression data for VEGF-B, VEGF-C and VEGF-D with previously published 
reports. 
 
Previous studies did not reveal overexpression of VEGF-B in colon carcinoma (Table 4.2). Also 
we did not observe increased VEGF-B mRNA levels in samples obtained by surgical resection. 
However, this lack of overexpression appears to be a consequence of the surgical sampling 
method rather than a characteristic intrinsic to colon carcinoma. This conclusion is based on the 
pronounced expression increment we observed in carcinoma tissue obtained by colonoscopic 
biopsy. These opposite results clearly identify the strong impact of the sampling procedure on 
VEGF-B mRNA-levels and challenge the conclusions of previous studies using samples obtained 
by surgical resection [5, 7, 8]. VEGF-C resembles VEGF-B in the impact of the clinical sampling 
method, showing a weak overexpression in resections as opposed to a pronounced, highly 
significant overexpression in biopsies (Table 4.2). Two out of five previously published reports 
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similarly documented increased VEGF-C expression levels. Other reports using either biopsy or 
resected material failed however to detect significant changes. These conflicting data may be due 
to confounding factors other than the sampling method, namely the inclusion of rectal samples in 
these studies. Because radiotherapy prior to surgery is standard procedure in rectal cancer, we 
excluded such patients from our study. Finally, also VEGF-D shows a strong impact of the 
sampling method on its differential mRNA expression (Table 4.2). Here however, resected tissue 
samples show a pronounced underexpression as opposed to the absence of a differential 
expression in biopsy samples. This surgery-created signature again emphasizes the importance of 
taking into account the clinical procedure used for colon tissue sampling when performing colon 
cancer expression studies. 
Our study included a total of 77 patients. Though this is a large cohort, clearly it is not large 
enough to exclude biases due to type I error. To detect type I errors, we statistically analyzed the 
likelihood that group-related disparities in gender, tumor grade, sample location and age 
confounded the conclusions of our study. As shown in the supplementary data (tables S4.1, S4.2, 
S4.3, S4.4 and S4.5), we did not detect specific biases that could contribute to the observed 
differential gene expression patterns. Yet, expansion of this study to a larger patient cohort may 
help to further corroborate our findings of direct relevance for colon cancer diagnosis and basic 
research. 
Conclusions 
Our comparative gene mRNA expression analysis of healthy and carcinoma colon tissue shows 
that the sampling procedure - surgical resection versus colonoscopic biopsy - has an important 
impact on the read-out of VEGF family members as potential colon cancer mRNA-markers. The 
sampling-induced modulation of VEGF gene expression profiles could be related to cellular 
stress caused by hypoxia elicited in resected tissue samples by clamping of blood vessels during 
surgery. The higher sensitivity of healthy tissue to surgery-induced cellular stress compared to 
the relative insensitivity of carcinoma tissue affected to different degrees the reliability of 
individual VEGF-members as mRNA-markers for colon carcinoma. Therefore, samples obtained 
by biopsy provide a more reliable VEGF mRNA-marker read-out than samples obtained by 
surgical resection.  
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SUPPLEMENTAL DATA 
Gene 
Biopsies Resections 
Healthy colon Colon carcinoma Healthy colon Colon carcinoma 
p-Value Sign diff? 1 
p-
Value 
Sign 
diff? 1 
p-
Value 
Sign 
diff? 1 
p-
Value 
Sign 
diff? 1 
COX2 0.6119 no - - 0.4253 no - - 
5-LOX 0.9860 no - - 0.3413 no - - 
GLUT-1 0.9025 no - - 0.2268 no - - 
CAIX 0.6618 no - - 0.3159 no - - 
VEGF-A 0.1008 no 0.8708 no 0.9184 no 0.9417 no 
VEGF-B 0.0948 no 0.5643 no 0.6290 no 0.4732 no 
VEGF-C 0.1315 no 0.3831 no 0.0868 no 0.8721 no 
VEGF-D 0.0426* * 0.0765 no 0.7363 no 0.4642 no 
PlGF 0.2312 no 0.9176 no 0.8952 no 0.9184 no 
1
 Sign diff?: Significant difference between samples from male or female patients? 
Biopsies: male: n=22; female: n=16 
Resections: male: n=25; female: n=14 
Table S4.1 - Comparison of expression levels in male versus female patients with Mann-Whitney test. *: p<0.05 
 
Figure S4.1 - Comparison of VEGF-D expression levels in male versus female patients in healthy colon biopsy 
samples with Mann-Whitney test. *: p<0.05 
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Gene 
Biopsies Resections 
Healthy colon Colon carcinoma Healthy colon Colon carcinoma 
p-
Value 
Sign 
diff? 1 
p-
Value 
Sign 
diff? 1 
p-
Value 
Sign 
diff? 1 
p-
Value 
Sign 
diff? 1 
COX2 0.0883 no - - 0.0397 * - - 
5-LOX 0.4667 no - - 0.1646 no - - 
GLUT-1 0.5942 no - - 0.7709 no - - 
CAIX 0.3980 no - - 0.6819 no - - 
VEGF-A 0.5775 no 0.3662 no 0.6067 no 0.2818 no 
VEGF-B 0.8955 no 0.8589 no 0.6085 no 0.6771 no 
VEGF-C 0.9849 no 0.5805 no 0.1073 no 0.0321 * 
VEGF-D 0.4946 no 0.6100 no 0.6195 no 0.1850 no 
PlGF 0.0394 * 0.9056 no 0.2856 no 0.8994 no 
1
 Sign diff?: Significant difference between samples from different tumor grade? 
Biopsies: low grade: n=3;  moderate grade: n=18;  high grade: n=12 
Resections: low grade: n=5;  moderate grade: n=24;  high grade: n=7 
Table S4.2 - Comparison of expression levels in colon carcinoma with tumor grade low versus moderate 
versus high with Kruskal Wallis test. *: p<0.05 
 
Figure S4.2 - Comparison of expression levels in colon carcinoma with tumor grade low versus moderate 
versus high for PlGF in healthy colon biopsy samples and for COX2 in healthy colon resection samples with 
Kruskal Wallis test. *: p<0.05. For PlGF, the difference between the medians is statistically significant (p<0.05), but 
Dunn’s multiple comparison test detects no specific significant difference between two groups. 
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Gene 
Biopsies Resections 
Healthy colon Colon carcinoma Healthy colon Colon carcinoma 
p-Value Sign diff?1 
p-
Value 
Sign 
diff? 1 
p-
Value 
Sign 
diff? 1 
p-
Value 
Sign 
diff? 1 
COX2 0.6734 no - - 0.6011 no - - 
5-LOX 0.3685 no - -  0.0613 no - -  
GLUT-1 0.3680 no - - 0.1770 no - - 
CAIX 0.6838 no - - 0.6578 no - - 
VEGF-A 0.6942 no 0.7199 no 0.0800 no 0.3722 no 
VEGF-B 0.7275 no 0.6361 no 0.0337 * 0.1204 no 
VEGF-C 0.8051 no 0.5012 no 0.1017 no 0.1844 no 
VEGF-D 0.4686 no 0.7552 no 0.1827 no 0.6879 no 
PlGF 0.7782 no 0.7614 no 0.0993 no 0.1650 no 
1
 Sign diff?: Significant difference between samples with different Dukes classification? 
Biopsies: A: n=3;  B: n=15;  C: n=6;  D: n=13 
Resections: A: n=8;  B: n=12;  C: n=12;  D: n=5 
Table S4.3 - Comparison of expression levels in colon carcinoma with Dukes classification A versus B versus C 
versus D with Kruskal Wallis test. *: p<0.05 
 
Figure S4.3 - Comparison of VEGF-B expression levels in colon carcinoma with Dukes classification A versus 
B versus C versus D in healthy colon resection samples with Kruskal Wallis test. *: p<0.05 
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Gene 
Biopsies Resections 
Healthy colon Colon carcinoma Healthy colon Colon carcinoma 
p-
Value 
Sign 
diff? 1 
p-
Value 
Sign 
diff? 1 
p-
Value 
Sign 
diff? 1 
p-
Value 
Sign 
diff? 1 
COX2 0.1729 no - - 0.7113 no - - 
5-LOX 0.3979 no - - 0.9803 no - - 
GLUT-1 0.5928 no - - 0.0887 no - - 
CAIX 0.0136 * - - 0.7861 no - - 
VEGF-A 0.7927 no 0.6827 no 0.1227 no 0.9210 no 
VEGF-B 0.4835 no 0.9767 no 0.0490 * 0.3013 no 
VEGF-C 0.2674 no 0.6197 no 0.0490 * 0.2514 no 
VEGF-D 0.2540 no 0.3818 no 0.1127 no 0.1975 no 
PlGF 0.7703 no 0.6404 no 0.6403 no 0.1879 no 
1
 Sign diff?: Significant difference between samples from patients of ≤70 years or >70 years? 
Biopsies: ≤70 years: n=19;  >70 years: n=19 
Resections: ≤70 years: n=22;  >70 years: n=17 
Table S4.4 - Comparison of expression levels in patients younger than 70 years or of 70 years versus patients 
older than 70 with Mann-Whitney test. *: p<0.05 
 
Figure S4.4 - Comparison of expression levels in patients younger than 70 years or of 70 years versus patients 
older than 70 for CAIX in healthy colon biopsy samples and for VEGF-B and VEGF-C in healthy colon resections 
with Mann-Whitney test. *: p<0.05 
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Gene 
Biopsies Resections 
Healthy colon Colon carcinoma Healthy colon Colon carcinoma 
p-
Value 
Sign 
diff?1 
p-
Value 
Sign 
diff? 1 
p-
Value 
Sign 
diff? 1 
p-
Value 
Sign 
diff? 1 
COX2 n/a n/a - - n/a n/a - - 
5-LOX n/a n/a - -  n/a n/a - - 
GLUT-1 n/a n/a - - n/a n/a - - 
CAIX n/a n/a - - n/a n/a - - 
VEGF-A n/a n/a 0.0671 no n/a n/a 0.7597 no 
VEGF-B n/a n/a 0.5926 no n/a n/a 0.7546 no 
VEGF-C n/a n/a 0.2775 no n/a n/a 0.7456 no 
VEGF-D n/a n/a 0.8341 no n/a n/a 0.7937 no 
PlGF n/a n/a 0.5477 no n/a n/a 0.9067 no 
1
 Sign diff?: Significant difference between samples from different tumor sites? 
Biopsies: (A): n=8;  (B): n=9;  (C): n=20 
Resections: (A): n=7;  (B): n=14; (C): n=14 
Table S4.5 - Comparison of expression levels in healthy colon and colon carcinoma samples from different 
tumor sites ((A) caecum and Valve of Bauhin versus (B) colon ascendens, transversum, descendens and hepatic 
flexure versus (C) sigmoid) with Kruskal Wallis test. n/a: not applicable. 
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4.2 Additional data 
4.2.1 Similar inflammatory and angiogenic expression profiles for proximal and distal 
healthy colon samples 
To verify if the distance away from the tumor influences the expression profiles from healthy 
colon tissue samples in a similar way as the clinical procedure, paired proximal and distal healthy 
colon tissue samples were analyzed by RT-qPCR in a pilot study. The proximal sample biopsies 
were taken at approximately 5 cm from the tumor, whereas the distal biopsies were sampled as 
far away from the tumor as feasible, at least 20-40 cm away. The experimental setup was 
identical as described in the material and methods section of section 4.1.  
 
Figure 4.5 - Comparison of COX2 and 5-LOX expression levels between proximal and distal healthy colon 
tissue samples. Relative mRNA expression levels of the inflammatory eicosanoid enzymes COX2 and 5-LOX are 
shown for proximal and distal healthy colon tissue samples. Expression levels were normalized against reference 
genes TBP and SDHA and were scaled against the median of the distal samples (median set to 1). Expression data 
are depicted as scatter plots of the values obtained for each individual sample. ns: not significant with Wilcoxon 
signed-rank test. 
 
The expression levels of the eicosanoid enzymes COX2 and 5-LOX, analyzed as markers for 
inflammation and cellular stress, showed no difference between proximal and distal healthy colon 
tissue samples (Figure 4.5). Likewise, VEGF family members were expressed at similar levels in 
proximal and distal healthy colon tissue samples (Figure 4.6). Although the sample size was 
small (n=4), these results give no indication that expansion to a larger patient cohort may give 
any significant differences. Therefore, we believe that there is no difference in expression of the 
studied inflammatory and angiogenic genes between proximal – representing the “routine” 
healthy control samples – and distal healthy colon tissue samples. 
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Figure 4.6 - Comparison of VEGFs expression levels between proximal and distal healthy colon tissue 
samples. Relative mRNA expression levels of VEGF-A, VEGF-B, VEGF-C, VEGF-D and PlGF are shown for 
proximal and distal healthy colon tissue samples. Expression levels were normalized against reference genes TBP 
and SDHA and were scaled against the median of the distal samples (median set to 1). Expression data are depicted 
as scatter plots of the values obtained for each individual sample. ns: not significant with Wilcoxon signed-rank test. 
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Chapter 5 
Evolution of the VEGF family during the progression of 
colon cancer 
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Abstract 
The vascular endothelial growth factor family members (VEGF-A, -B, -C, -D and placental growth factor 
(PlGF)) are key players in the development, maintenance and remodeling of the vascular and lymphatic 
microcirculation as well as in the outgrowth of solid tumors. However, data on the expression of VEGF 
family members in colon carcinoma and during its malignant progression are scattered and often 
contradictory, rendering it almost impossible to obtain a global picture. Therefore, we now performed a 
comprehensive analysis of the mRNA expression signatures of all VEGF family members at the different 
stages of progression towards malignancy. This resulted in the identification of VEGF-B and VEGF-C as 
carcinoma stage-specific angiogenic genes who are upregulated only in carcinoma and metastasis samples 
whereas PlGF and VEGF-A are overexpressed compared to matched healthy colon tissue already at the 
stage of adenoma. An expression increment of VEGFs in liver metastases was observed independent of 
the healthy tissue calibrator, either healthy liver or healthy colon. Remarkably, the angiogenic signature of 
colon carcinomas was highly conserved in liver metastases but differed significantly from colon 
adenomas. This illustrates the occurrence of a stage-specific deviation in the expression of VEGF family 
members during colon carcinoma progression, VEGF-A and/or PlGF showing overexpression already at 
the adenoma stage and at the malignant carcinoma and metastasis stages becoming further supplemented 
with overexpressed VEGF-B and VEGF-C. 
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5.1.1 Introduction 
Angiogenesis and lymphangiogenesis are crucial processes implicated in normal physiology but 
also in pathological conditions such as inflammation and cancer. In cancer, the formation of new 
blood vessels to deliver nutrients and oxygen to the growing tumor constitutes a vital process in 
solid tumor development and progression [1, 2]. Therefore, angiogenesis has become a main 
target for anti-tumoral therapy. Blocking the development of tumor vasculature (angiostatic 
therapy) and/or disrupting established tumor vasculature not only limits the outgrowth of solid 
tumors but may also prevent the formation of distant metastases [1-4] 
A central constituent in the development, maintenance and remodeling of the vascular 
microcirculation is vascular endothelial growth factor (VEGF). Since its identification in 1983 
[5], the family of vascular active cytokines has grown to include VEGF-A, VEGF-B, VEGF-C, 
VEGF-D and placental growth factor (PlGF) [6]. VEGF-A, the member first discovered, induces 
endothelial cell proliferation, survival and migration as well as tube formation [7]. VEGF-A 
expression is readily induced during inflammation but also in most solid tumors, including colon 
cancer [6, 8]. Neutralization of tumor-expressed VEGF-A with humanized monoclonal antibodies 
such as bevacizumab has resulted in significant clinical improvement of patients with colorectal, 
non-small cell lung, renal and breast cancer when combined with conventional fluorouracil-based 
chemotherapy [9]. However, the effect of VEGF-A neutralizing treatments remains modest in 
other cancers. In addition, resistance tends to develop after a transitory period of clinical benefit, 
resulting in regrowth of the tumors and progression of the disease. Angiogenic escape involving 
the compensatory (over)expression of VEGF-related angiogenic factors has been proposed to 
contribute to this limited response to VEGF-A directed angiogenic therapy [9, 10]. In line 
herewith, Fan et al. showed increased expression levels of VEGF-A, -B, -C and PlGF in 
colorectal cell lines after chronic exposure to bevacizumab [11]. In addition, bevacizumab 
induced reactivity to VEGF-C and VEGF-D in human brain and tumor derived endothelial cells 
[12]. In patients with refractory metastatic renal cell carcinoma, VEGF-A targeted angiostatic 
treatment concurred with increased PlGF plasma levels [13]. Next to a role for PlGF in 
angiogenic rescue, the VEGF-homolog may also contribute to neo-angiogenesis during solid 
tumor growth as indicated by the correlation of PlGF expression and preoperative serum levels 
with disease progression, reduced patient survival and recurrence in colorectal cancer [9, 14-16]. 
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Increased mRNA and protein expression levels also of VEGF-B, VEGF-C and VEGF-D have 
been demonstrated in various cancers, including colon cancer [17-20], and have been correlated 
with lymphatic invasion, lymph node metastases and prognosis of patients with colon cancer [19, 
21-23]. In addition, VEGF-C plasma levels have been evaluated as a predictive marker for 
lymphatic and venous invasion and poor outcome of colorectal cancer patients [24, 25]. 
Although nearly each VEGF family member has been described to be upregulated in colon 
cancer and/or has been correlated to clinicopathological features as described above, other studies 
claim unaltered expression levels in colon carcinoma of individual VEGF family members [18, 
22, 23, 26-28]. This controversy is even more apparent when considering other stages of colon 
carcinoma, i.e. colon adenoma preceding the carcinoma stage and metastases derived from the 
primary colon carcinoma. In colon adenoma, VEGF-A, VEGF-B and VEGF-C expression has 
been reported to be unaltered compared to healthy colon or in contrary to show elevated levels 
[26, 27, 29]. In liver metastases, mainly VEGF-A expression has been verified. Here, VEGF-A 
mRNA expression levels have been reported to be either similar or higher compared to primary 
colon carcinoma [30, 31]. The analysis of these VEGF angiogenic factors individually and/or in 
small cohorts and by means of different analytical methods, likely is at the basis of these 
contradictory reports. Further adding to the confusion, it remains largely unclear to what extent 
individual carcinomas concomitantly express multiple VEGFs, thus acquiring redundancy in 
angiogenic function, and to what extent such a deviant trait evolves during progression from 
adenoma to carcinoma and metastasis. In order to circumvent these limitations, we here 
performed a comprehensive study determining in a single experimental setup the mRNA 
expression signatures of all VEGF family members during malignant progression from adenoma 
to carcinoma and liver metastasis.  
5.1.2 Materials and methods 
Biological samples 
Samples were obtained from colon adenoma (n=16) and primary colon carcinoma (n= 37 ) and 
liver metastasis (n=23) at the Ghent University Hospital. Adenoma and carcinoma were sampled 
by biopsy in the infiltrating area of the growth. Histopathological examination confirmed the 
adenoma/carcinoma state of the tissue. From each patient, a corresponding healthy colon sample 
was taken from the same colon segment. None of the patients had received chemo- or 
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radiotherapy before colonoscopy. Liver metastasis samples from colon carcinoma patients and 
healthy liver tissue from the same patients were obtained by surgical resection. Seventy-eight 
percent of the patients had received chemotherapy before metastasectomy. Tissue samples were 
collected immediately after isolation in RNAlater® Solution (Ambion/Applied Biosystems, 
Foster City, CA). All samples were kept at -80°C until RNA extraction. The clinicopathological 
features of the patients are summarized in tables 5.1, 5.2 and 5.3. All tissues were obtained 
following informed consent of the patients and approval of the study by the Ethics Committee of 
the Ghent University Hospital. 
Variable Number of patients 
Sex  
    Male   21 
    Female 16 
Age at diagnosis  
    Median age (range, years) 71 (39–85) 
Site of tumor  
    Sigmoid 20 
    Colon descendens 1 
    Colon transversum 2 
    Hepatic flexure 1 
    Colon ascendens 5 
    Caecum 7 
    Not specified 1 
Differentiation grade  
    Low 12 
    Moderate 17 
    High 3 
    Unknown 5 
Dukes classification  
    Dukes’ A 3 
    Dukes’ B 15 
    Dukes’ C 7 
    Dukes’ D 12 
    Unknown 0 
T category  
    T1-T2 3 
    T3-T4 26 
    Tx 8 
Lymphatic spread  
    N0 18 
    N+ 10 
    Nx 9 
Metastasis  
    M0/Mx 25 
    M+ 12 
Table 5.1 - Clinicopathological features of the colon carcinoma patients. 
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Variable Number of patients 
Sex  
    Male   10 
    Female 6 
Age at diagnosis  
    Median age (range, years) 68 (18-80) 
Site of tumor  
    Sigmoid 9 
    Colon transversum 2 
    Hepatic flexure 1 
    Colon ascendens 1 
    Caecum 3 
Dysplasia  
    Low 10 
    High 4 
    Unknown 2 
Classification  
    Tubular 8 
    Tubulovillous 6 
    Villous 1 
    Unknown 1 
Table 5.2 - Clinicopathological features of the colon adenoma patients. 
Variable Number of patients 
Sex  
    Male   16 
    Female 7 
Age at diagnosis  
    Median age (range, years) 62 (35-80) 
Site of primary tumor  
    Colon 14 
    Rectum 9 
Synchronicity   
    Synchronous  15 
    Metachronous 8 
Therapy before liver resection  
    None 5 
    Chemotherapy 12 
    Chemotherapy & bevacizumab 4 
    Chemotherapy & panitumab 1 
    Chemotherapy & bevacizumab                                           
s                            & cetuximab 1 
Table 5.3 - Clinicopathological features of the liver metastasis patients. 
 
RNA-extraction, RNA-quality control and cDNA-synthesis 
Total RNA was extracted with the RNeasy Plus mini kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s instructions. This kit contains a gDNA-elimination step to avoid gDNA 
contamination. After extraction, RNA quality and integrity were verified using an RNA 6000 
Nano Chip Kit on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). 
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Only samples with adequate quality and integrity (adenoma samples 16/18, carcinoma samples 
37/39, metastasis samples 23/23) were used for the RT-qPCR analysis. cDNA was synthesized 
from 1 µg of total RNA using Superscript® II reverse transcriptase (Invitrogen, Merelbeke, 
Belgium) according to the manufacturer’s instructions. 
RT-qPCR 
Real-time quantitative PCR (RT-qPCR) was performed using the LC 480 Sybr Green I master kit 
on a LightCycler® 480 Real-Time PCR system (both from Roche Applied Science, Penzberg, 
Germany). Primers were designed using PrimerSelect (DNASTAR, Madison, USA) and 
purchased from Invitrogen. The primers were designed for gene-specific expression profiling and 
cover all splice variants. The sequences of the forward and reverse primers were as follows: 
VEGF-A 5’-TGAGTTGCCCAGGAGACCAC-3’ and 5’-GAAGGGGAGCAGGAAGAGGAT-
3’; VEGF-B 5’-CCGGAAGCTGCGAAGGTGACA-3’ and 5’-
GGGAGACAAGGGATGGCAGAAGAG-3’; VEGF-C 5’-CACGGCTTATGCAAGCAAAGA-
3’ and 5’-TCCTTTCCTTAGCTGACACTTGT-3’; VEGF-D 5’-
GCAGCCCTAGAGAAACGTG-3’ and 5’-AGGTGCTGGTGTTCATACAGAT-3’; PlGF 5’-
TGCGGCGATGAGAATCTGC-3’ and 5’-AGCGAACGTGCTGAGAGAAC-3’; COX2 5’-
TTGCTGGAACATGGAATTACC-3’ and 5’-TGCCTGCTCTGGTCAATG-3’; 5-LOX 5’-
TGGCGCGGTGGATTCATAC-3’ and 5’-CAGGGGAACTCGATGTAGTCC-3’; TFF3 5’-
CTTGCTGTCCTCCAGCTCT-3’ and 5’-CCGGTTGTTGCACTCCTT-3’; LXRalpha 5’-
GGAGGTACAACCCTGGGAGT-3’ and 5’-AGCAATGAGCAAGGCAAACT-3’; ApoE 5’-
CTTCATGGTCTCGTCCATCAGC-3’ and 5’-AAGGACGTCCTTCCCCAGGAGC-3’. All 
samples were assayed in triplicate. Relative expression values were calculated using the 2(-delta 
delta C(T)) method and were normalized against reference genes: TATA-binding protein (TBP) 
and succinate dehydrogenase complex subunit A (SDHA) (primers: TBP 5’-
CGGCTGTTTAACTTCGCTTC-3’ and 5'-CACACGCCAAGAAACAGTGA-3’; SDHA 5’-
TGGGAACAAGAGGGCATCTG-3’ and 5’-CCACCACTGCATCAAATTCATG-3’). For liver 
samples, only SDHA was used as a reference gene due to the instability of TBP as a reference 
gene in liver metastasis samples. In these calculations we took into account the PCR efficiency of 
the individual PCR reactions, calculated on the basis of linear regression as described in Ruijter 
et al [32]. The normalized relative expression values were scaled against the median of the 
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respective healthy tissue samples (median of healthy samples set to 1). The specificity of 
amplification was confirmed by evaluation of the melting curves. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism® software (GraphPad Software Inc., La 
Jolla, California, USA). For comparisons of paired samples, the Wilcoxon signed rank test was 
used. Comparisons of the n-fold induction between stages of progression were performed with 
the Kruskal-Wallis one-way ANOVA with Dunn’s multiple comparison test. Comparisons of 
expression levels between three or four groups were performed with one-way-ANOVA with 
Bonferroni post-test. Significant p-values were ranked as p<0.05 (*), p<0.01 (**) and p<0.001 
(***). 
5.1.3 Results 
Stage-dependent induction of VEGF family members during colon cancer progression 
The mRNA expression levels of VEGF family members in samples from colon adenoma (n=16), 
colon carcinoma (n=37) and liver metastases (n=23) were determined by RT-qPCR. Differential 
expression levels were obtained by comparison with healthy tissue samples obtained from the 
same patients. All colon tissue samples were obtained by biopsy. Samples from liver were 
obtained by surgical resection.  
Figure 5.1 shows the n-fold induction for each progression stage of VEGF-A, VEGF-B, VEGF-C, 
VEGF-D and PlGF with respect to matched healthy tissue samples. VEGF-A and PlGF were 
significantly (p<0.01 to <0.001) induced throughout all stages of colon cancer progression. 
However, whereas VEGF-A expression remained nearly constant in all three stages, the induction 
levels of PlGF increased concomitantly with disease progression from adenoma to carcinoma 
(p<0.1) and metastasis (p<0.01) (Figure 5.1A, E). Also VEGF-B and VEGF-C showed an 
expression increment, which however was stage-dependent, displaying significantly increased 
mRNA levels at the carcinoma and metastasis stages but not at the preceding adenoma stage 
(Figure 5.1B, C). Finally, VEGF-D appears to be the exception to the rule. No increased VEGF-D 
mRNA levels were observed in colon adenoma, carcinoma and metastasis samples (Figure 5.1D). 
Combined, these results indicate that already at the early stage of adenoma a distinct angiogenic 
signature is present, featuring the induction of VEGF-A and PlGF and further broadening towards 
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the expression of additional VEGFs upon malignant progression to carcinoma and carcinoma-
derived metastases. 
 
Figure 5.1 – The induction of VEGF family members during progression of colon cancer. n-Fold induction 
levels in adenoma, carcinoma and liver metastasis samples of (A) VEGF-A, (B) VEGF-B, (C) VEGF-C, (D) VEGF-
D and (E) PlGF are shown. The n-fold induction value represents the ratio of the expression value of the diseased 
sample against the expression value of the paired healthy sample. The box represents the median with interquartile 
range and the whiskers represent minimum and maximum ratios. Significance of the induction on its own is 
indicated beneath the minimum whisker with ##: p<0.01 and ###: p<0.001, calculated with Wilcoxon signed rank 
test. Significant differences in induction between the stages is indicated above the boxes with *: p<0.05; **: p<0.01; 
***: p<0.001, calculated with Kruskal-Wallis one-way ANOVA with Dunn’s multiple comparison test. 
 
Colon tissue signature of liver metastasis samples  
In the above analyses, liver metastasis samples from colon carcinoma patients were compared to 
matched healthy tissue from liver. This implies a comparison of cancerous tissue from colon 
origin with healthy tissue originating from a distinctly different organ. We therefore verified to 
what extent liver metastasis samples retained the characteristics of their tissue of origin. Hereto, 
we determined the mRNA expression levels of tissue markers specific for colon and liver on a 
subset of colon carcinoma (n=10) and liver metastasis samples (n=10). As shown in Figure 5.2B, 
the Trefoil Factor 3 (TFF3) colon marker was equally expressed in liver metastasis samples and 
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healthy colon samples as opposed to the absence of TFF3 expression in healthy liver samples. 
This differential expression pattern confirms the colonic nature of the liver metastases. However, 
liver metastasis samples also showed a liver-specific gene signature. This is apparent from the 
significantly higher expression levels in liver metastasis samples of the liver markers Liver X 
Receptor alpha (LXRalpha) and Apolipoprotein E (ApoE), showing values similar to (LXRalpha) 
or somewhat below (ApoE) healthy liver (Figure 5.2C-D). The reference gene SDHA was equally 
expressed in all sample groups, suggesting that the normalization on the samples was not 
influenced by the tissue (Figure 5.2A). 
 
Figure 5.2 – Comparison of colon and liver markers. Relative mRNA expression levels of the reference gene (A) 
SDHA, the colon marker (B) TTF3 and the liver markers (C) LXRalpha and (D) ApoE are shown for healthy liver 
and colon, colon carcinoma and liver metastasis samples. Expression levels were normalized (except SDHA) against 
the reference gene SDHA and were scaled against the median of the biopsy samples (median set to 1). Expression 
data are depicted as scatter plots of the values obtained for each individual sample. Significant differences are 
indicated by **: p<0.01 and ***: p<0.001, calculated with Kruskal-Wallis one-way ANOVA with Dunn’s multiple 
comparison test. 
 
Because of the colonic signature of liver metastasis samples and its contamination with a liver 
signature, we next verified in the same subset of the samples to what extent n-fold induction 
levels of VEGF family members in liver metastasis samples may be biased by the tissue origin – 
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liver or colon – of the healthy tissue calibrator. Except for VEGF-B showing similar n-fold 
induction values irrespective of the tissue origin of the healthy tissue calibrator (Figure 5.3B), all 
VEGF family members showed significantly higher levels of overexpression when liver 
metastasis samples were compared with healthy colon instead of healthy liver (Figure 5.3A, C-
E). This analysis indicates that at the stage of metastasis the expression increments may be even 
more pronounced than indicated on the basis of using healthy liver samples as calibrator (see also 
supplemental Figure S5.1).  
 
Figure 5.3 – Impact of the tissue origin – liver or colon – of the healthy tissue calibrator for liver metastasis 
samples. n-Fold induction levels in liver metastasis versus healthy liver and healthy colon of (A) VEGF-A, (B) 
VEGF-B, (C) VEGF-C, (D) VEGF-D and (E) PlGF are shown. The n-fold induction value represents the ratio of the 
expression value of each metastasis sample against the median expression value of the healthy liver or colon 
samples. The box represents the median with interquartile range and the whiskers represent minimum and maximum 
ratios. Significant differences in induction between the stages is indicated above the boxes with ns: not significant; 
**: p<0.01; ***: p<0.001, calculated with Mann-Whitney U test. 
 
Individual patient signatures reveal a cumulative angiogenic expression increment with 
malignant progression  
VEGF expression signatures from individual colon adenoma, colon carcinoma and liver 
metastasis samples were determined to verify to what extent the progression-associated 
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broadening of angiogenic gene expression we observed at the population level can be observed 
also at the level of the individual patient. For the analysis of liver metastases, a conservative 
approach was followed based on the usage of healthy samples from liver as a calibrator. The cut-
off for defining overexpression was set on the median value + (2.58 x SD) of the corresponding 
healthy tissue cohort. 
As illustrated in Figure 5.4, overexpression of a single VEGF family member is the 
predominating pattern at the adenoma stage (37%), closely followed by absence of 
overexpression (25%) and overexpression of two VEGF family members (25%). At the colon 
carcinoma stage, a pronounced shift towards the right of the axis is observed, illustrating co-
overexpression of three (27%) up to four (40,50%) VEGF family members. Metastasis samples 
confirm this shift towards overexpression of multiple VEGF genes and show an even more 
pronounced polarization towards the concomitant overexpression of four (52%) VEGF genes. 
 
Figure 5.4 – Angiogenic shifts in individual patient signatures during colon carcinoma progression. The graph 
shows the percentages of samples which overexpressed none up to four VEGF family members. The cut-off for 
overexpression was based on the median of the healthy samples for each population group +2.58SD. 
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5.1.4 Discussion 
Studies on the angiogenesis promoting function in colon cancer of VEGFs and their potential for 
angiogenic therapy are strongly focused towards VEGF-A. However, also VEGF-B, VEGF-C, 
VEGF-D and especially PlGF are emerging as candidate angiogenic factors promoting 
carcinogenesis [14, 17, 27]. Yet it remains unclear to what extent the different VEGFs are 
(co-)expressed in human colon cancer and evolve in the process of malignant transformation and 
progression. Despite numerous reports in literature, the often scattered and contradictory nature 
of the data makes it hard to obtain a global picture on VEGF angiogenic expression in colon 
cancer and during colon carcinoma progression. Here, we analyzed in a systematic way the 
mRNA expression levels of all individual VEGFs in colon carcinoma samples in comparison 
with colon adenoma and liver metastasis samples. 
Already at the early stage of colon adenoma, a distinctive angiogenic profile featuring a strong 
induction of VEGF-A and PlGF was apparent. This profile persisted in carcinoma and liver 
metastasis samples. Increased VEGF-A expression in adenomas that persists in carcinomas has 
been reported by several research groups [27, 33, 34] although others failed to detect VEGF-A 
mRNA expression at the adenoma [29, 35] or carcinoma stage [18]. Our results clearly point 
towards increased VEGF-A mRNA levels from the start of the adenoma-carcinoma sequence and 
persisting throughout the sequence. Furthermore, our expression analysis identifies PlGF as a 
second angiogenic factor expressed early on in colon cancer progression. The expression of PlGF 
already in colon adenomas and even more pronounced in colon carcinomas and liver metastases 
identifies PlGF as a potential target for angiogenic therapy and a possible cause of angiogenic 
escape upon VEGF-A-targeting therapy. Finally the expression patterns of VEGF-B and VEGF-C 
– lacking in colon adenoma but increased in colon carcinoma and liver metastasis – identify both 
angiogenic factors as potential markers for malignant progression. Again, these results are in line 
with previous reports by Rmali and Wang [18, 25] but contradict others reporting unchanged 
VEGF-B mRNA levels during neoplastic progression of colon tissue [22, 23, 26] or increased 
VEGF-B expression only in the adenoma stage [27]. Methodological differences including less 
quantitative mRNA-measuring techniques such as semi-quantitative RT-PCR [23, 29], Northern 
blot [26] or RT-PCR [27, 35] likely account for some of the contradictory observations. 
Furthermore, most studies included rectal samples [18, 22, 23, 27, 29, 35]. Because radiotherapy 
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prior to surgery is standard procedure in rectal cancer, we excluded such patients from our study 
[26]. A third confounding factor may in fact be the clinical procedure applied for obtaining tissue 
samples. Whereas several studies used samples obtained by surgical resection [18, 22, 26, 27, 
35], we used in this study colon samples obtained by colonoscopic biopsy. In a recent study we 
showed that biopsy samples provide a more accurate report on VEGF family mRNA levels than 
samples obtained by surgical resection since sampling-induced hypoxia in resection samples 
affects the mRNA expression of VEGF family members [36].  
The mRNA-analysis of liver metastases necessitates an extra consideration: do liver metastases 
have to be compared with healthy liver – the tissue where they were found – or with healthy 
colon – the tissue they originate from? To address this question, we examined in a subset of 
samples to what extent liver metastasis samples retained the characteristics of their tissue of 
origin or gained characteristics of their new environment. The expression pattern confirmed the 
colonic nature of the liver metastases, showing mRNA levels of the colon marker TTF3 similar to 
healthy colon. Yet, liver metastasis samples also scored positive for the liver tissue markers 
LXRalpha and ApoE. Likely, this additional liver tissue signature reflects the presence in the 
metastasis samples of residential liver cells. Importantly, the ectopic origin of the liver metastases 
did not affect the conclusions from our comparative VEGF gene expression analysis. Thus VEGF 
family members showed similar (VEGF-B) or even higher (VEGF-A, -C, -D and PlGF) higher 
induction values when liver metastasis samples were compared with healthy colon instead of 
healthy liver. This analysis therefore indicates that the angiogenic profile of colon carcinoma is 
conserved when metastasizing to other body tissues. This conclusion is further supported when 
looking at VEGF expression signatures from individual samples. Here, a strong shift towards the 
co-expression of multiple VEGFs is apparent upon progression from adenoma to carcinoma. In 
contrast, the VEGF signature of individual carcinoma samples is near indistinguishable from that 
of liver metastasis samples. From a therapeutic angle, the apparent conservation of angiogenic 
profiles indicates angiogenic therapy will equally target primary colon carcinoma and its 
secondary metastases, provided the therapy is individualized to the patient’s VEGF signature. 
Furthermore, the occurrence of co-expressed VEGFs in individual samples supports the notion 
put forward by Fan and colleagues using colorectal cell lines that co-expression of multiple 
VEGF family members is at the basis of angiogenic escape to VEGF-A neutralizing treatments 
[11].  
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In conclusion, this comprehensive and systematic analysis of VEGFs mRNA expression reveals 
the complex nature of angiogenic gene expression already at the stage of adenoma and its further 
deviation towards co-expression of multiple angiogenic genes upon progression to carcinoma and 
liver metastasis. Furthermore, our expression analysis identifies VEGF-B and VEGF-C as 
angiogenic genes who are upregulated only in carcinoma and metastasis stages whereas PlGF 
and VEGF-A are present already at the stage of adenoma. Unraveling the molecular pathway(s) at 
the basis of the manifold VEGF expression may help to resolve molecular processes controlling 
angiogenesis in cancer. 
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SUPPLEMENTAL FIGURE 
 
Figure S5.1 – Comparison of VEGF family members in colon and liver. Relative mRNA expression levels of (A) 
VEGF-A, (B) VEGF-B (C) VEGF-C, (D) VEGF-D and (E) PlGF are shown for healthy liver and colon, colon 
carcinoma and liver metastasis samples. Expression levels were normalized against the reference gene SDHA and 
were scaled against the median of the biopsy samples (median set to 1). Expression data are depicted as scatter plots 
of the values obtained for each individual sample. Significant differences are indicated by **: p<0.01 and ***: 
p<0.001, calculated with Kruskal-Wallis one-way ANOVA with Dunn’s multiple comparison test. 
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5.2 Additional data 
5.2.1 VEGF-A, VEGF-C and PlGF serum levels in colon adenoma and carcinoma patients 
The observed shift in VEGFs mRNA signatures between colon adenoma and carcinoma tissue 
samples gives rise to the question if similar signatures exist also at the protein level. Therefore 
the protein levels of VEGF-A, VEGF-C and PlGF were measured in serum from healthy 
individuals who underwent colonoscopy (n= 31) and from patients with either colon adenoma 
(n= 21) or colon carcinoma (n= 30). The analysis was performed with a quantitative Luminex®-
based multiplex immunoassay using a commercially available kit (MILLIPLEX®MAP Human 
Angiogenesis/Growth Factor Magnetic Bead Panel kit, Millipore, Overijse, Belgium). Because 
such analysis was not possible for VEGF-B due to a lack of commercially available and sensitive 
quantification assays, VEGF-B was omitted from this analysis. Also VEGF-D was not included 
on the basis of its inert mRNA expression in the different stages of colon cancer (see 5.1). 
Surprisingly, as shown in figure 5.5, VEGF-A, VEGF-C and PlGF serum levels were similar in 
the healthy, adenoma and carcinoma serum samples.  
 
 
Figure 5.5 - Protein levels of VEGF-A, VEGF-C and PlGF serum from healthy persons and patients with 
colon adenoma or colon carcinoma. The serum levels of VEGF-A, VEGF-C and PlGF are shown as measured by a 
quantitative Luminex®-based multiplex analysis in serum samples from healthy individuals and patients with colon 
adenoma or carcinoma. Protein levels are depicted as scatter plots of the values obtained for each individual sample. 
Significant differences were calculated with Kruskal-Wallis one-way ANOVA with Dunn’s multiple comparison 
test. 
 
In order to confirm these results, an ELISA was performed for PlGF (Quantikine® ELISA Human 
PlGF Immunoassay, R&D Systems, Abingdon, UK). In contrast to the similar PlGF serum levels 
obtained with the multiplex immunoassay, significant differences were observed between serum 
from healthy individuals and carcinoma patients (Figure 5.6).  
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Figure 5.6 - Serum levels of PlGF in adenoma and carcinoma serum samples obtained by ELISA. Serum levels 
of PlGF are shown as measured by ELISA  in serum samples from healthy individuals and patients with colon 
adenoma or carcinoma. Protein levels are depicted as scatter plots of the values obtained for each individual sample. 
Significant differences are indicated by ***: p<0.001, calculated with Kruskal-Wallis one-way ANOVA with 
Dunn’s multiple comparison test. 
 
Thus, two commercial kits produced opposite results on PlGF serum levels; no differences in 
PlGF-levels using the Luminex®-based immunoassay as opposed to significant differences 
between healthy and carcinoma serum samples using ELISA. Yet, the ELISA-based results agree 
well with previously published reports on increased serum levels of PlGF in colon cancer patients 
[1, 2]. On this basis we presume that the results from the ELISA-assay are authentic, indicating 
that at the stage of colon carcinoma increased PlGF serum levels may be present in the blood in 
line with the increased PlGF mRNA levels we observed by RT-qPCR in carcinoma biopsies. At 
the stage of colon adenoma, the increment in PlGF serum levels is not significant with Kruskal-
Wallis one-way ANOVA. However, when comparing the serum levels of the healthy individuals 
and adenoma patients by means of a Mann-Whitney U test, a significant increment (p<0.05) in 
serum PlGF levels is observed in the adenoma patients. Yet, expansion to a larger patient cohort 
is indicated to obtain solid conclusions on PlGF serum levels at the stage of colon adenoma. 
As for VEGF-A and VEGF-C serum levels, no significant differences were observed between 
healthy, colon adenoma and carcinoma samples using the Luminex®-based immunoassay. This is 
in contrast with previous studies reporting increased levels of serum VEGF-A and/or VEGF-C in 
colorectal cancer patients [3-8]. Although this discrepancy might be due to the detection assay 
used, also other features may underlie this discrepancy with literature. Because VEGF-A is also 
released by activated platelets during blood clotting, several studies have reported that the levels 
in serum do not necessarily reflect the actual level of circulating VEGF-A but rather platelet 
degranulation during clotting [9, 10]. Therefore, plasma VEGF-A levels rather than serum levels 
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may better reflect the ongoing angiogenic activity because less platelet activation is to be 
expected in plasma [9, 11]. In line herewith, plasma levels of VEGF-A have been ascribed a 
prognostic value in colorectal cancer [9, 12, 13]. Other studies however reported that plasma 
VEGF-A levels were not increased in colorectal cancer patients and showed no association with 
clinicopathological variables [14]. Possibly, VEGF-A released by platelets may also contribute to 
increased VEGF-A levels in plasma, although to a far lesser extent than in serum [15]. Also 
VEGF-C is released by platelets during clotting and therefore also VEGF-C serum levels may be 
confounded with platelet-derived VEGF-C [16, 17]. Clearly, the debate on the ideal type of blood 
sample for measuring circulating VEGF-A and VEGF-C is still ongoing. It is proposed when 
using serum to include platelet counts in the readout, thus allowing for normalization of platelet 
numbers between the samples and a better comparison between groups [18].  
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5.2.2 Association between VEGF family members and clinicopathological variables 
In order to verify whether any of the overexpressed VEGF family members are associated with 
clinicopathological features of colon adenoma, carcinoma and liver metastasis samples, multiple 
comparisons were performed between the VEGFs expression profiles and clinicopathological 
variables. VEGF-A, VEGF-B and VEGF-C expression levels correlated significantly with the 
histology (tubular or villous/tubulovillous) of colon adenoma samples (Table 5.4, Figure 5.7). 
VEGF-A expression levels were significantly higher in villous and tubulovillous adenoma than in 
tubular adenoma, whereas the expression levels of VEGF-B and VEGF-C were higher in tubular 
adenoma. However, since both VEGF-B and VEGF-C were not significantly induced in colon 
adenoma, this correlation probably is coincidental. Finally, no correlations were found with age, 
gender, localization in the colon or the grade of dysplasia in adenoma (Table 5.4). 
 
Figure 5.7 - Comparison of expression levels in tubular adenoma versus villous or tubulovillous adenoma for 
VEGF-A, VEGF-B and VEGF-C with Mann-Whitney test. *: p<0.05 
 
In colon carcinoma and liver metastasis, neither of the VEGFs correlated with general variables 
as age or gender or localization of the primary colon carcinoma (Table 5.5 and 5.6). Only 
VEGF-A showed significance when comparing carcinoma samples from different locations in the 
colon, although Dunn’s multiple comparison test did not find specific significant differences 
between the colonic regions (Table 5.5, Figure 5.8). 
Also disease specific variables – differentiation grade or Dukes classification, therapy before 
resection of liver metastases – showed no correlation with expression levels of VEGFs. On the 
other hand, overexpression of VEGF-A was significantly higher in metachronous liver metastases 
as compared to synchronous liver metastases (Table 5.6, Figure 5.9). 
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Figure 5.8 - Comparison of VEGF-A expression levels in carcinoma from proximal, middle or distal regions in 
the colon with Kruskal Wallis test. The difference between the medians is statistically significant (p<0.05), but 
Dunn’s multiple comparison test detects no specific significant difference between two groups. 
 
Figure 5.9 - Comparison of VEGF-A expression levels in synchronous versus metachronous liver metastases 
with Mann-Whitney test. *: p<0.05 
 
Overall, few significant correlations were found between the expression levels of VEGF family 
members and clinicopathological variables in either of the three stages of colon cancer. Only 
VEGF-A was found to correlate with villous and tubulovillous adenoma, which have a higher 
intrinsic risk of malignant transformation than tubular adenoma. However, since VEGF-A is not 
correlated with a high degree of dysplasia in adenoma – another adenomatous feature with an 
increased risk of malignant transformation – it is hard to state that high levels of VEGF-A are 
associated with an increased risk of malignant transformation. High expression levels of VEGF-A 
were also correlated with metachronous liver metastasis, which may indicate an association of 
higher VEGF-A mRNA levels with recurrence of metastasis. This agrees with a previous report 
by Min and colleagues, who found that high VEGF-A serum levels are associated with a high 
risk of metachronous liver metastasis and hepatic recurrence following the resection of 
synchronous liver metastasis [8]. In addition, pre-operative VEGF-A protein levels in serum and 
carcinoma samples from colorectal cancer patients have been demonstrated to predict recurrence 
and development of metastases following curative surgery of colorectal carcinoma [19-21]. 
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Abstract 
Shifts between colon adenoma and colon carcinoma stages in the expression profiles of vascular 
endothelial growth factor (VEGF) family members have been reported before. Because eicosanoids are 
well known inducers of VEGFs and angiogenesis, we performed a correlated mRNA expression analysis 
of enzymes involved in eicosanoid synthesis and VEGF family members. Hereto, a comparative RT-qPCR 
analysis was performed on colon adenoma and carcinoma samples to measure mRNA expression levels of 
VEGF-A, VEGF-B, VEGF-C and PlGF as well as of genes encoding the eicosanoid enzymes 
cyclooxygenase 2 (COX2) and 5-lipoxygenase (5-LOX). The observed eicosanoid enzyme expression 
levels revealed differential profiles with a 5-LOX signature present in adenoma samples and a COX2 
signature in carcinoma samples. Dual expression of COX2 and 5-LOX was associated with high grade 
dysplastic and villous adenoma samples and correlated in adenoma and carcinoma samples with the 
co-expression of multiple VEGF family members. This correlated mRNA expression analysis thus 
demonstrates the occurrence of distinctive 5-LOX and COX2 expression profiles for colon adenoma and 
carcinoma stages and their overexpression in these samples showing cumulative expression of multiple 
VEGF family members. In addition, dual expression of COX2 and 5-LOX  in adenoma may indicate an 
increased likelihood of malignant progression to carcinoma. 
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6.1.1 Introduction  
Eicosanoids comprise a set of lipid inflammatory mediators derived from arachidonic acid 
metabolism and play a pivotal role in cancer development and progression [1, 2]. Especially 
prostanoids, generated through cyclooxygenase (COX) 1 and COX2, and leukotriene-products of 
5-lipoxygenase (5-LOX) are inflammatory mediators promoting in addition to inflammation also 
angiogenesis through the induction of vascular endothelial growth factors (VEGF) [3-5]. 
Prostaglandin (PG) E2 has been shown to stimulate the translocation of HIF-1 to the nucleus and 
hereby to indirectly promote the expression of VEGF-A [6, 7]. Also the expression of VEGF-C is 
induced by COX2 via the PGE2-pathway [8]. From the leukotrienes (LT) generated through 5-
LOX, especially LTB4 and LTD4 have been shown to induce expression of VEGF-A [5, 9]. 
We have observed a substantial shift in expression signatures of VEGF family members between 
adenoma and carcinoma stages, with PlGF and VEGF-A overexpressed already at the adenoma 
stage and supplemented by VEGF-B and VEGF-C in the carcinoma stage [10]. Moreover, 
individual patient samples showed an increasing number of overexpressed VEGFs when 
comparing adenoma (0 to 2 VEGFs) with carcinoma (3 to 4 VEGFs) samples [10]. Because 
eicosanoids are well-known inducers of VEGFs and angiogenesis, we performed a correlation 
study to verify if the stage-dependent angiogenic signatures observed in colon cancer coincide 
with mRNA expression signatures of COX2 and 5-LOX. Although the expression of COX2 has 
already been reported to correlate with VEGF-A and VEGF-C expression in several types of 
cancer [3, 11-17], up to now no systematical expression analysis of the VEGF family members 
and eicosanoid enzymes has been reported for colon cancer. Therefore, we performed a 
correlated mRNA expression analysis of COX2 and 5-LOX as well as of VEGF-A, VEGF-B, 
VEGF-C and PlGF in colon carcinoma samples and colon adenoma samples. VEGF-D was not 
included in this study because previous results revealed invariable expression levels of VEGF-D 
in colon cancer [10]. 
6.1.2. Materials and methods 
Biological samples 
Samples were obtained from colon adenoma (n=16) and primary colon carcinoma (n= 37 ) at the 
Ghent University Hospital. Adenoma and carcinoma were sampled by biopsy in the infiltrating 
area of the growth. Histopathological examination confirmed the adenoma/carcinoma state of the 
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tissue. From each patient, a corresponding healthy colon sample was taken from the same colon 
segment. None of the patients had received chemo- or radiotherapy before colonoscopy. Tissue 
samples were collected immediately after isolation in RNAlater® Solution (Ambion/Applied 
Biosystems, Foster City, CA). All samples were kept at -80°C until RNA extraction. The 
clinicopathological features of the patients are summarized in tables 6.1 and 6.2. All tissues were 
obtained following informed consent of the patients and approval of the study by the Ethics 
Committee of the Ghent University Hospital.  
Variable Number of patients 
Sex  
    Male   21 
    Female 16 
Age at diagnosis  
    Median age (range, years) 71 (39–85) 
Site of tumor  
    Sigmoid 20 
    Colon descendens 1 
    Colon transversum 2 
    Hepatic flexure 1 
    Colon ascendens 5 
    Caecum 7 
    Not specified 1 
Differentiation grade  
    Low 12 
    Moderate 17 
    High 3 
    Unknown 5 
Dukes classification  
    Dukes’ A 3 
    Dukes’ B 15 
    Dukes’ C 7 
    Dukes’ D 12 
    Unknown 0 
T category  
    T1-T2 3 
    T3-T4 26 
    Tx 8 
Lymphatic spread  
    N0 18 
    N+ 10 
    Nx 9 
Metastasis  
    M0/Mx 25 
    M+ 12 
Table 6.1 - Clinicopathological features of the colon carcinoma patients. 
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Variable Number of patients 
Sex  
    Male   10 
    Female 6 
Age at diagnosis  
    Median age (range, years) 68 (18-80) 
Site of tumor  
    Sigmoid 9 
    Colon transversum 2 
    Hepatic flexure 1 
    Colon ascendens 1 
    Caecum 3 
Dysplasia  
    Low 10 
    High 4 
    Unknown 2 
Classification  
    Tubular 8 
    Tubulovillous 6 
    Villous 1 
    Unknown 1 
Table 6.2 - Clinicopathological features of the colon adenoma patients. 
 
RNA-extraction, RNA-quality control and cDNA-synthesis 
Total RNA was extracted with the RNeasy Plus mini kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s instructions. This kit contains a gDNA-elimination step to avoid gDNA 
contamination. After extraction, RNA quality and integrity were verified using an RNA 6000 
Nano Chip Kit on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). 
Only samples with adequate quality and integrity (adenoma 16/18, carcinoma 37/39) were used 
for the RT-qPCR analysis. cDNA was synthesized from 1 µg of total RNA using Superscript® II 
reverse transcriptase (Invitrogen, Merelbeke, Belgium) according to the manufacturer’s 
instructions. 
RT-qPCR 
Real-time quantitative PCR (RT-qPCR) was performed using the LC 480 Sybr Green I master kit 
on a LightCycler® 480 Real-Time PCR system (both from Roche Applied Science, Penzberg, 
Germany). Primers were designed using PrimerSelect (DNASTAR, Madison, USA) and 
purchased from Invitrogen. The primers were designed for gene-specific expression profiling and 
cover all splice variants. The sequences of the forward and reverse primers were as follows: 
VEGF-A 5’-TGAGTTGCCCAGGAGACCAC-3’ and 5’-GAAGGGGAGCAGGAAGAGGAT-
3’; VEGF-B 5’-CCGGAAGCTGCGAAGGTGACA-3’ and 5’-
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GGGAGACAAGGGATGGCAGAAGAG-3’; VEGF-C 5’-CACGGCTTATGCAAGCAAAGA-
3’ and 5’-TCCTTTCCTTAGCTGACACTTGT-3’; PlGF 5’-TGCGGCGATGAGAATCTGC-3’ 
and 5’-AGCGAACGTGCTGAGAGAAC-3’; COX2 5’-TTGCTGGAACATGGAATTACC-3’ 
and 5’-TGCCTGCTCTGGTCAATG-3’; 5-LOX 5’-TGGCGCGGTGGATTCATAC-3’ and 5’-
CAGGGGAACTCGATGTAGTCC-3’. All samples were assayed in triplicate. Relative 
expression values were calculated using the 2(-delta delta C(T)) method and were normalized 
against reference genes: tata-binding protein (TBP) and succinate dehydrogenase complex 
subunit A (SDHA) (primers: TBP 5’-CGGCTGTTTAACTTCGCTTC-3’ and 5'-
CACACGCCAAGAAACAGTGA-3’; SDHA 5’-TGGGAACAAGAGGGCATCTG-3’ and 5’-
CCACCACTGCATCAAATTCATG-3’). In these calculations we took into account the PCR 
efficiency of the individual PCR reactions, calculated on the basis of linear regression as 
described in Ruijter et al [18]. The normalized relative expression values were scaled against the 
median of the respective healthy tissue samples (median of healthy samples set to 1). The 
specificity of amplification was confirmed by evaluation of the melting curves. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism® software (GraphPad Software Inc., La 
Jolla, California, USA). For comparisons of paired samples, the Wilcoxon signed rank test was 
used. Statistical significance of comparisons between two independent groups was determined 
with the two-tailed Mann-Whitney U test. Correlations between the expression levels of genes 
were calculated with the Spearman’s correlation test. Significant p-values were ranked as p<0.05 
(*), p<0.01 (**) and p<0.001 (***). 
6.1.3 Results 
Stage-dependent expression profiles of eicosanoid enzymes 
n-Fold induction values of COX2 and 5-LOX were determined for colon adenoma and carcinoma 
samples with respect to matched healthy tissue samples. COX2 was significantly induced only in 
carcinoma samples (Fig 6.1A). 5-LOX on the other hand was significantly increased in both 
adenoma and carcinoma stages albeit at a significantly higher level in adenoma samples 
compared to carcinoma samples (Fig 6.1B). 
In a next step, we compared the COX2 and 5-LOX expression signatures from individual colon 
adenoma and carcinoma samples with their matched healthy samples. The cut-off for 
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overexpression was set on the median +(2.58 x SD) of the corresponding healthy tissue cohort. 
5-LOX was overexpressed in 75% of the adenoma samples either alone (37,5%) or in 
combination with COX2 (37,5%) (Figure 6.1D). COX2 on the other hand was only overexpressed 
in addition to 5-LOX (Figure 6.1C). Strikingly, carcinoma samples revealed opposite expression 
profiles with overexpression of COX2 in almost every sample either alone (48,5%) or in 
combination with 5-LOX (43%), whereas 5-LOX was only overexpressed in samples with COX2 
overexpression (Figure 6.1). 
Combined, these results indicate that adenoma samples have a predominantly 5-LOX profile 
while carcinoma samples mainly have a COX2 mRNA expression profile. 
 
Figure 6.1 – The induction of COX2 and 5-LOX during progression of colon cancer. n-Fold induction levels in 
adenoma and carcinoma samples of (A) COX2 and (B) 5-LOX are shown in the graphs above. The n-fold induction 
value represents the ratio of the expression value of the diseased sample against the expression value of the paired 
healthy sample. The box represents the median with interquartile range and the whiskers represent minimum and 
maximum ratios. Significance of the induction on its own is indicated beneath the minimum whisker with ##: p<0.01 
and ###: p<0.001, calculated with Wilcoxon signed rank test. Significant differences in induction between the stages 
is indicated above the boxes with **: p<0.01; ***: p<0.001, calculated with Mann-Whitney U  test. 
The graphs below show for COX2 (C) and 5-LOX (D) the percentages of colon adenoma and carcinoma samples 
which are either negative or overexpressing one or both eicosanoid enzymes. The cut-off for overexpression was 
determined based on the median of the healthy samples for each population group +(2.58 x SD). 
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Dual expression of COX2 and 5-LOX is associated with increased risk of malignant 
transformation in adenoma 
Colon adenomas showing a high grade of dysplasia and featuring a villous morphology have an 
increased risk of further progressing to the carcinoma stage. In the current study, 16% of 
adenoma samples had high grade dysplastic or villous features. Strikingly, as shown in figure 6.2 
all of these samples displayed a dual COX2 and 5-LOX profile. Moreover, high-risk-adenoma 
samples represented 66% of the adenoma samples overexpressing both COX2 and 5-LOX. Thus, 
a dual COX2 and 5-LOX eicosanoid enzyme profile is strongly associated with an increased risk 
of malignant transformation into carcinoma. 
 
 
Figure 6.2 - Risk of malignant transformation versus number of overexpressed eicosanoid enzymes in colon 
adenoma samples. The cut-off for overexpression was determined based on the median of the healthy samples for 
each population group +(2.58 x SD). 
 
Correlation with angiogenic gene expression 
Especially COX2-produced prostanoids but also leukotrienes produced by 5-LOX have been 
shown to promote angiogenesis through the induced expression of especially VEGF-A. We 
showed the occurrence of PlGF and VEGF-A overexpression already at the adenoma stage with 
an additional overexpression of VEGF-B and VEGF-C in the carcinoma stage. To verify whether 
the overexpression of COX2 and 5-LOX is correlated with the overexpression of VEGF family 
members, we performed a Spearman’s correlation analysis. As shown in figure 6.3, colon 
carcinoma samples showed significant correlations between the overexpression of COX2 and the 
overexpression of VEGF-A and PlGF, and to a lesser extent of VEGF-C. In contrast, in adenoma 
samples no significant correlations between COX2 overexpression and overexpression of VEGFs 
emerged. Also for 5-LOX, no significant correlations appeared in either of the sample cohorts. 
This analysis indicates that an inflammatory COX2-associated expression of VEGFs may exist in 
colon carcinoma, but not in colon adenoma. 
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Figure 6.3 - Correlation between overexpression of VEGF family members and overexpression of eicosanoid 
enzymes in colon adenoma and carcinoma samples. Relative mRNA expression levels of VEGF-A (▲), VEGF-B 
() , VEGF-C () and PlGF () versus those of (A, C) COX2 and (B, D) 5-LOX are shown in scatter plots for (A-
B) colon adenoma and (C-D) colon carcinoma. The best-fit line is depicted for each gene pair. Expression levels 
were normalized against reference gene TBP and SDHA and were scaled against the median of the paired healthy 
colon samples (median set to 1). The tables underneath the scatter plots summarize the results of the Spearman’s 
correlation analysis with rs representing the Spearman correlation coefficient which ranges from 1 to -1 with 1 
standing for a perfect correlation, 0 for no correlation, and -1 for a perfect inverse correlation. The p-value (p) 
quantifies the likelihood that the correlation is found by chance and the variables don’t really correlate. Significant 
correlations are indicated by *: p<0.05, **: p<0.01 and ***: p<0.001. 
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Co-expression of VEGF family members coincides with overexpression of eicosanoid 
enzymes  
VEGF expression signatures from individual colon adenoma and carcinoma samples were 
determined, applying a similar cut-off for overexpression or not for COX2 and 5-LOX above. 
Combining both sets of expression signatures then allowed us to picture to what extent the shift 
toward co-expression of VEGFs observed upon progression from colon adenoma to colon 
carcinoma coincides with the overexpression of eicosanoid enzymes. Strikingly, this combined 
analysis revealed a strong interdependency between overexpression of VEGF family members 
and overexpression of COX2 and/or 5-LOX. Co-expression of VEGFs occurs almost exclusively 
in colon adenoma and carcinoma samples which have also eicosanoid enzymes overexpressed 
(Figure 6.4A, C). However, neither adenoma nor carcinoma samples achieved statistical 
significance in their contingency tables, though the p-values were low, 0.052 and 0.086 
respectively (Table 6.3). Nevertheless, when regarding the proportional presence of eicosanoid 
enzyme overexpression in the group of samples overexpressing none or one VEGF and in the 
group with co-expression (Figure 6.4B, D), it clearly shows that co-expression of VEGF family 
members associates with the presence of overexpressed eicosanoid enzymes. 
Adenoma 
Eicosanoid 
enzymes   Carcinoma 
Eicosanoid 
enzymes  
Absent Present Total  Absent Present Total 
V
EG
Fs
 No or 1 4 6 10  
V
EG
Fs
 No or 1 2 5 7 
Co-
expression 0 6 6  
Co-
expression 1 29 30 
 Total 4 12 16   Total 3 34 37 
Table 6.3 – Contingency tables for VEGF family members and eicosanoid enzymes for colon adenoma and 
carcinoma samples. Statistical significance was calculated with Fisher’s exact test. 
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Figure 6.4 - Correlation between co-expression of VEGFs and overexpression of eicosanoid enzymes for 
individual colon adenoma and carcinoma patients. The graphs show the percentages of colon adenoma (A) and 
carcinoma (C) samples that overexpressed none or one VEGF or multiple VEGF family members, concomitant with 
the absence or presence of overexpressed eicosanoid enzymes. Also the proportional presence of overexpressed 
eicosanoid enzymes within each VEGF-signature-group is shown for colon adenoma (B) and carcinoma (D) samples. 
’Absent” means no eicosanoid enzymes were overexpressed, “present” means that either COX2, 5-LOX or both were 
overexpressed. “Co-expressed” means that 2, 3 or 4 VEGF members were overexpressed. The cut-off for 
overexpression was determined based on the median of the healthy samples for each cohort  +(2.58 x SD). 
 
6.1.4 Discussion 
Previous studies on the correlation of the expression of eicosanoid enzymes and VEGF family 
members in (colon) cancer are strongly focused on COX2 and VEGF-A along with VEGF-C [3, 
11-17]. Yet, it remains unclear to what extent overexpression of VEGF-B and PlGF correlate 
with COX2 overexpression and if any correlation can be found with 5-LOX. Here, we performed 
a correlated mRNA expression analysis of COX2, 5-LOX and VEGF family members during the 
progression from colon adenoma towards carcinoma. 
Already at the early stage of colon adenoma, a distinctive inflammatory profile with a strong 
expression increment of 5-LOX was apparent. Overexpression of 5-LOX has been proposed 
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before to be present in colon adenomas [19, 20]. Similarly an induction of COX2 in adenoma 
samples has been described [21-23]. Also we detected COX2 overexpression but only in 
combination with 5-LOX and mainly restricted to adenoma samples showing a villous 
morphology and/or exhibiting a high degree of dysplasia, two characteristics indicative of greater 
risk of malignant transformation. Applying the dual expression of COX2 and 5-LOX as a marker 
for malignancy, we thus could identify all adenoma samples at higher risk of malignant 
transformation. Conversely, two thirds of the samples with dual expression were marked by an 
independent pathological examination as being at higher risk. Yet, since also COX2 expression 
per se correlated with the grade of dysplasia (supplemental Table S6.1), it is not possible to state 
at this point whether the observed association with increased risk is caused by the dual COX2 and 
5-LOX overexpression or by COX2 alone. Expansion of this analysis to larger cohort size may be 
indicated to fully resolve this issue of obvious importance for chemoprevention of colon cancer. 
The finding by Mohammed and colleagues that treatment of Apc-/+ mice with the dual 5-
LOX/COX2 inhibitor, licofelone, prevented successfully the development of colon adenomas and 
outgrowth of colon carcinomas [24] clearly corroborates our proposition of an association 
between high-risk adenoma phenotypes and the occurrence of a dual COX2 and 5-LOX 
overexpression. 
Also colon carcinoma samples showed an inflammatory signature on the basis of a pronounced 
COX2 expression increment in almost all samples. However, the 5-LOX increment observed in 
adenoma samples was less apparent. Looking for inflammatory pro-angiogenic triggers 
contributing to the observed expression profiles of VEGF family members [10], we found a 
strong correlation between COX2 and VEGF-A mRNA levels in colon carcinoma samples by 
means of Spearman’s correlation analysis, thus confirming previous reports on the association of 
COX2 expression with expression of VEGF-A [11, 25]. Interestingly, this analysis also revealed 
a novel and strong association between COX2 and PlGF. However, although also reported in 
literature, we observed only a weak, yet statistically significant association between COX2 and 
VEGF-C [3, 12]. Finally, from adenoma samples no association between VEGF genes and 
eicosanoid enzyme genes emerged. Apparently, a non-inflammatory/non-eicosanoid mechanism 
underlies the expression of single VEGF family members in colon adenomas. 
These observed correlations in carcinoma samples between overexpressed COX2 and increased 
mRNA levels of especially VEGF-A and PlGF may indicate that eicosanoids are implicated in 
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the cumulative co-expression of multiple VEGF family members during progression from colon 
adenoma toward colon carcinoma. Mapping the VEGF signatures against the presence of 
eicosanoid enzymes indeed revealed in colon carcinoma samples a clear convergence of the 
overexpression of multiple VEGF family members with the presence of overexpressed eicosanoid 
enzymes. Strikingly, such convergence was also observed in colon adenoma samples 
overexpressing two or more VEGFs. As a whole, this correlation analysis strongly points to a role 
for COX2- and/or 5-LOX-derived eicosanoids in driving the aberrant expression of multiple 
VEGF family members in both adenoma and carcinoma stages of colon cancer but not or to a 
lesser extent the physiological expression of single VEGF family members. 
In conclusion, this correlated analysis of COX2, 5-LOX and VEGFs mRNA expression levels 
reveals the complex and intertwined nature of inflammatory and angiogenic gene expression 
already at the stage of adenoma and upon further progression to carcinoma. Thus, our expression 
analysis identifies 5-LOX as the predominant eicosanoid enzyme overexpressed in colon 
adenoma and COX2 in colon carcinoma. In both stages, the occurrence of overexpressed 
eicosanoid enzymes is associated with the cumulative co-expression of multiple VEGFs. In 
addition, dual expression of COX2 and 5-LOX in colon adenoma is correlated with an increased 
risk of malignant transformation, thus identifying both enzymes as clinically relevant targets for 
chemoprevention as well as treatment of colon cancer. 
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SUPPLEMENTAL DATA 
 
 COX2 5-LOX VEGF-A VEGF-B VEGF-C PlGF 
Age1 0.5040 0.8749 0.7925 1.000 0.3530 0.1806 
Gender2 0.1063 0.2198 0.7925 0.2198 0.9130 0.3676 
Localization3 0.6407 0.1852 0.2418 0.1846 0.2912 0.4128 
Dysplasia4 0.0267* 0.6354 0.3736 0.3037 0.2273 0.6354 
Histology5 0.7683 0.7789 0.0401* 0.0205* 0.0228* 0.3969 
1
 Comparison of expression levels in patients younger than 70 years versus patients (n=10) of 70 years or older (n=6) 
with Mann-Whitney test. 
2
 Comparison of expression levels in male (n=10) versus female (n=6) patients with Mann-Whitney test. 
3
 Comparison of expression levels in samples from different adenoma sites (caecum and Valve of Bauhin (n=3)   
versus colon ascendens, transversum, descendens and hepatic flexure (n=4) versus sigmoid (n=9)) with Kruskal 
Wallis test. 
4
 Comparison of expression levels in samples with low grade (n=10) versus high grade (n=4) dysplasia with Mann-
Whitney test. *: p<0.05 
5
 Comparison of expression levels in samples from tubular (n:-=8) versus villous/tubulovillous (n=7) adenoma with 
Mann-Whitney test. *: p<0.05 
Additional table S6.1 - Comparison of the expression of COX2, 5-LOX and VEGF family members with 
clinicopathological features of colon adenoma. 
 
Figure S6.1 – Comparison of COX2 expression levels in colon adenoma with low versus high dysplasia with 
Mann-Whitney test. *:p<0.05 
 
Figure S6.2 - Comparison of expression levels in tubular adenoma versus villous or tubulovillous adenoma for 
VEGF-A, VEGF-B and VEGF-C with Mann-Whitney test. *: p<0.05 
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6.2 Additional data 
6.2.1 Eicosanoids promote invasion of human colon carcinoma cells 
In order to elucidate the mechanism behind the observed mRNA signatures of COX2, 5-LOX and 
VEGF-family members in human clinical samples (section 6.1), we aimed to re-translate these 
observations to more basic ex vivo or in vitro scientific models. A first approach hereto was to 
determine the effect of eicosanoids on malignancy of human colon carcinoma cell lines. This 
suggestion is based on the observed correlation between the dual overexpression of COX2 and 
5-LOX with an increased risk of malignant transformation in adenoma. Because malignancy is 
not a measurable in vitro parameter, invasiveness was used as a criterion for malignancy. After 
all, the capability to invade is a critical feature that distinguishes malignant cells from benign 
cells. Eicosanoid agonists, PGE2 and LTD4, as well as COX2 and 5-LOX inhibitors, meloxicam 
and zileuton, were tested for their effect on invasiveness of colon carcinoma cells using an in 
vitro invasion assay. The invasion assay was based on the preparation of a native collagen type I 
gel on top of which colon carcinoma cells were seeded as single cells [1]. After culture for 24 
hours, the single-cell invasion was evaluated with an inverted phase-contrast microscope and 
quantified by calculating the invasion index (the number of cells with invasive extensions/the 
total number of cells counted x 100) for a total of 10 fields. 
The experimental setup consisted of the human colon carcinoma cell lines HCT-8 (HCT-8/E11), 
HCT-116, DLD-1 and HT29, stimulated with PGE2 and/or LTD4 or inhibited with meloxicam 
and/or zileuton. In order to determine the effect of either PGE2 or LTD4 alone, PGE2 was added 
to the cells together with zileuton to block the endogenous production of leukotrienes, and LTD4 
was added with meloxicam to block the endogenous production of prostaglandins. As positive 
control, the cells were treated with TGF-α.  
The obtained results indicated that HCT-116 and HT-29 are not suitable for this invasion assay. 
HCT-116 cells showed massive invasion in every condition, including the negative control 
(Figure 6.5C,D). In contrast, no invasion was observed with HT-29 cells in any of the conditions 
assayed (data not shown). DLD-1 and HCT-8 cells showed however a clear induction of invasion 
after treatment with TGF-α (Figure 6.5A,B). In DLD-1 cultures, a substantial amount of invasive 
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cells was already present in the negative control sample, leading to a smaller window of 
measurement. 
 
Figure 6.5 – Representative pictures of HCT-8 and HCT-116 cell invasion. Phase contrast pictures of single 
HCT-8 (A, B) and HCT-116 (C, D) colon cancer cells seeded on collagen type I gel and cultured for 24 h in culture 
medium (negative control) or culture medium supplemented with TGF-α (10ng/ml) (positive control). Arrows 
indicate invasive extensions in A and B.  
 
As shown in figure 6.6, both PGE2 and LTD4 promoted invasion of the HCT-8 and DLD-1 cells 
to a similar extent as the TGF-α positive control. Only a limited additional invasion was observed 
when both eicosanoids were added to the cultures. In contrast, both zileuton and meloxicam had 
minimal effects on the invasion of both cell types. Interestingly, inhibition of COX2 abolished 
the induction of invasion by LTD4 and conversely, the promotion of invasion by PGE2 was 
abolished by zileuton. 
The promotion of invasion by PGE2 agrees well with previous studies reporting a PGE2-
promoted invasion of colon cancer cells [2, 3]. No published data were found for LTD4. 
Strikingly, the inhibition of the alternate eicosanoid pathway, abolished the increased invasion by 
A           HCT-8 control B            HCT-8 TGF-α 
D            HCT-116 TGF-α C           HCT-116 control 
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both PGE2 and LTD4 although the addition of both eicosanoids did only barely induce an 
additional invasion, thus indicating interdependence rather than synergy between COX2- and 
5-LOX-pathways for the stimulation of invasion.  
 
Figure 6.6 – LTD4 and PGE2 promote invasion in colon cancer cells. The n-fold induction of invasion is shown 
for HCT-8 and DLD-1, with reference to the invasion index of the negative control (NC), which was set to 1. Used 
concentrations were: TGF-α [1 µM], PGE2 [1 µM], LTD4 [1 µM], meloxicam [10µM] en zileuton [10µM]. 
. 
In conclusion, these results show for the first time that next to PGE2, also LTD4 may promote 
invasiveness of colon cancer cells. However, the observed correlation in adenoma samples 
between increased risk of malignant transformation and dual overexpression of COX2 and 5-
LOX, was only partially found because dual administration of PGE2 and LTD4 did not show an 
additional effect. Yet, suppression of either factor inhibited the invasion promoting effect of the 
other, indicating interdependence but not synergy between both eicosanoid pathways for the 
promotion of colon cancer cell invasiveness.  
.  
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6.2.2 Eicosanoids don’t affect COX2, 5-LOX and VEGFs expression patterns in human 
colon carcinoma cells 
In a second approach to re-translate our observations on clinical samples to more basic ex vivo or 
in vitro scientific models, we verified to what extent COX2- and 5-LOX-derived eicosanoids may 
impact VEGF expression levels. Based on the results presented in section 6.1, we hypothesized 
that the administration of eicosanoids (PGE2 or LTD4) may induce the co-expression of VEGFs, 
whereas the administration of COX2- and 5-LOX-inhibitors (meloxicam or zileuton) may inhibit 
their expression. The human colon carcinoma cell lines HT-29, HCT-116 and CaCo-2 were 
selected for this experiment because of their distinct behavior. Whereas CaCo-2 is a slow 
growing cell line, HCT-116 behaves rather aggressive in the invasion assay described above (see 
6.2.1). HT-29 is a less aggressive, though still a rapidly proliferating cell type. Cells were seeded 
at 1.25 x105 cells in twelve-well plates and cultured for 24 hours before administration of 
eicosanoid agonists or antagonists. TNF-α was added as a positive control and DMSO was added 
as mock control. After one, three and six hours of treatment, RNA was isolated and cDNA-
synthesis followed by RT-qPCR were performed as described before (see 6.1.2).  
 
Figure 6.7 – COX2 expression is induced by TNF in HT-29 colon carcinoma cells. n-Fold induction levels of 
COX2 in the HT-29 human colon carcinoma cell line is shown. The n-fold induction value represents the ratio of the 
expression value of the treated sample against the expression value of the basal condition. 0.5 and 2-fold inductions 
(red lines) were evaluated as respectively significant reduction and induction. Treatment conditions were: PGE2-l 
(low): 0.5 µg/ml, PGE2-h (high): 5 µg/ml, LTD4-l: 0.05 µg/ml, LTD4-h: 0.5 µg/ml, meloxicam-l: 5 µg/ml, 
meloxicam-h: 10 µg/ml, zileuton-l: 5 µg/ml, zileuton-h: 10 µg/ml, TNF-α: 250 IU/ml (positive control), DMSO, 
2µl/ml (mock control). 
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As expected, a significant induction of COX2 was observed for the treatment condition with 
TNF-α at all three time points in cell line HT-29 (Figure 6.7). However, the other cell lines, 
DLD-1 and Caco-2, showed no induction of COX2 after treatment with TNF-α (data  not shown). 
In addition, none of the other treatment conditions had an effect on the expression of COX2 in the 
three cell lines. To our surprise, also the expression levels of 5-LOX, VEGF-A, VEGF-B or PlGF 
were not affected by any treatment condition in all three cell lines. Figure 6.8 shows the 
expression of PlGF in CaCo-2 as a representative example. Similar graphs were obtained for all 
the genes – VEGF-A, VEGF-B, PlGF, COX2 and 5-LOX – in the three cell lines assayed. In 
addition, VEGF-C expression was below the detection limit in all three cell lines. 
 
Figure 6.8 – PlGF mRNA expression levels in CaCo-2 cells. n-Fold induction levels of PlGF in the CaCo-2 
human colon carcinoma cell line is shown. The n-fold induction value represents the ratio of the expression value of 
the treated sample against the expression value of the basal condition. 0.5 and 2-fold inductions (red lines) were 
evaluated as respectively significant reduction and induction. Treatment conditions were: PGE2-l (low): 0.5 µg/ml, 
PGE2-h (high): 5 µg/ml, LTD4-l: 0.05 µg/ml, LTD4-h: 0.5 µg/ml, meloxicam-l: 5 µg/ml, meloxicam-h: 10 µg/ml, 
zileuton-l: 5 µg/ml, zileuton-h: 10 µg/ml, TNF-α: 250 IU/ml (positive control), DMSO, 2µl/ml (mock control). 
 
These (negative) results clearly show that the expression signatures observed in clinical samples 
cannot be reproduced in the human colon cell lines HT-29, CaCo-2 and HCT-116. Possibly, this 
is due to the absence of a functional micro-environment in the culture and/or by the optimal 
growth-conditions for the tumor cells in vitro. Performing these assays under hypoxic culture 
conditions might more closely mimic the growth conditions of the colon tumor cells in vivo 
although the addition of TNF-α to the cultures as a stress-trigger had no effect (data not shown). 
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Alternatively, short-term cultures of fresh samples of colon adenoma and carcinoma may be 
considered. As these samples contain all the cellular components of real-life tumors, they may be 
more responsive to the treatment conditions. Hypoxic culture conditions may additionally be 
applied to mimic in vitro the in vivo tumor situation as accurately as possible. 
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Discussion and perspectives 
The expression of VEGF family members in colon cancer: from Pandora’s box to a holistic 
view 
The VEGF family members have been studied many times by many means in many settings on 
many levels and in many types of specimens. More specific, these “many’s” stand for the fact 
that different research groups have studied VEGFs by a range of different methods (RT-qPCR, 
PCR, northern blot, western blot, ELISA, immunohistochemistry,…) in different combinations 
(individual VEGFs, by pairs, by three or by four) at different levels (mRNA or protein) and in 
different specimens (blood, serum, plasma, cell lines or tissue). We believe that all these 
‘many’s’ and ‘different’s’ contribute to the contradictory results that are yielded when 
performing a literature search for the expression of VEGF family members in colon cancer. Even 
when considering one specific methodological setting, namely tissue mRNA levels by RT-qPCR, 
still contradictory reports on the expression levels of VEGFs in colo(n)(rectal) cancer persist [1-
6]. Yet, we identified two possible confounding factors in those studies. 
First of all, these studies used tissue samples obtained by two different clinical procedures, either 
resection or biopsy [1-6]. By analyzing the difference between both sample types, we may have 
opened Pandora’s box since we revealed that this “small” difference holds major implications 
toward the reliability and capacity of VEGF family members as tissue markers for colon cancer. 
All VEGF family members showed significantly higher expression levels in healthy colon 
samples obtained by resection as compared to healthy colon biopsy samples. Because VEGFs are 
inducible by hypoxia [7, 8] and because also the expression levels of hypoxia inducible COX2 
and the hypoxia markers GLUT-1 and CAIX were significantly increased in healthy resection 
samples, we presume that these expression increments are due to hypoxic stress. In addition, 
similar expression levels of the hypoxia insensitive 5-LOX were observed in both sample types, 
which corroborates our premise. The colon tissue may be prone to hypoxia during surgical 
resection which takes 30 to 90 minutes. Throughout this time, part of the colon is clamped off 
and thus this tissue is cut off from the blood circulation and oxygen delivery. Therefore, it is our 
assumption that hypoxic stress is intrinsic to samples obtained by surgical resection. The 
consequences for mRNA expression analysis of resection samples were rather dramatic because 
the hypoxia-induced expression in healthy resection samples, abolished the differential 
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expression of VEGF-B and VEGF-C in matched carcinoma resection samples and created a 
surgery-induced underexpression of VEGF-D. As a consequence, based on resection samples, 
VEGF-B and VEGF-C provided low accuracy and potential as colon cancer mRNA markers 
whereas underexpression of VEGF-D emerged as a strong and potent marker. These observations 
are however in absolute contrast with those in biopsy samples where VEGF-B and VEGF-C 
emerged as potential and carcinoma stage-specific mRNA markers and a differential expression 
of VEGF-D was completely absent. Such a dramatic effect of the sampling procedure on the 
expression levels of VEGF family members may very well contribute to the contradictory results 
in literature. In addition, our data indicate that biopsy samples, which require only minutes to 
collect, provide a more accurate report on the expression levels of hypoxia-sensitive genes like 
the VEGF family members. 
The use of biopsies implies an additional consideration, namely that a single tumor may display 
several expression signatures, dependent on the location within the tumor. For instance, the 
invasive edge of a tumor has different needs than a necrotic region in the middle of the tumor, 
which may translate in a differential expression pattern in both regions. Since tumor biopsies 
cover only a small part of the tumor, regional differences within the tumor may cause variable 
expression levels between biopsy samples from a single tumor. It would therefore be interesting 
to analyze several (characterized) areas from the same tumor but the sampling of multiple 
biopsies from a single tumor is not something to be taken for granted as it increases the risk of 
bleeding for the patient drastically. Although no explicit analysis was performed to compare 
several biopsy samples from the same carcinoma, two independent experiments – each analyzing 
a combination of 2 biopsies – were performed on a subset of the carcinoma samples (n=23), thus 
providing datasets on different biopsies from these carcinomas. When comparing the results of 
both experiments, the main conclusions are identical. Moreover, despite minor methodological 
differences between both experiments, 87% of these carcinomas showed a similar profile (no or 1 
VEGF versus co-expression) in both experiments. This indicates at least that the biopsies (n=4) 
received as a single carcinoma sample, were obtained in regions with rather homogenous 
expression of VEGFs. 
A second possible confounding factor was found in the fact that most expression studies use 
colorectal samples and thus colon as well as rectal samples [2-6]. However, rectal cancer patients 
near always receive neo-adjuvant therapy prior to surgery. Therefore, the inclusion of rectal 
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samples may constitute a confounding factor. As radiation and chemotherapy have been shown to 
induce hypoxia and upregulation of VEGF-A in experimental as well as clinical samples [9-12], 
it is not unthinkable that neo-adjuvant therapy upregulates the expression of certain VEGF family 
members in rectal cancer samples. Further research, involving a comparative expression analysis 
– as we performed for resection and biopsy samples – is indicated to compare the expression 
levels of VEGF family members in healthy rectal and rectal carcinoma samples before and after 
neo-adjuvant therapy. Such an analysis may validate our hypothesis that also the inclusion of 
rectal samples constitutes a confounding factor. 
By exclusion from our analyses samples obtained by resection as well as samples of rectal origin, 
we avoided interference of these confounding factors. Next, we addressed the limitations of 
previously published studies on the expression of VEGF family members in colon cancer by a 
systematic and comprehensive analysis of the mRNA expression levels of all individual human 
VEGFs in a single experimental setup. To provide an insight in the expression of these genes 
upon progression from healthy colon to a metastasized disease, also colon adenoma and liver 
metastasis samples were included. 
However, the inclusion of liver metastasis samples, presented a novel complexity; we needed to 
consider if liver metastases had to be compared with healthy liver – the tissue where they were 
found – or with healthy colon – the tissue they originate from. The mRNA expression levels of 
the colon marker TTF3 and the liver markers LXRalpha and APoE in a subset of healthy colon, 
healthy liver and liver metastasis samples, taught us that liver metastasis samples retained the 
characteristics of their tissue of origin and gained characteristics of their new environment. 
Indeed, TTF3 levels in liver metastasis samples were similar to those in healthy colon and 
LXRalpha and ApoE levels resembled those in healthy liver. Probably, this additional liver 
signature reflects the presence of residential liver cells in the metastasis samples. The 
contributions of different cell types in the liver metastasis samples to the expression signature 
could be verified in detail by isolation of specific cell subsets with a laser-dissection microscope. 
Yet, of most relevance to this thesis is the observation that the ectopic origin of the liver 
metastases did not affect the conclusions from our comparative VEGF gene expression analysis. 
In fact, similar (VEGF-B) or even higher (VEGF-A, -C, -D and PlGF) expression increments 
were obtained when liver metastasis samples were compared with healthy colon instead of 
healthy liver. This indicates that for metastasis samples the expression increments may be even 
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more pronounced than indicated on the basis of using healthy liver samples as calibrator. 
Nevertheless, we have chosen to follow a conservative approach based on a comparison with 
healthy liver samples because it is far less obvious in the clinical practice to acquire at the same 
time healthy colon samples and liver metastasis samples from one individual patient.  
The normalization of liver metastasis samples was done with only SDHA, due to instability of 
TBP as reference gene in liver metastasis samples. Although we realize that at least two reference 
genes are compulsory for normalization of RT-qPCR analyses, we could not repeat the entire 
experiment with two (new) stable reference genes due to technical issues. In addition, SDHA was 
found to be the most stable reference gene out of ten for liver metastasis samples. After careful 
deliberation, these considerations led to the decision to use only SDHA as a reference gene for 
normalization of liver metastasis samples. It would be ideally to repeat the entire experiment with 
at least two reference genes, stable for all the samples analyzed. 
Finally, our comprehensive and systematic analysis of the mRNA expression of VEGF family 
members revealed the complex nature of angiogenic gene expression already at the stage of 
adenoma and its further deviation towards co-expression of multiple angiogenic genes upon 
progression to carcinoma and liver metastasis. A clear stage-associated progression was apparent 
evolving from VEGF-A and/or PlGF overexpression in adenoma samples toward the additional 
overexpression of VEGF-B and/or VEGF-C in carcinoma as well as metastasis samples. Thus, we 
identified VEGF-B and VEGF-C as angiogenic genes which are upregulated only in carcinoma 
and metastasis stages. Individual patient samples revealed correspondingly discriminating 
signatures with none up to two VEGFs overexpressed in adenoma samples and three up to four 
VEGFs in carcinoma and metastasis samples. In addition, we found a striking conservation 
between colon carcinoma and liver metastasis samples of the VEGF expression signatures, 
indicating that the VEGF expression signatures of colon carcinoma are conserved when 
metastasizing to other body tissues. In order to further corroborate the apparent conservation of 
VEGF expression signatures between primary colon carcinoma and its secondary metastasis, it is 
indicated to compare the expression levels in liver metastasis samples and primary colon 
carcinoma samples from the same patient. Regretfully, for practical reasons it was not possible to 
perform such a matched analysis in the course of the PhD. In addition, it may be interesting to 
perform similar analyses on colon cancer metastases from other body sites than the liver in order 
to verify if this conclusion holds true for metastases in other organs. 
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Ultimately, mRNA-expression is one thing, protein expression is something else. Transcription of 
DNA to mRNA does not necessarily lead to the translation to a functional protein. Nevertheless, 
mRNA levels may correlate with protein levels and preliminary data on samples from mouse 
tumor models have shown similar mRNA and protein expression levels at least for VEGF-A and 
COX2. Attempts to detect the various VEGF members on human colon carcinoma tissue slides 
by immunohistochemistry have however failed due to major background staining. The secreted 
nature of the angiogenic factors was most likely at the basis of the background staining. 
Alternative methods to analyze the protein levels were impeded by the lack of an available 
ELISA-test for VEGF-B and the limited sample size of human biopsies. These limitations have 
obliged us to remain with the quantification of mRNA expression levels, although a parallel 
mRNA-protein profiling is indicated to further corroborate the results discussed in this study. 
VEGFs as diagnostic markers for colon cancer 
Worldwide, colon cancer is the second leading cause of cancer-related mortality and accounts for 
over 1,2 million new cases on a yearly basis. Colon carcinoma evolves from a premalignant 
precursor stage, the so-called polyps or adenoma, through a multistep process, which involves 
sequential and cumulative genetic and epigenetic alterations. Early detection, an essential 
prerequisite to increase patient survival, is difficult by clinical presentation because of the 
asymptomatic nature of colon carcinoma and its adenoma precursor stage. At present, screening 
of the population at risk (age 50 and over) is hampered by the lack of patient-friendly, sensitive 
and affordable detection methods. Endoscopic examination of the colon by colonoscopy is still 
the gold standard for the detection of colon adenoma and carcinoma but its broad application is 
strongly hampered by the invasiveness of the procedure, thus rendering the procedure unpopular 
and unfit for large-scale screening of the population at risk. Non-invasive screening methods for 
the early detection of colon adenoma and carcinoma are therefore urgently needed. 
Because the VEGF family members are readily secreted upon gene induction, we verified to what 
extent the increment in PlGF and VEGF-A mRNA levels observed in colon carcinoma and colon 
adenoma biopsies translates into increased levels in the blood, thus effectively verifying the 
potential of PlGF and/or VEGF-A blood levels to serve as biomarker for the presence of colon 
carcinoma and colon adenoma. The validation of PlGF and/or VEGF-A as a serum biomarker for 
colon carcinoma and adenoma would, if successful, offer a much needed non-invasive and cost-
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effective screening method for the early detection of colon cancer. In addition, also VEGF-C 
serum levels were determined to verify if they could serve as a blood marker, specific for the 
carcinoma stage. Despite previous studies reporting increased levels of serum VEGF-A and 
VEGF-C in colon cancer patients [13-16], we found for neither of them differential serum levels 
in healthy individuals compared to patients with colon adenoma or carcinoma. However, there is 
considerable controversy about the ideal type of blood sample – serum or plasma – for 
measurement of VEGF-A and VEGF-C since both factors are also released by platelets upon 
blood clotting, which is applied to obtain serum [17-19]. Platelet-derived VEGF-A and/or VEGF-
C in serum may thus increase background values and hence mask tumor-derived increments. 
There is therefore an urgent need for a systematic analysis of VEGF-A and VEGF-C levels in 
different blood sample types. A potential experiment to address this query would be an ELISA 
performed on serum and plasma from the same patients in combination with platelet counts to 
allow normalization of differential platelet numbers between the samples, as has been suggested 
by George and colleagues [20]. Such a systematic analysis may clearly determine the differences 
between serum and plasma levels, taking into account a potential contribution of platelets. A 
simultaneous analysis of the expression of the angiogenic genes in adenoma or carcinoma tissue, 
may than allow a further comparison between tissue and blood levels and determine whether 
plasma or serum levels provide the best reflection of VEGF-A and VEGF-C levels in the 
diseased tissue. Such approach may resolve the current discrepancies and lead to the 
establishment of a standard method for the measurement of VEGF-A and VEGF-C in blood. 
On the other hand, serum levels of PlGF were significantly higher in samples from patients with 
colon carcinoma than in samples from healthy individuals. Increased serum levels of PlGF have 
been shown before in colorectal cancer [21, 22] but no reports are available in literature for PlGF 
serum levels in colon adenoma. We did not observe significant higher levels of PlGF in serum of 
patients with colon adenoma, although a tendency of an increment was apparent. Thus, the serum 
levels of PlGF may correlate with the mRNA expression profile of PlGF, at least at the stage of 
colon carcinoma. In order to validate these observations, an extended population study is required 
in which PlGF blood levels are determined and correlated with the results of endoscopic 
examination by colonoscopy for the presence of colon adenoma or carcinoma. 
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VEGFs in combination with eicosanoid enzymes as markers for colon cancer 
Research preceding this thesis has demonstrated in mouse tumor models that the contribution of 
COX2-derived prostaglandins to the growth and malignancy of tumors is considerably more 
complex than anticipated [23]. Based on different mouse tumor models, it appears that besides 
the well-known COX2-dependent expression of VEGF-A [24, 25], also a COX2-independent 
deregulated VEGF-A expression may exist. The occurrence of COX2-independent expression in 
highly aggressive tumor models indicated that this deregulated expression of VEGF-A may be 
associated with a high degree of malignancy [26]. Therefore, the original aim of the current study 
was to translate these observations in mouse tumor models to human colon cancer. The 
hypothesis that COX2-independent expression of VEGF-A may be associated with malignancy in 
human colon cancer was however rapidly overthrown by our data, showing high levels of COX2 
in most of the colon carcinoma samples (92%), thus demonstrating that a COX2-indepent 
expression of VEGF-A does not occur in human colon cancer. On the other hand, the systematic 
analysis of mRNA expression levels of COX2, 5-LOX and VEGF family members in colon 
adenoma and carcinoma revealed other interesting findings. Firstly, 5-LOX was the predominant 
eicosanoid enzyme in colon adenoma samples, whereas in carcinoma samples it was mainly 
COX2. This may indicate that both enzymes are involved in defined steps of tumorigenesis and 
malignancy. Secondly, adenoma samples with upregulation of both 5-LOX and COX2 were at 
greater risk of malignant transformation into carcinoma (Figure I). Expansion of the population 
study to a larger cohort size clearly is indicated to further corroborate these findings and to 
determine the frequency of false negatives. At this point, we cannot exclude that the observed 
association with malignancy is to be attributed to COX2 alone, rather than to the dual expression 
of COX2 and 5-LOX. COX2 in adenoma samples has been described in association with typical 
risk factors of malignant transformation of adenoma [27-29]. Our study revealed a correlation 
between COX2 expression and the grade of dysplasia in adenoma samples, which was not found 
for 5-LOX. In addition, although colon carcinoma cells became more invasive in vitro when 
either PGE2 or LTD4 were added to the culture medium, there was no additional increase in 
invasiveness when both agonists were added. On the other hand, elimination of either COX2- or 
5-LOX-derived eicosanoids in vitro abolished the observed increase in invasion by respectively 
LTD4 or PGE2, indicating that both are required for increased invasiveness. Short-term cultures 
of freshly isolated colon adenoma tissue may allow to determine if either COX2 or the 
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combination of both eicosanoid enzymes causes a higher risk of malignant transformation. 
Finally, we found that the overexpression of eicosanoid enzymes was associated with the 
cumulative co-expression of VEGF family members in both adenoma and carcinoma samples 
(Figure I) and that the expression of COX2 was associated with the expression of VEGF-A, 
VEGF-C and PlGF.  
 
Figure I – Schematic summary of the intertwined inflammatory and angiogenic gene expression in colon 
adenoma and upon progression to carcinoma. Adenoma samples show a pronounced signature with predominant 
expression of 5-LOX as well as VEGF-A and/or PlGF. Adenoma with COX2 expression in addition to 5-LOX have 
an increased risk for malignant transformation to carcinoma. The overall signature of carcinoma samples is a 
predominant expression of COX2 with the co-expression of three to four VEGF family members. 
 
Nevertheless, we failed to reproduce in vitro any association between eicosanoids and VEGF 
family members. Future attempts to reproduce these correlations in vitro may involve the 
implementation of hypoxic conditions to the cell cultures to better mimic the in vivo. The lack of 
responsiveness of colon carcinoma cell lines to the addition of eicosanoids and their inhibitor, 
may indicate that the observed signatures in human carcinoma samples are largely attributable to 
the micro-environment of the tumor. Nevertheless, the tumor cells are likely steering the 
expression signatures as indicated by the conservation of the signatures between colon carcinoma 
and liver metastasis samples. Because established cell lines are derived from a single clone of 
cells and lack therefore the diversity of cancerous as well as environmental cells, they may in fact 
be incompetent to reproduce the observed signatures. Therefore, the use of short-term cultures of 
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fresh colon adenoma and carcinoma samples may be more successful than using established cell 
lines because these clinical samples contain all the cellular components of real-life tumors.  
Considerations for therapy 
Angiogenesis and lymphangiogenesis are important biological responses that crucially contribute 
to the outgrowth of solid tumors and metastases. Targeting these processes and their mediators as 
a consequence holds important therapeutic promises. The VEGF family members are crucial 
angiogenic factors involved in every mechanism of tumor vascularization. However, drugs 
interfering with VEGF-A or its receptors only show modest effects in most cancers and resistance 
tends to develop after a transitory period of clinical benefit. Angiogenic escape responsible for 
this limited response to VEGF-A directed angiogenic therapy is among others stimulated by the 
compensatory expression of VEGF-related angiogenic factors. In line herewith, increased 
expression levels of VEGF-A, -B, -C and PlGF have been shown in colorectal cell lines after 
chronic exposure to bevacizumab [30]. Our comprehensive and systematic analysis of the VEGF 
family members in colon cancer revealed indeed the co-expression of three to four VEGFs in 
colon carcinoma and liver metastasis samples. This excessive expression of multiple angiogenic 
genes may contribute to the observed resistance toward VEGF-A targeting therapy. The 
assessment of VEGF expression profiles in samples before and after treatment with anti-
angiogenic therapy and in samples at apparent therapy-resistance is indicated to determine if the 
treatment stimulates a further upregulation of VEGF family members, which would indicate that 
they are effectively contributing to therapy-resistance. Considering the observed association 
between eicosanoids and co-expression of VEGF-family members, patients may benefit from a 
combination therapy targeting angiogenic VEGF signaling as well as eicosanoids to additionally 
suppress the co-expression of multiple VEGFs. 
Tumor size and hypoxia, future perspectives on the impact of angiogenic gene signatures 
Colon cancer is staged according to the TNM classification whereby T represents the mural depth 
of the tumor. Because the size of a colon tumor is not necessarily related to the stage of the 
cancer, clinicopathological data concerning the size of carcinomas were incomplete and mainly 
TNM scores were documented in the thesis. However, the size of a tumor may possibly influence 
its hypoxic conditions and thus the expression levels of hypoxia-sensitive genes as COX2 or 
VEGF family members. The determination of expression levels of hypoxia markers in addition to 
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the gene-set analyzed in this thesis, may elucidate whether expression levels of VEGFs and/or 
COX2 are correlated with those of hypoxia markers and thus with the level of hypoxia within a 
tumor. Supplementary, it may be interesting to perform this experiment on carcinoma samples 
with characterized size and vascularity to analyze an eventual association with 
clinicopathological features. 
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Dankwoord 
Zo zijn we dan (uit)eindelijk aangekomen bij pagina 175 en de laatste (nu nog) lege pagina’s die 
beschreven moeten worden. Deze keer geen wetenschappelijke cijfers of overdenkingen maar 
wel een dankwoord om allen die op één of andere manier hebben bijgedragen tot deze thesis te 
bedanken en dat zijn vele mensen… 
Laat ik beginnen bij het begin, over het algemeen een goede plek om te beginnen. Johan, zes jaar 
geleden heb je iets gezien in mij waardoor je mij de kans gaf om in jouw labo te beginnen aan 
een boeiend project met hoge verwachtingen. Alhoewel al redelijk snel bleek dat muizen en 
mensen toch niet echt hetzelfde zijn, heb je me succesvol weten klaar te stomen voor het IWT. 
De vijf volgend jaren, ben je me blijven inspireren en steunen. Een belangrijke les die ik geleerd 
heb tijdens mijn doctoraat is: “panikeer niet, vooraleer je Johan ziet”. Hoe wanhopig mijn data 
aanvankelijk ook leken te zijn, na elke vergadering kwam ik buiten met vele nieuwe ideeën en 
mooie vooruitzichten op een (snel) top-artikel. Bedankt voor het vertrouwen, de steun en het 
grondig nalezen van deze thesis. 
Mede aan de wieg van dit doctoraat staat Marc. Beste Marc, bedankt voor het vertrouwen 
waardoor je mij als groentje in het wetenschappelijk onderzoek de kans gegeven hebt om 
onderzoek te verrichten op kostbare menselijke stalen. Doorheen de jaren ben je me steeds met 
veel interesse blijven volgen, zelfs na je verhuis naar Antwerpen. Jouw klinische kijk was een 
grote troef tijdens mijn doctoraat en leverde vaak nieuwe invalshoeken en mogelijkheden. Ik kijk 
dan ook met veel dankbaarheid terug op onze samenwerking.  
Een derde sleutelrol in dit doctoraat is ongetwijfeld gespeeld door Nancy. Nancy, wat heb ik veel 
van jou geleerd en wat heb jij veel voor mij gedaan! Van staaltjes en klinische data opzoeken en 
verwerken tot het nalezen van teksten en praktische hulp bij experimenten en ter tijd en stond een 
gezellige babbel, steeds kon ik bij jou terecht. Mijn eerste reactie op het nieuws dat jij het UZ 
verliet, was dan ook paniek. Maar je hebt mij nieuwe contacten binnen het UZ aangereikt en ook 
nadat je in Brussel aan de slag ging, kon ik steeds op je rekenen. Bedankt voor alles Nancy. 
Tegenwoordig zien we elkaar nog het meest nu we ook effectief collega’s zijn op het Belgisch 
Kankerregister, de wereld is soms klein. Tot morgen! 
Via Nancy heb ik Karen, Evi en Ellen leren kennen. Bedankt voor al jullie hulp met het 
verzamelen en doorspelen van stalen en klinische gegevens en ook voor de steeds hartelijke 
ontvangst in het UZ. 
Als je een doctoraat doet dat voor 98% bestaat uit qPCR, heb je nood aan een “q-PCR-hulplijn-
en-redder-in-nood”. Bram, ik denk dat je het bij momenten al benauwd kreeg als ik weer eens aan 
jouw bureau stond. Het had voor mij wel handig geweest, waren jij en de Lightcycler iets vroeger 
dan het laatste jaar verhuisd naar een aangrenzende labo. Bijna alles wat ik weet over qPCR, heb 
ik van jou geleerd, wat jouw aandeel in mijn doctoraat meteen naar grote hoogten katapulteert. 
Bedankt voor je hulp, je inzichten en je eindeloos geduld met al mijn vragen.  
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Uiteraard wil ik ook de (semi-/ex-)leden van de LMI-clan bedanken. Seppe, mijn oud-‘cubicle’-
genoot, ondanks het feit dat onze onderzoeksvelden en onze werkuren niet veel gemeen hadden, 
heb ik veel van jou opgestoken, van multiple alignments en het creëren van primers tot het 
werken met CorelDraw. Voor het invullen van WK-voetbal-pronostieken denk ik evenwel dat er 
betere partners dan wij denkbaar zijn. Veel geluk in Duitsland! Stefaan en Thomas, jullie zijn 
buiten Johan de enige “constanten” geweest tijdens mijn LMI-tijd. Ook bij jullie kon ik terecht 
voor goede raad en de nodige portie scheve moppen en absurde gespreksonderwerpen. Muriel, 
Charlotte, Jelle, Caroline, Ilke en Ans, alhoewel de oestrogenenbron in mijn begintijd bij de LMI 
zeer beperkt was, is de balans ondertussen volledig overgeslagen. Bedankt voor de gezellige 
momenten, uitstapjes en babbels. Muriel en Charlotte, jullie zijn de volgenden, veel succes met 
het afwerken van jullie doctoraat. Ans, ik ga, jij komt of is het omgekeerd? Als jongste telg bij de 
LMI wens ik je veel succesvolle experimenten! Jouw goede humeur werkt aanstekelijk. Last but 
not least, Ilke. Die vriendelike klik was daar dadelik. Baie baie dankie vir jou vriendskap en 
ondersteuning en baie baie dankie vir die lees en die verbetering van my tesis. Spijtig genoeg 
vertrek jy nou net vir even na huis en mis jy die einde van my doktorsgraad en ek jou huwelik 
maar dat sal ons dan later wel inhaal. Baie geluk met jou trou en jou verdere doktorsgraad! Ons 
sien mekaar gou weer! 
Buiten het LMI wil ik ook graag Jannick, Chantal en Rudy bedankten voor de vele gezellig 
middagen en momenten. Verder wil ik ook graag iedereen bedanken die meewerkt aan de goede 
gang van zaken binnen het departement. Bedankt Daisy, het gezamenlijk verjaren was fijn; Ann 
en Wilma voor de organisatie van de weefselkweek; Nancy voor de vele pakjes; Ann en 
Christiane voor het verzorgen van een onuitputtelijke bron proper en geautoclaveerd materiaal; 
Marita, Chantal, Veerle, Myriam en Rik, de mensen van IT, Charly, Geert en al wie ik nog 
vergeten ben. 
Ook mijn vrienden waren steeds geïnteresseerd in mijn doctoraat en zorgden daarenboven voor 
de broodnodige momenten van ontspanning. Uit de thuishaven: Sylvie, Wim, Steffie, Kockel en 
Erika en Hanne, Wim en Belinda en kids, Jeroen, …Bedankt voor de vele fijne momenten, 
etentjes, uitstapjes, gezelschapspelletjes-avonden en zoveel meer. Ik weet dat ik het laatste (half) 
jaar wel van de aardbol verdwenen leek, maar nu ben ik er weer, dus haal die agenda’s maar 
alvast boven! Joke en Ellen, onze vriendschap begon in het eerste jaar biomedische en ik hoop 
dat nog veel van onze 3 à 4–maandelijkse “dates” gaan beleven met de kids en de mannen. Jolien, 
ons verhaal loopt reeds 17 jaar, ondertussen hebben we beiden een gezin en het is nog steeds fijn 
om elkaar te zien. Katleen en Carlos, Marijke en Lennin, Thomas en Sandrien, de “kotreunies” 
krijgen steeds vaker het label “speeldate voor de kindjes” en dat is steeds zeer fijn! Vaker en 
meer zou ik zeggen! Olivier, bedankt voor het ontwerp van de cover en de lay-out van mijn 
thesis. 
Uiteraard verdient ook mijn familie een woordje van dank. Tantes en nonkels, neven en nichten, 
jullie waren steeds geïnteresseerd en dat deed deugd! Broertje Jonas en (schoon)zusje Carla, 
jullie zijn er altijd voor ons. Bedankt voor de interesse en de steun en binnenkort gaan we nog 
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eens een avondje gezelschapspelletjes spelen. De volgende feest is voor jullie! Meme, altijd op de 
eerste rij om te helpen, om op Lore te passen en gelukkig ook om eens goed te babbelen of te 
feesten! Al voor zolang ik me kan herinner, sta je klaar voor mij en nu ook voor mijn eigen gezin. 
Langs deze weg wil ik laten weten hoezeer ik je waardeer! Ik wil ook mijn schoonouders 
bedanken, Georges en Marita, jullie staan altijd klaar voor ons, bedankt! 
 
Mama en papa, het is met geen woorden te beschrijven wat jullie voor mij gedaan hebben en nog 
steeds doen. Ik heb op zijn minst een nieuwe thesis nodig om alles te kunnen neerschrijven, dus 
ik ga hier gewoon heel kort en krachtig: “Bedankt voor ALLES” zeggen. Het doet deugd om te 
weten dat jullie mij steeds steunen en achter me staan en dat ik steeds bij jullie terechtkan. Ik mag 
met gelukkig prijzen met jullie als ouders! 
Rafaël, ik scholier en jij student, ik student en jij student, ik student en jij werkend, ik 
doctorerend en jij werkend, verliefd, verloofd, getrouwd, mama en papa van een prachtige 
dochter, jij en ik, ik en jij, wij hebben al heel wat stadia samen beleefd. Nu er weer een nieuw 
hoofdstuk aanbreekt, wil ik je uit de grond van mijn hart bedanken. En ja, ook voor het runnen 
van het huishouden wat je de laatste maanden volledig op jou genomen hebt (en neen, ik ga geen 
opsomming geven), maar vooral voor je vertrouwen, je geduld, je steun en je liefde. Ik weet 
zeker dat er een mooie toekomst voor ons in het verschiet ligt en ik ben helemaal klaar voor het 
volgende hoofdstuk! 
Mijn lieve kleine Lore, als geen ander beschik jij over het vermogen om mij alles te doen 
relativeren. Een kus en een knuffel van jou doen de zon steeds weer schijnen. Je hebt de laatste 
maanden veel geduld moeten hebben,  maar nu komt er veel mama-Lore tijd vrij! 
 
BEDANKT!!! 
Sarah 
